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Introduction 
The human leukocyte antigens 
Human Leukocyte Antigen (HLA) is the human variant of the Major Histocompatibility 
Complex (MHC) found in all vertebrates, and its main role is the presentation of 
exogenous and endogenous peptides to the immune system. The initial thought that a 
genetic factor would determine susceptibility or resistance to allogeneic tissue came 
from multiple mouse studies, performed in the first decades of the 20th century, 
showing that the genetic background of a mouse determined whether allogeneic 
tumours could grow or were rejected. Mice crossbreeding experiments subsequently 
indicated that mice that were rejecting tumours produced antibodies against antigens 
that were encoded by the highly complex H-2 locus, with the H standing for 
histocompatibility. In the 1950s, the first leucocyte antigen groups, currently known as 
the HLA-A and HLA-B loci, were identified based on series of observations that sera 
from patients that underwent multiple blood transfusions or from multiparous women 
triggered agglutination of allogeneic leucocytes. A third locus, HLA-C, was also 
discovered, albeit, having a lower surface expression than HLA-A and -B. These three 
loci are now known as the HLA class I genes. In mixed lymphocyte cultures, a second 
class of HLA loci was discovered by the observation that a “leucocyte reaction” could 
occur even when the leucocytes were derived from HLA class I identical individuals. It 
was shown that these reactions were caused by polymorphism located outside the 
HLA class I genes in the so-called D-locus. The first defined HLA-D locus was HLA-DR  
(R for D-Related) and additional cellular and serological assays led to the discovery of 
two other HLA class II loci, HLA-DQ and HLA-DP (1-5). The desire to fully understand 
the highly complicated HLA genes led to the first full genomic foldout map of HLA in 
1993 (6), followed by a sequence-based map in 1999 (7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The position of the HLA loci on chromosome 6 
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The HLA genes are the most polymorphic loci in the human genome, located on the 
short arm of chromosome 6 (6p21.3) (Figure 1) and they are divided into three major 
classes, HLA class I, II and III. The HLA class I genes are subdivided into the classical HLA 
class I genes: HLA-A, -B and -C, and the non-classical genes: HLA-E, -F and -G. For the 
HLA class II genes, three classes of classical gene groups have been identified: HLA-DR, 
-DQ and -DP, and two non-classical, HLA-DM and -DO, each comprised of an α- (A) and 
β- (B) chain. The last class of genes in the HLA complex, HLA class III, encodes for a 
multitude of non-HLA genes involved in the immune system, such as proteins for the 
complementary system (C2, C4, etc.), cytokines (TNF-α, etc.) and the stress-induced 
signalling heat shock proteins (2, 3, 8, 9). 
 
HLA class I molecules 
The HLA class I molecules are expressed on most somatic cell types, albeit varying in 
expression levels dependent on the tissue. They are encoded by one of the HLA class I 
highly polymorphic classical loci (HLA-A, -B and -C) or by the less polymorphic  
non-classical HLA class I loci (HLA-E, -F and -G) (3, 10). 
Genetically the HLA class I genes are encoded by 8 exons (7 exons for HLA-B), with 
exon 1 encoding for the leader peptide which is removed during intracellular 
processing. Exons 2, 3 and 4 encode for the three extracellular domains, α1, α2 and α3 
respectively, which form a single extracellular α-chain. Combined, the α1 and α2 
domains form the peptide binding groove, with an antiparallel β-sheet as the floor 
flanked by two α-helixes as side walls, which is responsible for the binding and 
presenting of peptides to T-cells and expresses the highest degree of HLA 
polymorphism. These polymorphism are mostly present in specialized pockets of the 
peptide binding groove acting as peptide anchor positions and thus determine the 
peptide binding specificity. The α3 domain is non-covalently associated with a  
β2-microglobulin protein encoded on chromosome 15, with a size of ±12 kDa, and is 
necessary for the HLA class I cell surface expression and stability of the peptide binding 
groove. The HLA class I molecule is anchored in the cell membrane by a 
transmembrane domain encoded by exon 5, which in turn is followed by a short 
cytoplasmic tail encoded by exons 6-8. The complete HLA class I molecule has a size of 
±43 kDa (3, 11). 
The peptides presented by HLA class I molecules are mostly derived from intracellular 
proteins, e.g. self-peptides from housekeeping genes while in a virally infected cell, 
class I presented peptides can also be of viral protein origin. Intracellular proteins, 
targeted for degradation, are proteolytically broken down by the proteasome into 
peptides which are transferred into the Endoplasmic Reticulum (ER) through the 
Transporters Associated with antigen Processing complex (TAP). After a suitable 
peptide, with a size varying between 8 to 16 residues, has emerged from the TAP 
channel into the ERs lumen, it is bound to a HLA molecule bound to the luminal  
ER surface. The peptide-HLA complex subsequently translocates to the cell membrane 
by transport vesicles produced in the Golgi apparatus (3). 
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On the cell surface the HLA class I molecule presents its peptide to the T-Cell Receptor 
(TCR) of CD8+ cytotoxic T-lymphocytes. Healthy cells mainly present peptides derived 
from self-proteins which will normally not lead to an activation of the CD8+ T-cells due 
to negative selection of autoreactive T-cells in the thymus. However, when a foreign 
peptide is presented, as a result of e.g. a viral infection, the CD8+ T-cells can recognize 
the peptide, become activated, and eliminate the cell presenting the foreign peptide. 
HLA class I molecules can also act as ligands for both activating and inhibitory 
receptors on Natural Killer (NK) cells. NK-cell activation is determined by the balance 
between activating and inhibitory receptors. HLA interaction with activating receptors 
presumably is important for antiviral NK reactivity. Interaction with inhibitory 
receptors, e.g. Killer-cell Immunoglobulin-like Receptors (KIRs) and the c-type lectin 
like CD94/NKG2A provides an inhibitory signal important to protect healthy cells from 
being killed by NK-cells. Consequently, cells lacking HLA class I expression will be 
susceptible for killing by NK-cells. This is an important mechanism to control virally 
infected or in malignant cell that have down-regulated the surface expression of HLA 
class I molecules to escape from T-cells (3, 12, 13). 
 
HLA class II molecules 
The HLA class II molecules are under normal conditions only expressed on certain 
subsets of antigen presenting immune cells, activated T-cells and on thymic epithelial 
cells. They are divided into three classical loci involved in peptide presentation, the 
HLA-DR, -DP and DQ loci, and two non-classical loci, indicated as HLA-DM and HLA-DO, 
which play a role in the regulation of the classical class II molecules (3). 
The HLA class II molecules consist of two non-covalently bound protein chains, the  
α- (±34 kDa) and β-chain (±29kDa), encoded by the A and B gene, respectively. Both 
genes have a leader peptide encoded by exon 1, which is involved in intracellular 
transport and is removed from the resulting protein. The extracellular class II molecule 
is formed by two domains of the α- and β-chain encoded by exons 2 and 3. Combined, 
the α1 and β1 domains form the highly polymorphic peptide binding groove, with the 
β1 expressing the highest degree of polymorphism, composed of a floor of antiparallel 
β sheets and two antiparallel α helixes as sides. The α2 and β2 domains are proximally 
positioned to the cell membrane acting as backbone and co-receptor binding place. 
The last exons, 4 through 6, encode for the transmembrane anchor and a short 
cytoplasmic tail (3, 14). 
HLA class II molecules mainly present peptides originating from the exogenous 
proteins. These proteins are internalized from the extracellular environment by 
endocytosis and are transported and degraded in the cell by the  
endosomal-lysosomal system. The HLA class II molecule originates from the ER where 
its α- and β-chains are combined, and bound to a non-polymorphic chaperone protein 
called the invariant chain (Ii). This li chain inhibits the binding of antigenic peptides 
until it is proteolytically degraded. After the merging of the vesicle containing the 
extracellular protein and the vesicle containing the HLA class II molecule, the protein is 
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broken down into peptides by proteases. At the same time, the li chain is degraded by 
a stepwise proteolysis system which leaves a small fragment of the li chain in the 
binding groove called the CLIP fragment, or CLass II-associated Invariant chain Peptide. 
This CLIP fragment has to be removed before a suitable peptide can be bound to the 
class II molecule. The removal of CLIP is facilitated by HLA-DM, which in turn is 
regulated by HLA-DO, that causes a conformational change leading to the dissociation 
of the CLIP fragment. After the dissociation of the CLIP fragment, a suitable peptide 
with a size up to 30 amino acids can bind to the HLA molecule. Class II binding peptides 
can be larger than the peptides presented by HLA class I due to the open-ended HLA 
class II peptide binding groove. The resulting complex of the HLA class II-peptide will be 
transported to the surface (3, 14). 
On the cell surface, the peptide-loaded class II molecule interacts with the T-cell 
receptor of CD4+ T-cells. These cells can get activated when a foreign peptide is 
detected on the HLA class II molecule and polarize into specific T helper cell subsets 
(Th1, Th2, Th17). Through the production of cytokines, these T helper cells can 
subsequently facilitate other immune effector responses such as the production of 
antibodies by B cells, stimulation of CD8 T-cells, NK-cells or macrophages (3, 14). 
 
HLA nomenclature 
Due to the high degree of polymorphic diversity of the HLA genes, it was necessary to 
define a worldwide regulated system for naming the HLA genes. The World Health 
Organisation (WHO) Nomenclature Committee for Factors of the HLA System is 
responsible for naming new HLA genes and allele sequences and established the 
IMGT/HLA database, an online database documenting information on all HLA genes, to 
help manage and store the information documented and reported by this committee. 
The first version of the IMGT/HLA database was released on 16 December 1998 and 
included a total of 964 HLA alleles, the most recent version of the database  
(version 3.22) includes a total of 13,840 HLA alleles, illustrating the enormous diversity 
of the HLA genes (15). 
The nomenclature for the HLA alleles is based on identifying the exact HLA protein by 
using four fields of allele codes divided by a colon. In the example of a HLA-A*02 allele 
in Figure 2, the first letters after the hyphen refer to the HLA gene locus, in this 
example the HLA-A locus. The * indicates that the allele is identified by DNA 
techniques. The numbering of the first field indicates the allele group which is usually 
identical to the serologically defined antigen except for HLA-DP where the numbering 
in this field does not correlate to the serological antigen but indicates the order of 
when the allele was identified. The second field identifies the specific protein 
nucleotide substitutions leading to changes in the amino acid sequence of a protein, 
identified as nonsynonymous substitutions. The third field represents polymorphism in 
the coding regions that do not lead to a change in amino acid sequence, these 
polymorphism are called synonymous substitutions. The last and fourth field indicates 
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polymorphism positioned outside the coding regions, e.g. polymorphism in the introns 
(15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 HLA nomenclature 
 
 
In addition to the four fields identifying the unique allele number, certain alleles have 
an aberrant surface expression pattern identified by a suffix added to the end of the 
HLA name. Alleles that are not expressed on the cell surface receive a  
“N” (Null) suffix while alleles having a relatively low surface expression level receive a 
“L” (Low). Some alleles encode for HLA molecules that are not expressed on the cell 
surface and exclusively occur in a soluble, extracellular form, these alleles are 
identified by a “S” (Secreted). The “C” suffix (Cytoplasm) is for HLA alleles encoding for 
a HLA product which is only present in the cytoplasm, and an “A” (Aberrant) suffix 
indicates an allele for which there is still doubt as to whether a protein is expressed. 
The “Q” (Questionable) alleles have an unknown surface expression pattern that has 
yet to be revealed and they have a mutation that has been shown to have a clear 
effect on surface expression. The correct identification of the alleles identified by these 
suffixes is extremely important for Stem Cell Transplantation (SCT), as an aberrant 
surface expression can influence the level of T-cell reactivity and resulting patient 
outcome in a SCT (15, 16). 
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HLA in disease and transplantations 
Under physiological conditions, the immune system protects the human body by 
eliminating invading pathogens. The highly polymorphic nature of the HLA system 
enables the presentation and recognition of a broad diversity of peptides by the 
immune system which is, on individual as well as population level, very important to 
deal with the great variety of pathogens encountered throughout life. HLA binding 
peptides can be derived from a foreign source, e.g. from bacteria or viruses, or from 
endogenous, self-proteins. Under physiological circumstances, the presentation of  
self-peptides does not trigger a strong autoreactive T-cell response due to mechanisms 
of central and peripheral tolerance. However, in some cases tolerogenic mechanisms 
fail which can lead to development of autoimmune diseases, e.g. rheumatoid arthritis, 
diabetes or systemic lupus erythematosus (3, 12, 17, 18). 
For several autoimmune diseases, disease susceptibility is associated with the 
presence of specific HLA alleles, a clear example is ankylosing spondylitis and 90% of all 
patients express HLA-B*27. One of the explanations for the association between HLA 
genotypes and disease susceptibility is that HLA polymorphism can have an impact on 
the exact repertoire of HLA binding peptides. Certain HLA alleles can therefore bind 
disease associated (self) peptides enabling excessive and unwanted T-cell activation, 
while other alleles do not. This has clearly been shown in celiac disease where specific 
HLA-DQ2 and/or –DQ8 alleles (e.g. DQA1*02:01 or *05:01 with HLA-DQB1*02:01) 
predispose for disease development due to their capacity to bind gluten peptides (19). 
Comparable associations exist for hypersensitivity to abacavir which is strongly 
associated with HLA-B*57:01. Typing for disease predisposing HLA alleles can therefore 
be important during disease diagnosis or to prevent adverse effects of drugs like 
abacavir in individuals having HLA-B*57:01 (20). 
The highly polymorphic nature of the HLA genes poses a problem when tissues are 
transplanted from one individual to another. During maturation, T-cells with a 
relatively low affinity binding to self-HLA molecules have been positively selected in 
the thymus. While high affinity interactions with self-HLA molecules presenting self-
peptides normally does not occur, due to negative selection, this can take place upon 
encounter of nonself-HLA resulting in activation and clonal expansion of “alloreactive  
T-cells” and the production of allo-HLA-specific antibodies by B cells. For 
transplantation, the effector response triggered by the antibodies can, at least partly, 
be prevented by selection of donors that lack the HLA alleles for which the patient has 
antibodies caused by previous sensitizing events (e.g. pregnancy, transfusions or an 
earlier transplantation) and by matching for patient and donor HLA. In addition, 
immunosuppressive agents can be used after transplantation to avoid excessive T-cell 
alloreactivity and graft rejection by the patients’ immune system. While the 
immunosuppressive agents have greatly improved survival of (partially) mismatched 
kidney grafts, high-resolution matching for HLA is still critical in allogeneic 
Haematopoietic Stem Cell Transplantation (allo-SCT). Allo-SCT is a possible curative 
medical procedure for certain blood or bone marrow malignancies during which 
patients receive stem cells isolated from a healthy donor. In the allo-SCT setting, 
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discrepancies between donor and patient HLA can lead to severe and sometimes lethal 
immunological reactions of the donor’s lymphocytes attacking the host, causing  
Graft-Versus-Host Disease (GVHD), or the recipient rejecting the graft, called host 
versus graft (HvG) reactivity. The most ideal donor to minimize the risk of GVHD or 
HVG upon allogeneic SCT is a HLA identical sibling. However, for a large percentage of 
patients needing allo-SCT such a sibling is not available, and a search has to be 
performed to find a suitable unrelated donor by matching the HLA of the patient to a 
database comprised of possible donors. In the current matching procedures, the 
patient and donor are matched for HLA-A, -B, -C, -DRB1 and -DQB1, resulting in a 
10/10 match. It has been shown that patients with a match for their HLA-A, -B, -C  
and -DRB1 loci, have a significantly better outcome than transplantations with a single 
or multiple mismatches especially for the HLA-A and -B loci, compared to HLA-C. 
Whether there has to be an additional match for HLA-DQB1 and DPB1 is still under 
debate (21-26). 
There are a number of methods available to determine the HLA type of patient and 
donor based on serological or molecular techniques. The Complement-Dependent 
Cytotoxicity test (CDC), flow cytometric crossmatches, ELISA and single antigens are 
applied to determine the presence and/or specificity of HLA-specific antibodies in the 
patient. Specificity of the HLA alleles, present in patient and/or donor, can be 
determined by serological typing using antisera, monoclonal or polyclonal antibodies 
directed against known epitopes of the HLA surface molecules. However, nowadays 
this is typically done by molecular typing techniques that are mainly based on using 
specifically designed PCR primers attaching to polymorphism in the HLA genes, 
resulting in an amplification product that can be used for a positive or negative result 
determined on electrophoresis gels or measured on the Luminex based HLA typing 
system. To exactly determine and visualize the nucleotide sequence of the HLA gene, 
the resulting amplification products can also be used for Sequence-Based Typing (SBT). 
A more recent development has been the introduction of Next-Generation Sequencing 
(NGS) techniques which are able to perform large numbers of clonal sequencing 
reactions (27-29). 
 
The additional value of RNA approaches in HLA typing 
The current DNA-based and serological techniques all have their shortcomings. 
Serological HLA typing is hampered by the limited availability and specificity of antisera 
or antibodies, especially for HLA-C. Furthermore, these antibodies can only detect the 
presence of specific epitopes resulting in the determination of the major antigen 
groups but not individual alleles. Amino acid variation that does not have an influence 
on the epitopes will therefore not be detected while it can be immunogenic and thus 
important especially in the allo-SCT setting. These variations can be determined by 
molecular techniques, albeit, requiring the design of a multitude of heterozygous-, 
allele-group-, or allele-specific PCR primers. Full-length gene polymorphism can be 
determined by SBT sequencing, when required, each additional exon requires a 
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separate amplification and sequencing reaction. The introduction of NGS made the 
simultaneous sequencing of multiple clonal reactions possible, however, the high 
amount of HLA polymorphism causes problems in aligning the resulting sequence 
reads to reference genes. Furthermore, when only DNA templates are considered as a 
marker for the HLA surface molecules, surface expression levels or additional aspects 
influencing HLA expression such as alternative mRNA splicing will be missed (27-29). 
As will be explained in more detail below, these aspects can be immunologically 
relevant. 
Polymorphism positioned outside the peptide binding groove have been shown to lead 
to diverse immune effects depending on the exon and resulting domain they are 
placed in. For example, certain polymorphism have been shown to lead to a decrease 
in surface expression when located in the leader peptide or cytoplasmic tail, or affect 
the interaction with the immune cells when positioned in the α3 domain or 
transmembrane anchor (30-38). However, due to the direct functional relevance of the 
peptide binding groove, there has always been a focus in HLA SBT strategies to 
determining the polymorphic content of the exons encoding for this area. This resulted 
in a large percentage of the currently known HLA alleles in the IMGT/HLA lacking their 
full-length allele sequences. This is hampering studies that aim to determine the exact 
functional relevance of polymorphism outside the peptide binding groove in 
transplantations (15). The short amplicon length of mRNA compared to DNA, class I 
±1100 bp versus 2700 bp, enables full-length sequencing in a single or two PCR 
amplification reactions, resulting in the characterization of the full-length polymorphic 
content. 
Besides polymorphism encoding for amino acid changes, some polymorphism are able 
to disrupt normal pre-mRNA splicing reactions, catalysed by the spliceosome, when 
placed in certain nucleotide sequences recognized as splice sites, or by activating a 
cryptic splice site. Both situations will lead to the formation of alternatively spliced HLA 
mRNA transcripts usually encoding for a HLA molecule having an aberrant surface 
expression level. These mRNA isoforms would be identifiable by RNA sequencing and 
can be recognized as mRNA sequences having inserted or deleted nucleotides in their 
transcript (39). DNA sequencing will namely only identify the alternative splicing 
causing polymorphism as a new Single Nucleotide Polymorphism (SNP), and classify 
them as an encoding or synonymous SNP. For example, the polymorphism seen in the 
HLA-A null allele A*01:11N would have been classified as a new A*01:01:XX allele 
based on DNA sequencing results, with a non-coding polymorphism in codon 175 
(GGG>GGT). However, RNA analysis revealed that the synonymous polymorphism in 
A*01:11N activates a cryptic 5’ splice in exon 3, leading to the deletion of 8 amino 
acids at the 3’ end of the α3 domain resulting in a null surface protein expression (40). 
In addition to aberrant surface expression levels, the overall surface expression levels 
of the HLA molecules has been shown to be linked to the defence against pathogens. 
The onset of, and defence against, HIV/AIDS has been shown to be delayed and 
increased, respectively, in individuals having higher HLA-C surface expression (41-43). 
Some pathogens are known to decrease the surface expression to avoid an activation 
of the immune system, e.g. the CMV-, Adeno- and Herpes- viruses (44-46). Besides the 
influence of HLA surface expression on the defence against pathogens, it can also have 
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an effect on the outcome of allo-SCT and, in addition to the number of HLA 
mismatches, the surface expression level of a mismatched locus has been shown to be 
important. This effect has been shown for HLA-C mismatches where the surface 
protein levels influence the immunogenicity of a mismatch in a SCT (47). Incorporating 
RNA sequencing in HLA typing strategies could give some indication of mRNA 
expression levels (48). 
RNA-SBT could be a platform to obtain information on full-length polymorphism; to 
identify alternatively spliced mRNA transcripts; and to provide an indication on mRNA 
expression levels (49). RNA-SBT will therefore facilitate further studies on the 
functional relevance of full-length HLA polymorphism which will help to better 
understand the immunological function of HLA in health and disease; to more 
accurately predict immunogenicity of HLA alleles; and to optimize transplantation 
procedures. 
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Outline of the thesis 
The HLA class I and II genes belong to the most polymorphic gene system in the human 
genome. The genes encoding for the HLA molecules exist out of 8 exons for class I and 
6 for class II. Exons 2 and 3 encode for the peptide binding groove and display the 
majority of the polymorphism, the other exons were however shown to express a 
relatively high degree of polymorphism as well (Polymorphic Index chapter 2 and 3). 
Some of these extended polymorphism have been shown to have a defined functional 
role by affecting the surface stability and expression of the molecule or influencing the 
interaction with immune cells. However, the functional relevance of polymorphism 
outside exons 2 and 3 remains difficult to study since a large percentage of HLA alleles 
have unknown full-length nucleotide sequences in the IMGT/HLA database. In the 
present study, the feasibility and additive value of RNA-SBT to obtain full-length 
sequences and to study alternative splicing was investigated. First, a HLA class I and 
HLA-DRB1 RNA-SBT approach was developed that illustrated that RNA-SBT is an easy 
platform to generate full-length coding sequences of HLA alleles (chapters 2 and 3). 
 
Besides achieving full-length nucleotide sequences for the HLA alleles, RNA-SBT 
amplification can also reveal and visualize alternatively splicing of HLA alleles, which is 
not possible by using DNA-SBT approaches. In chapter 4, current knowledge on 
alternative splicing of HLA is reviewed. Alternative splicing of HLA alleles is mostly 
caused by polymorphism influencing pre-mRNA splicing catalysed by the spliceosome. 
Elements of this complex molecular machine recognise the splice sites based on the 
presence of specific conserved nucleotides that determine the resulting strength of a 
splice site. Polymorphism are able to disrupt the normal splicing machinery by creating 
secondary, or deactivating the regular, splice sites, thereby resulting in the production 
of mRNA isoforms usually encoding for HLA molecules that are unable to be presented 
on the cell surface. Beside polymorphism causing an aberrant surface expression, 
there are multiple polymorphism in the HLA genes that could act as secondary splice 
sites that, when strong enough, are in competition with the normal splice site and lead 
to the rise of mRNA isoforms co-expressed alongside the normal mRNA variant 
(chapter 4). 
 
Certain aberrantly expressed HLA alleles still have an unknown and unconfirmed 
surface expression pattern, and are categorized as questionable alleles. It is important 
to resolve the expression patterns of these alleles as they can affect the HLA matching 
procedures and transplantation outcome. Since RNA sequencing can be used to 
identify alternatively spliced HLA mRNA variants, this approach was applied for the 
questionable HLA-A*23:19Q allele. This revealed the absence of a full-length mRNA 
and the presence of two alternatively spliced variants, one missing exon 3 and the 
other having intron 2 and 3 retained. Based on the presence of these alternatively 
spliced variants only and the absence of surface protein expression, this allele was 
reclassified as a null expressing allele and was renamed HLA-A*23:19N (chapter 5). 
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RNA-SBT was also used to study full-length RNA sequences of all major HLA-C allele 
groups. One new mRNA variant was identified that was missing exon 5, encoding for 
the transmembrane anchor, and that was expressed aside the normal full-length 
variant. This specific mRNA isoform was only present in specific HLA-C allele groups 
and, most likely, encodes for a soluble HLA protein (chapter 6). 
 
Together these studies emphasize the feasibility and applicability of RNA-SBT as a 
platform to obtain full-length sequences and to study alternative splicing. RNA-SBT can 
therefore be instrumental to investigate the functional consequences of extended HLA 
polymorphism. 
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Abstract 
The functional relevance of human leukocyte antigen (HLA) class I allele polymorphism 
beyond exons 2 and 3 is difficult to address because more than 70% of the HLA class I 
alleles are defined by exons 2 and 3 sequences only. For routine application on clinical 
samples we improved and validated the HLA sequence-based typing (SBT) approach 
based on RNA templates, using either a single locus-specific or two overlapping  
group-specific polymerase chain reaction (PCR) amplifications, with three forward and 
three reverse sequencing reactions for full-length sequencing. Locus-specific HLA 
typing with RNA-SBT of a reference panel, representing the major antigen groups, 
showed identical results compared to DNA-SBT typing. Alleles encountered with 
unknown exons in the IMGT/HLA database and three samples, two with null alleles 
and one with a low expressed allele, have been addressed by the group-specific  
RNA-SBT approach to obtain full-length coding sequences. This RNA-SBT approach has 
proven its value in our routine full-length definition of alleles. 
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Introduction 
Immune recognition of infectious pathogens is mediated through the presentation of 
foreign peptides by the human leukocyte antigen (HLA) molecules. Genes encoding the 
HLA molecules are located on the short arm of chromosome 6 and comprise two major 
gene clusters, HLA classes I and II (1). HLA class I (A, B and C) and class II (DR, DQ and 
DP) genes are the most polymorphic loci in the human genome with a total of 10,691 
different HLA alleles currently known (IMGT/HLA v3.15) (2). Most polymorphisms are 
located in exons 2 and 3 for HLA class I, which encode the peptide binding groove 
involved in binding and presenting peptides to T-cells (3, 4). The high degree of 
polymorphism and importance of the peptide binding groove resulted in a focus on the 
identification of polymorphisms in exons 2 and 3. Therefore, among the HLA class I 
allele sequences about 80% have unknown sequences for other exons based on the 
sequences in the IMGT/HLA database (v3.15).  
Full-length gene sequencing defines the polymorphic content of an allele. Complete 
allele sequences can refine the allele definition and will characterize more precisely 
the alleles and assignment in the Common and Well Documented (CWD) HLA allele 
database that has been originally based on exons 2 and 3 (5, 6). For several alleles, 
because of lack of full-length sequence data, the most common appear to be rare and 
those thought to be rare were the common occurring alleles (7, 8). In these alleles the 
difference distinguishing the common from the infrequent allele is located outside 
exons 2 and 3 and can only be identified with full-length sequencing, as is the case 
with HLA-C*07:06. This allele has one nucleotide difference in exon 5 (position 992) 
and one in exon 6 (position 1043) compared to C*07:01, and has been encountered 
frequently in the Equatorial Guinea Bubi population associated with B*44:03:02. Both 
B*44:03:02 and C*07:06 were not found in any of the Dutch Caucasian individuals with 
haplotype B*44 - C*07 (9). This example shows that ethnic diversity and full-length 
high-resolution typing influences the CWD allele definition. 
Although polymorphism outside exons 2 and 3 might not have a direct function in the 
binding of peptides, they still show a certain degree of polymorphism, as was shown in 
previous studies for HLA-B (10) and -C (11). It is hypothesized that exon 4 
polymorphism might play a role in indirectly affecting peptide binding by influencing 
the β2-microglobulin binding to the α3 domain (12). Furthermore, the α3 domain acts 
as a binding site for CD8 and polymorphism in this domain, e.g. in HLA-A*68  
(Ala to Val), showed a decreased CD8 binding (13, 14). Polymorphism in exon 1, the 
leader peptide, might play a role in the targeting, folding and stabilizing of the  
pro-peptide (15). The transmembrane part anchors the HLA protein into the cell 
membrane and variations in the transmembrane domain length has been shown to 
affect cell surface stability (16). Furthermore, polymorphism in this area is able to lead 
to the formation of soluble HLA caused by the skipping of exon 5 as was seen in HLA-A 
and -B (17). The functional relevance of HLA polymorphism outside exons 2 and 3 is 
still unknown and can hardly be studied because of the lack of knowledge of 
polymorphism in those regions and justifies the need for determining full-length 
polymorphism. 
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In this study we aim to determine the polymorphic content of the full-length coding 
region for alleles having unknown exon sequences outside exons 2 and 3, making 
functional studies of those polymorphisms possible. We improved and validated a HLA 
RNA-SBT method based on earlier approaches. RNA templates have the advantage 
over DNA approaches that, because of the absence of introns, the  
full-length coding sequence can be amplified in a single polymerase chain reaction 
(PCR) and sequenced using three forward and three reverse sequencing primers.  
Full-length sequencing on a RNA template was performed originally by cDNA cloning 
and subsequent sequencing (18), Santamaria et al. (1993) developed a locus-specific 
amplification method for exons 2 to 4, missing the other exons (19). Full-length cDNA 
was amplified with different amplification primers combined with cloning strategies 
before sequencing (20–22). We modified and redesigned primers to establish an 
uniform locus-specific amplification in a single PCR. Moreover we developed  
group-specific amplification primers allowing the unambiguous identification of the  
full-length allele sequences. Once low resolution typing data, obtained with any 
method, is available, this information is used to directly amplify the individual alleles 
with the group-specific amplification primers. Our approach is universally applicable on 
peripheral blood mononuclear cells (PBMC) from clinical samples to generate the  
full-length sequences. The RNA-SBT approach is validated on a reference panel, and a 
panel of samples (PBMC) available in our laboratory that has alleles with unknown 
exon sequences in the IMGT/HLA database which were identified with the  
group-specific sequencing approach. To determine whether this method could also 
detect alleles with an aberrant expression profile, three samples, two with null alleles 
and one with a low expressed allele, were included. 
 
Material and methods 
RNA isolation and cDNA synthesis 
PBMC were isolated from 5 ml ethylenediaminetetraacetic acid (EDTA) blood using 
Lymphoprep (Axis-Shield, Oslo, Norway). Approximately 5×106 cells were used for total 
RNA isolation using the RNeasy minikit (Qiagen, Hilden, Germany) following the 
manufacturer’s protocol. The RNA quality was determined by measuring the A260/280 
ratio using the NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, 
DE). To ensure removal of all DNA in the samples, a DNase step was performed using 
the deoxyribonuclease I kit (Life Technologies, Bleiswijk, The Netherlands). cDNA was 
synthesized with the Superscript III first-strand synthesis system for RT-PCR  
(Life Technologies) using oligo(dT) primers following protocol. 
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Sequence-based typing on RNA templates 
Samples with low resolution data available can directly be amplified with the 
corresponding group-specific primers. In samples with unknown HLA alleles,  
locus-specific amplification and sequencing is performed first. Locus-specific 
sequencing is achieved by amplification of HLA-A, -B and -C using primers located in 
the 5′ and 3′ untranslated regions (UTR) as illustrated in Figure 1A. For HLA-A the 
combination of one forward and one reverse primer amplifies all variants. For  
HLA-B and -C a combination of two forward and two reverse primers is needed to 
cover all known alleles (see wobble in primer Table 1A). Group-specific amplification is 
achieved by combining a 5′ locus-specific with a 3′ group-specific primer and a  
5′ group-specific with a 3′ locus-specific primer resulting in two overlapping amplicons 
as illustrated in Figure 1B. All primers used for this study are shown in Table 1. 
 
 
 
 
 
 
 
 
 
Figure 1 The RNA-SBT approach for HLA-A, -B and -C with individual exons indicated as blocks.  
(A): Locus-specific amplification was achieved by positioning generic locus-specific primers in the 5’ and  
3’ Untranslated Region (UTR) indicated in the figure as            . (B): Group-specific amplification was achieved 
by combining the generic locus-specific 5’ and 3’UTR primers with group-specific primers indicated as 
 …….   positioned in the exons. Three forward and three reversed sequencing primers (indicated as →) and 
amplification primers were used as sequencing primers were sufficient for full-length forward and reversed 
sequencing. 
 
 
Amplification reactions were carried out in a total volume of 30 μl, containing  
67 mM Tris–HCl (pH 8.8) (Merck, Darmstadt, Germany), 16.6 mM ammonium sulphate 
(Merck), 0.01% Tween 20 (Merck), 1.5 mM MgCl2 (Life Technologies),  
0.2 mM of each dNTP (GE Healthcare, Diegem, Belgium), 0.1 μg/μl cresol red  
(Sigma-Aldrich, St. Louis, MO), 5% glycerol (Alfa Aesar, Karlsruhe, Germany),  
15 pmol of each primer (7.5 for each split primer) (Sigma-Aldrich), 1.4 U Expand High 
Fidelity Enzyme mix (Roche, Basel, Switzerland) and 3 μl of cDNA. The cycling 
conditions consisted of an initial denaturation step of 2 min at 94oC; 10 cycles of  
15 s at 94oC, 30 s at 63oC and 4 min at 68oC; followed by 10 cycles of 15 s at 94oC, 30 s 
at 60oC and 6 min at 68oC; and 10 cycles of 15 s at 94oC, 30 s at 60oC and  
10 min at 68oC followed by a final elongation step of 7 min at 68oC. Resulting 
amplification products were checked for size on a 1.5% agarose gel with a final 
concentration of 0.5 μg/ml ethidium bromide (Sigma-Aldrich). Purification of the PCR 
products was achieved by ExoSAP-IT (Affymetrix, Santa Clara, CA) following 
manufacturers protocol.  
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Table 1 Primers used for this study. Primers 123 are modified from (20), (21) and (22), respectively. 
Location is indicated as position in the cDNA sequence. 
 
 
Subsequent bidirectional sequencing with six sequence primers resulted in the 
identification of the full-length coding sequence. The sequencing reaction was 
performed on 1 μl of the PCR product by adding 1 μl of BigDye Terminator v1.1 mix 
(Life Technologies), 1.5 μl 5× BigDye Terminator sequencing buffer (Life Technologies), 
0.5 μl sequencing primer (5 pmol) and 6 μl of water. Cycle sequencing was performed 
with 1 min at 96oC; followed by 25 cycles of 10 s at 96oC, 5 s at 50oC and 4 min at 60oC. 
After purification by Sephadex G-50 (GE Healthcare), the sequencing reaction products 
were electrophoresed on the ABI 3730 DNA analyser (Applied Biosystems, Foster City, 
USA). SEQPILOT software (version 3.5.2, JSI medical systems GmbH, Kippenheim, 
(A) HLA class I locus-specific amplification primers. 
Locus 5’ primer (5’-3’) 3’ primer (5’-3’) 
A CCAGACGCCGAGGATGGCC1 ACACAAGGCAGCTGTCTCACA1 
B CCACCCGGACTCAGARTCTC2 GCATCTCRGTCCCTCACAAGA2 
C SATTCTCCCCAGASGCCGAG3 TCACAAAGGARAGGTGTGAAGA 
 
(B) Primers for group-specific amplification. 
Allele 5’ primer (5’-3’)  Location  3’ primer (5’-3’)  Location 
A*01:37 CTCCATGAGGTATTTCTTCACA 81-102 CCTCCAGGTAGACTCTCCG 538-556 
A*01:11N GAGCCCCGCTTCAACGCC 127-144 GAGCCACTCCACGGACCG 559-576 
A*02:17:02 GAGCCCCGCTTCAACGCA 127-144 GGGCCGCCTCCCAGTTGT 506-522 
A*03:01:03 CGGAATGTGAAGGCCCAGT 265-283 CCTCCAGGTAGGCTCTCAA 538-556 
A*24:02:01:02L CCACTCCATGAGGTATTTCTC 78- 98 GACCCCACGTCGCAGCCAA 368-386 
A*24:09N CCACTCCATGAGGTATTTCTC 78- 98 GACCCCACGTCGCAGCCAA 368-386 
B*07:15 TTCCCACTCCCATTGGGTATT -113 to -93 GGAGCCACTCCACGCACTC 559-577 
B*14:06:01 CGCCGCGAGTCCGAGAGA 198-206 CTCTCAGCTGCTCCGCCT 527-544 
B*27:10 GGTCTCACACCCTCCAGAAT 344-363 CTCTCAGCTGCTCCGCCT 527-544 
B*27:17 GGAGCCCCGCTTCATCACC 126-144 CTCTCAGCTGCTCCGCCA 527-544 
B*35:42:01 CGCCGCGAGTCCGAGGAC 189-206 GCCATACATCCTCTGGATGA 353-372 
B*55:11 ACAGATCTACAAGGCCCAG 264-282 TAATCCTTGCCGTCGTAGGCT 420-440 
B*56:07 CGCCGCGAGTCCGAGAGA 198-206 TAATCCTTGCCGTCGTAGGCT 420-440 
C*03:35 ACTCCCATTGGGTGTCGGA -107 to -89 GCCTGGTCTCCACAAGCTCA 756-775 
C*04:11 GGAGGCGCCGCGTTGG -211 to -196 TCGTGCTGAACATGGCACT 845-863 
C*17:03 AGTCCAAGAGGGGAGCCG 196-213 GTCACGTGTGTCTTTGGGC 623-641 
 
(C) HLA class I sequencing primers. 
Locus Direction Primer sequence 5’-3’ Location  
A 5’ CCAGACGCCGAGGATGGCC1  -13 to 6 
 5’ TACAACCAGAGCGAGG 324-340 
 5’ CCCAGGACACGGAGC 746-760 
 3’ GCGATGTAATCCTTGCCG 429-446 
 3’ CCAGGTCAGTGTGATCT3 707-723 
 3’ ACACAAGGCAGCTGTCTCACA1 1093-1114 
B 5’ CCACCCGGACTCAGARTCTC2 -33 to -14 
 5’ GCAAGGATTACATCGCC 431-447 
 5’ CACCCTGAGGTGCTGG1 669-684 
 3’ CCTCGCTCTGGTTGTAG1 324-340 
 3’ CCAGGTCAGTGTGATCT3 707-723 
 3’ GCATCTCRGTCCCTCACAAGA2 1285-1306 
C 5’ CGAGATGCGGGTCATG -4 to 12 
 5’ GCAAGGATTACATCGCC 431-447 
 5’ CACCCTGAGGTGCTGG1 669-684 
 3’ CCTCGCTCTGGTTGTAG1 324-340 
 3’ CCAGGTCAGTGTGATCT3 707-723 
 3’ ATCAGAGCCCTGGGCAC1 1055-1071 
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Germany) was used for analysis and HLA typing. Lasergene software (DNASTAR 
Lasergene 9 Core Suite, Madison, WI) was used to align and visually inspect the 
electropherogram patterns for new and unknown exon sequences or aberrant 
sequencing results. 
 
Results 
The percentage of unknown class I exon sequences in the IMGT/HLA database (v3.15), 
reaches to about 80% for exon 1, more than 60% for exon 4 and over 80% for exons 5, 
6 and 7 (Table 2). The polymorphic index shown in Table 3, defined as the number of 
polymorphic positions of each exon over the length of that particular exon, points to a 
relatively high degree of polymorphism in the other exons. 
 
 
 
 
 
 
 
Table 2 Percentage of unknown exons in HLA class I alleles (IMGT/HLA v3.15). Exons 2 and 3 
sequences are fully known and the percentage unknown for the remaining exons is indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Polymorphic index (PI) of each individual exon. The polymorphic index is defined by the 
number of polymorphic positions (IMGT/HLA v3.15) over the length of that particular exon. 
 
  
 
 Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
HLA-A 82% 0% 0% 63% 84% 92% 92% 92% 
HLA-B 80% 0% 0% 64% 83% 91% 91% - 
HLA-C 85% 0% 0% 70% 86% 86% 91% 93% 
 
 
 HLA-A HLA-B HLA-C 
 # Polymorphic 
positions 
Exon 
length 
PI # Polymorphic 
positions 
Exon 
length 
PI # Polymorphic 
positions 
Exon 
length 
PI 
Exon 1 10 73 0.14 15 73 0.21 12 73 0.16 
Exon 2 267 270 0.99 258 270 0.96 229 270 0.85 
Exon 3 259 276 0.94 256 276 0.93 258 276 0.93 
Exon 4 152 276 0.55 119 276 0.43 89 276 0.32 
Exon 5 16 117 0.14 24 117 0.21 29 120 0.24 
Exon 6 3 33 0.09 0 33 0.00 4 33 0.12 
Exon 7 2 48 0.04 1 44 0.02 4 48 0.08 
Exon 8 0 5 0.00 - - - 1 5 0.20 
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Table 4 HLA typing of the reference panel covering the majority of antigen groups consisting of  
25 HLA-A alleles, 38 HLA-B and 30 HLA-C alleles. Moreover, two null alleles and one low expressed allele 
were included (indicated in bold). Number of samples per allele is indicated between brackets. 
 
 
Validation of the developed locus-specific RNA-SBT method was performed on a 
reference panel representing the major allele groups as shown in Table 4. This panel 
has previously been typed at allele level resolution by our in-house DNA-SBT approach 
(23). The panel included 17 out of 21 groups for HLA-A, 26 out of 35 for -B and  
13 out of 14 for -C. In addition three samples, two with null alleles: AHPEN  
(HLA-A*01:11N, 02:06:01) and IHW9422 (HLA-A*24:09N, 29:02:01) and one with a low 
expressed allele: TER268 (HLA-A*24:02:01:02L,31:01:02) were added. The length of 
the amplicons with the locus-specific primers (Table 1A) were 1127 bp for HLA-A, 1342 
bp for HLA-B and 1177 bp for HLA-C. The RNA-SBT results of the reference panel, albeit 
ambiguous for exons 2 and 3 (genotype ambiguity), were identical to the typing results 
obtained by DNA-SBT approaches. Allele ambiguities, caused by polymorphisms 
 
HLA-A HLA-B HLA-C 
*01:01:01:01 (8) *07:02:01 (7) *01:02:01 (4) 
*01:03 (1) *07:06 (1) *02:02:02 (1) 
*01:11N (1) *08:01:01 (2) *03:02:02:01 (1) 
*02:01:01 (11) *13:01:01 (1) *03:03:01 (1) 
*02:03:01 (1) *13:02:01 (1) *03:04:01 (4) 
*03:01:01 (5) *14:01:01 (1) *03:04:02 (1) 
*11:01:01 (3) *14:02:01 (1) *04:01:01:01 (3) 
*23:01:01 (1) *15:01:01 (2) *04:01:01:02 (2) 
*24:02:01 (5) *15:02:01 (1) *04:03 (1) 
*24:02:01:02L (1) *15:10:01 (1) *04:06 (1) 
*24:09N (1) *15:17:01 (2) *05:01:01 (1) 
*24:10:01 (1) *18:01:01:02 (2) *05:01:01:02 (2) 
*25:01:01 (1) *18:02 (1) *06:02:01:01 (5) 
*26:01:01 (2) *27:05:02 (1) *07:01:01 (3) 
*29:02:01 (3) *35:01:01 (3) *07:01:01:01 (4) 
*29:02:03 (1) *35:03:01 (1) *07:01:02 (1) 
*30:01:01 (2) *37:01:01 (1) *07:02:01 (3) 
*30:02:01 (1) *38:01:01 (2) *07:02:01:01 (2) 
*31:01:02 (2) *38:02:01 (1) *07:02:01:03 (4) 
*32:01:01 (2) *39:01:01 (1) *07:04:01 (2) 
*33:01:01 (1) *40:01:02 (4) *08:01:01 (1) 
*33:03:01 (1) *40:02:01 (2) *08:02:01 (2) 
*34:01:01 (1) *40:06:01:02 (1) *12:02:02 (1) 
*34:02:01 (1) *41:02:01 (1) *12:03:01 (2) 
*66:01 (1) *44:02:01 (2) *12:03:01:01 (1) 
*68:01:02 (2) *44:03:01 (2) *14:02:01 (1) 
*68:02:01 (1) *45:01 (1) *15:02:01 (2) 
*69:01 (1) *46:01:01 (1) *15:05:01 (1) 
 *47:01:01:01 (1) *16:01:01 (1) 
 *49:01:01 (2) *17:03 (1) 
 *51:01:01 (2)  
 *52:01:01 (1)  
 *53:01:01 (1)  
 *55:01:01 (1)  
 *56:01:01 (1)  
 *57:01:01 (1)  
 *58:01:01 (1)  
 *73:01 (1)  
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outside exons 2 and 3, were resolved with group-specific amplification and subsequent 
full-length sequencing. In case the unknown exon sequence information of one allele 
was identical to the other allele, locus-specific sequences for the ‘unknown exons’ 
were already indicative. 
Samples in the reference panel that possess B*73:01 and C*17:03, showed a highly 
heterozygous pattern in their electropherogram profiles using the locus-specific 
approach. Because those alleles are known to have insertions and deletions in the 
allele sequences compared to the co-expressed allele, full-length sequences have been 
obtained by group-specific amplification and subsequent sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Locus- and group-specific RNA-SBT sequencing results of AHPEN: HLA-A*01:11N, 02:06:01. 
(A): Overlapping sequences downstream position 595 caused by the nucleotide substitution at position 597 
(G>T) that leads to a splice variant defined by RNA sequencing. (B): Group-specific amplification of  
HLA-A*01:11N and HLA-A*02:06:01. The mRNA splice variant of HLA-A*01:11N has a deletion of 24 
nucleotides in exon 3 compared to the sequence of HLA-A*02:06:01. Only forward sequencing is illustrated. 
 
 
A number of alleles having an aberrant expression profile was included in this study. 
HLA-A*01:11N has a synonymous substitution at position 597 (G>T) which introduces 
an alternative splice site that causes a deletion of the last 24 nucleotides of exon 3 
(24). This polymorphism does not affect the mRNA expression level and the allele was 
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directly identified with the locus-specific RNA-SBT approach. The resulting 
electropherogram of this sample, illustrated in Figure 2A, indicated overlapping 
sequences downstream of position 595 caused by the substitution at position 597 
complicating the sequence interpretation. Group-specific amplification resulted in the 
identification of the deletion in the HLA-A*01:11N allele of the last 24 nucleotides of 
exon 3 and the full-length sequence of the co-expressed HLA-A*02:06:01 allele as 
shown in Figure 2B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Group-specific sequencing results of alleles with an aberrant expression profile.  
(A): Part of exon 2 full-length group-specific sequencing result of both HLA-A*24:02:01:02L, 31:01:02 alleles 
of sample TER268. (B): Part of exon 2 sequences of both alleles of sample IHW9422 (HLA-A*24:09N, 
29:02:01) obtained by group-specific amplification and sequencing. Only forward sequencing is illustrated. 
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Locus-specific sequencing of two samples, HLA-A*24:09N, 29:02:01 and  
HLA-A*24:02:01:02L, 31:01:02 resulted in a significantly reduced mRNA expression 
level of the aberrantly expressed alleles which were identified with the  
group-specific amplification approach. This allowed the unambiguous identification of 
these low expressed and null alleles as shown in Figure 3A and B, respectively. 
To test the applicability of the technique to obtain full-length cDNA sequences for 
those alleles that were not yet completely sequenced for all exons, 13 individuals 
(three HLA-A, 7 -B and 3 -C) with incomplete full-length allele sequences according to 
the IMGT/HLA database (v3.15), were encountered in routine DNA-SBT diagnostics. 
PBMC’s of those 13 individuals were used for full-length group-specific RNA-SBT 
sequencing which resulted in the identification of all exons. Results were submitted to 
the EMBL and IMGT/HLA databases and assigned as confirmatory sequences by the 
World Health Organization (WHO) Nomenclature Committee (25, 26). The EMBL 
accession and IMGT/HLA submission numbers are shown in Table 5. Sequence results 
did not show additional polymorphisms in the unknown exons compared to the known 
alleles found in the IMGT/HLA database (v3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 Alleles with incomplete sequences encountered in routine diagnostics. EMBL accession 
numbers and IMGT submission numbers are shown. 
 
Discussion 
The high degree of HLA polymorphism is an ongoing challenge for the unambiguous 
identification of the alleles. Current HLA typing approaches are mainly focussed on the 
identification of polymorphism in exons 2 and 3. By calculating the polymorphic index 
of the remaining exons, shown in Table 3, it became clear that the exons outside exons 
2 and 3 also display a relatively high degree of polymorphism. 
 
  
Allele 
 
Compared to 
EMBL 
Accession number 
IMGT 
Submission number 
HLA-A *01:37 *01:01:01:01 HG327116 HWS10020123 
 *02:17:02 *02:01:01:01 HG327118 HWS10020139 
 *03:01:03 *03:01:01:01 HG327114 HWS10020119 
HLA-B *07:15 *07:02:01 HG514457 HWS10021550 
 *14:06:01 *14:01:01 HG327121 HWS10020133 
 *27:10 *27:02:01 HG327122 HWS10020131 
 *27:17 *27:02:01 HG327115 HWS10020121 
 *35:42:01 *35:01:01:01 HG327120 HWS10020135 
 *55:11 *55:01:01 HG327117 HWS10020125 
 *56:07 *56:01:01 HG327119 HWS10020137 
HLA-C *03:35 *03:02:02:01 HG974570 HWS10022845 
 *04:11 *04:01:01:01 HG974569 HWS10022843 
 *17:03 *17:01:01:01 HG514458 HWS10021548 
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The SBT method based on RNA templates can be applied on individual PBMC samples 
encountered in routine diagnostics and has the advantage of a short sequence length 
of the coding region. However, the group-specific approach has the disadvantage that 
allele groups can only be selected based on known (low resolution) typing data. 
Nevertheless, when alleles are encountered by DNA typing in routine diagnostics that 
have unknown exons according to the IMGT/HLA database, full-length unambiguous 
sequences are generated by group-specific amplification and subsequent sequencing. 
Improved RNA isolation procedures allow the application of this method on either 
fresh or frozen peripheral blood mononuclear cells from clinical samples. Preliminary 
evidence indicates that RNA can be isolated from dried blood spots (27), buccal 
epithelial cells (28) or sputum (29) with commercially available RNA isolation kits. This 
broadens the applicability of the RNA approach and will provide full-length coding 
sequences once alleles with incomplete allele sequences are encountered in routine 
(DNA) diagnostics. 
Another advantage of the RNA-SBT approach is that aberrantly spliced alleles are 
identified. Alternative splicing of HLA-G mRNA leads to the formation of at least four 
membrane-bound and three soluble isoforms (30, 31). It is suggested that these HLA-G 
variants play a role in immune regulation in pregnancy (32). Norgaard et al. (1999) 
identified four different alternatively spliced HLA-A transcripts, each missing or 
including exons 2, 3 and/or 4 (33). Alternative splicing can also lead to the complete 
deletion of an exon as is the case in the HLA-B*44:02:01:02S allele or elongation of the 
transcript as in HLA-C*04:09N. HLA-B*44:02:01:02S has a splicing mutation leading to 
a complete deletion of exon 5, the transmembrane part of the molecule, resulting in 
the formation of a soluble HLA molecule (34). HLA-C*04:09N has an inclusion of  
32 amino acid residues at the end of its cytoplasmic domain leading to the formation 
of this null allele (35). Interestingly, 3′UTR polymorphism is involved in regulating the 
immune response by microRNAs as shown by Kulkarni et al. (2011). They showed that 
a particular HLA-C 3′UTR polymorphism determines the binding of a particular 
microRNA (Hsa-miR-148a) to its target which regulates the HLA-C surface expression 
and is associated with the control of human immunodeficiency virus (HIV) (36). 
Null and low expressed alleles can be characterized in routine HLA DNA typing 
techniques based on their specific polymorphism. However, synonymous substitutions 
may lead to alternative spliced alleles that can only be identified by RNA sequencing as 
shown for the HLA-A*01:11N allele (24). DNA sequencing would classify the 
polymorphism present in this allele as synonymous, GGG to GGT both encoding for the 
amino acid glycine. RNA sequencing identified this null allele by showing an 
alternatively spliced mRNA form (24). 
The aberrantly expressed HLA alleles of samples with the genotype,  
HLA-A*24:02:01:02L, 31:01:02 and HLA-A*24:09N, 29:02:01, are characterized by a 
low mRNA expression level and were included in this study (37). Since, the 
interpretation of the heterozygous RNA-SBT data in samples including a null or low 
expressed allele, due to a low mRNA expression, might lead to the conclusion of 
homozygosity of the sample for the other expressed allele. It is a common practice, 
especially in the case of confirming homozygosity, to repeat the typing  
(EFI standards version 6.1), preferentially with another technique. Because DNA typing 
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will identify the null allele, according our strategy, this allele can subsequently be 
amplified with the group-specific RNA-SBT approach. 
The results of this study provide a straightforward approach for the identification of 
full-length allele polymorphism using mRNA templates to define the relevance of 
extended polymorphism. 
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Abstract 
Currently 1582 HLA-DRB1 alleles have been identified in the IMGT/HLA database 
(v3.18). Among those alleles, more than 90% have incomplete allele sequences, which 
complicates the analysis of the functional relevance of polymorphism beyond exon 2. 
The polymorphic index of each individual exon of the currently known allele 
sequences, shows that polymorphism is present in all exons, albeit not equally 
abundant. Full-length HLA-DRB1 RNA sequencing identifies polymorphism of the 
complete coding region. Here we describe a hemizygous full-length RNA  
sequence-based typing approach based on group-specific HLA-DRB1 amplification and 
subsequent sequencing. RNA full-length sequences can easily be accessed because of 
the short amplicon length (801 bp). The RNA-SBT approach was successfully validated 
to a panel of DRB1 alleles having fully known coding sequences according to the 
IMGT/HLA database, and cover all serological equivalents. Subsequently, the approach 
was applied on a panel of 54 alleles with incomplete allele sequences, resulting in  
full-length coding sequences and the identification of one new and one corrected 
allele. This study shows the universal applicability of the RNA-based sequencing 
approach to identify full-length coding sequences and to define the polymorphic 
content of HLA-DRB1 alleles. 
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Introduction 
The human leukocyte antigen (HLA) genes are the most polymorphic in the human 
genome, resulting in the identification of 12,406 different alleles (IMGT/HLA v3.18) (1). 
HLA alleles are clustered in classical HLA class I genes (HLA-A, -B and -C) and class II 
genes (HLA-DR, -DQ and -DP), based on their structural and functional differences (2). 
The HLA class II surface molecule consists of two chains, α and β, each encoded by 
their individual genes, A and B. The peptide binding groove of HLA-DR is formed by the 
low polymorphic α-chain and the high polymorphic β-chain, which focussed the 
attention to the identification of polymorphism in exon 2 of the HLA-DRB1 gene. 
HLA-DRB1 diversity of exon 3 was shown in a study of the 14th IHIWS workshop (3), in 
which exon 3 sequences of 42 different HLA-DRB1 alleles were completed by 
amplification and subsequent sequencing the target DNA. The data showed that exon 
3 was more polymorphic than previously expected. This study also showed that four of 
six samples previously typed as HLA-DRB1*14:01 appeared to be HLA-DRB1*14:54 (3). 
Also in other studies, it has been shown that DRB1*14:54 is more frequent than 
DRB1*14:01 (4, 5). Therefore, the Common and Well Documented (CWD) database 
listed the HLA-DRB1*14:54 allele as common, indicating that high-resolution typing of 
all exons is required for an appropriate CWD allele definition (6). Molecular modelling 
showed that the nonsynonymous polymorphism in exon 3, that distinguishes  
HLA-DRB1*14:54 from DRB1*14:01, has a minimal impact on allorecognition (4, 5), 
whereas in vitro assays showed no primary mixed lymphocyte culture response (7), 
both implicating that DRB1*14:54 is compatible with DRB1*14:01 in stem cell 
transplantation. The importance of exon 1 has been shown for HLA-DRB1*12:01 and 
HLA-DRB1*12:10 which differ in a single nucleotide present in exon 1. The functional 
role of leader peptides, in HLA encoded by exon 1, has been studied in multiple classes 
of proteins produced via the ribosome and includes among others, correct processing 
and assisting the folding and stabilization of the pro-peptide (8). The functional effect 
of polymorphism in other HLA-DRB1 exons remains largely unknown. 
Full-length DRB1 RNA sequencing defines the polymorphic content of the complete 
HLA-DRB1 coding sequence. DNA-based sequence approaches are hampered by a long 
and variable intron 1 with a length varying between approximately 5 and  
10 kb. In a study addressing the complete HLA-DRB1 coding sequence, 40 single 
nucleotide polymorphisms (SNP) were identified outside exon 2 in 22 HLA-DRB1 alleles 
with partially known allele sequences (9). This study also indicated a higher 
polymorphic content outside the HLA-DRB1 exon 2 than previously expected. 
For class I, RNA templates have been shown to be valuable in the identification of 
unknown polymorphism in partially known HLA allele sequences (10).  
The advantage of a RNA Sequence-Based Typing (SBT) approach for HLA-DRB1 is the 
short amplicon length of 801 bp, that can be fully sequenced by five sequencing 
primers, including four primers that are also used as amplification primers and one 
single additional specific sequencing primer. Santamaria et al. (1992) developed an SBT 
approach focussed on the identification of exon 2 polymorphism by sequencing mRNA 
templates (11). Full-length HLA-DRB1 RNA sequencing was accomplished since 2005, 
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combining a locus-specific primer in the 5′ untranslated region (UTR) with a  
group-specific primer in the 3′UTR, although the approaches were limited to certain 
allele groups and required cloning procedures for the separation of some alleles  
(9, 12, 13). 
Here, we describe a universally applicable hemizygous RNA Sanger sequencing 
approach for HLA-DRB1. Group-specific hemizygous full-length sequences are 
generated by combining two overlapping amplification reactions. This approach allows 
the identification of full-length allele sequences for partially known HLA-DRB1 alleles in 
routine clinical practice. 
 
Material and methods 
Sample panels 
The reference panel used for validation of the method consists of 13 samples,  
5 peripheral blood mononuclear cells (PBMC) samples and 8 cell lines (obtained from 
the Terasaki UCLA B-cell line exchange program), selected based on covering the 
serological HLA-DR antigen groups and having alleles with known full-length allele 
coding sequences (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Reference panel of alleles having full-length coding allele sequences and representing the 
HLA-DR serological groups (IMGT/HLA v3.18). 
 
 
Subsequently, the RNA-SBT approach was applied on a panel of 54 HLA-DRB1 alleles 
(Table 2) having partial allele sequences in the IMGT/HLA database (v3.18). These 
alleles were encountered in our routine diagnostic samples (n=7) and cell lines from 
the Terasaki UCLA B-cell line exchange program (n=45). 
PBMC were isolated from 5 ml EDTA blood using Lymphoprep (Axis-Shield, Oslo, 
Norway) and used for subsequent RNA isolation. B-cell lines were cultured in  
Sample ID Reference 
HLA-DRB1 allele 
TER161 *01:01:01 
KG01 *03:01:01:01 
TER140 *04:04:01 
TER364 *07:01:01:01 
KG02 *08:03:02 
TER158 *09:01:02 
TER246 *10:01:01 
TER241 *11:01:02 
KG03 *12:01:01 
KG04 *13:02:01 
KG05 *14:54:01 
TER301 *15:01:01:01 
TER262 *16:02:01 
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RPMI-1640 (Gibco, Life Technologies, Bleiswijk, the Netherlands) containing 15% FCS 
(Gibco) and 2% Penstrep (Gibco). 
RNA isolation and cDNA synthesis 
Approximately, 5 × 106 cells were used for total RNA isolation using the RNeasy minikit 
(Qiagen, Hilden, Germany) following the manufacturer’s protocol.  
RNA quality was determined by measuring the A260/280 ratio on the NanoDrop  
ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE). To ensure the 
removal of any residual DNA, a DNase step was performed by deoxyribonuclease I 
treatment (Life Technologies). Subsequently, cDNA was synthesized using the 
Superscript III first-strand synthesis system for reverse transcription polymerase chain 
reaction (RT-PCR) (Life Technologies) with oligo(dT) primers following manufacturer’s 
protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Panel of 54 alleles having partial allele sequences (IMGT/HLA v3.18). The sequence part that 
was not yet known was compared with the allele equivalent indicated. EMBL accession and IMGT/HLA 
submission numbers are shown. Resulting sequences were assigned as confirmatory sequences by the WHO 
Nomenclature Committee. New and corrected allele are indicated in bold. 
 
  
Allele Compared  
with 
Sample 
ID 
EMBL IMGT/HLA Allele Compared 
with 
Sample 
ID 
EMBL IMGT/HLA 
*03:04:01 *03:01:01:01 TER336 LM611904 HWS10023969 *11:14:01 *11:01:01 TER457 HG974584 HWS10023531 
*03:07 *03:01:01:01 TER459 LN623522 HWS10024463 *11:19:01 *11:01:01 TER408 HG974591 HWS10023535 
*03:15 *03:01:01:01 TER317 LK391773 HWS10023222 *11:21 *11:01:01 TER435 HG974598 HWS10023549 
*04:03:02 *04:01:01 TER337 HG974599 HWS10023551 *11:29 *11:01:01 TER428 HG974578 HWS10023521 
*04:14 *04:01:01 TER464 HG974603 HWS10023965 *13:03:01 *13:01:01 TER434 HG974572 HWS10023517 
*04:15 *04:01:01 TER394 HG974575 HWS10023519 *13:04 *13:01:01 KG09 HG974577 HWS10022990 
*04:16 *04:01:01 TER260 HG974594 HWS10023541 *13:06 *13:01:01 TER406 LK391775 HWS10023226 
*04:25 *04:01:01 KG06 HG974573 HWS10022984 *13:08 *13:01:01 TER332 HG974595 HWS10023543 
*04:26 *04:01:01 TER423 HG974593 HWS10023539 *13:10 *13:01:01 TER382 HG974587 HWS10024565 
*04:31 *04:01:01 TER287 HG974581 HWS10023525 *13:11:01 *13:01:01 TER321 LK391774 HWS10023224 
*04:32 *04:01:01 TER475 HG974580 HWS10023523 *13:14:02 *13:01:01 TER445 LK391781 HWS10024559 
*07:04 *07:01:01:01 TER454 HG974601 HWS10024573 *13:17 *13:01:01 TER351 HG974589 HWS10024569 
*08:77 New allele TER181 LN854575 HWS10025381 *13:20 *13:01:01 TER440 HG974582 HWS10023527 
*08:04:01 *08:01:03 TER473 LK391782 HWS10023513 *13:26:01 *13:01:01 KG10 HG974571 HWS10022982 
*08:06 *08:01:03 TER444 LK391780 HWS10024557 *13:36 *13:01:01 TER446 HG974583 HWS10023529 
*08:07 *08:01:03 TER323 HG974592 HWS10023537 *14:02:01 *14:03:01 TER490 LK391784 HWS10023515 
*08:10 *08:03:02 TER468 HG974605 HWS10024577 *14:06:01 *14:03:01 TER411 LK391776 HWS10023228 
*08:11 *08:01:03 TER324 HG974588 HWS10024567 *14:08 *14:54:01 KG11 HG974576 HWS10022988 
*08:14 *08:03:02 TER334 HG974604 HWS10024575 *14:10 *14:54:01 TER422 LK391779 HWS10024555 
*08:16 *08:01:03 TER369 LK391772 HWS10023220 *14:14 *14:54:01 TER235 LK391778 HWS10023509 
*08:35 *08:03:02 KG07 LK391783 HWS10023214 *14:17 *14:03:01 TER479 HG974602 HWS10023971 
*11:05 *11:01:01 TER315 HG974586 HWS10024563 *14:21 *14:03:01 TER282 LK391771 HWS10023218 
*11:06:01 *11:01:01 KG08 HG974579 HWS10022992 *14:24 *14:03:01 TER411 LK391777 HWS10023511 
*11:08:02 *11:01:01 TER427 HG974597 HWS10023547 *15:02:02 *15:01:01:01 TER332 HG974596 HWS10023545 
*11:09 *11:01:01 TER328 HG974590 HWS10023533 *15:07:01 *15:01:01:01 TER291 HG974600 HWS10024571 
*11:11 Corrected allele TER144 LN830949 HWS10025227 *16:04 *16:01:01 TER330 HG974585 HWS10024561 
*11:13:02 *11:01:01 TER363 LM611905 HWS10023967 *16:07 *16:01:01 KG12 HG974574 HWS10022986 
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Figure 1 The RNA-SBT approach for HLA-DRB1 with blocks depicting the individual exons.  
Group-specific amplification was achieved by combining DRB-specific primers positioned in the 5′ and 
3′ untranslated regions indicated in the figure as , with group-specific 5′ and 3′ primers positioned in 
exons 2 or 3 illustrated as , resulting in two overlapping amplification reactions. Full-length bidirectional 
hemizygous sequencing was performed using the amplification primers as sequence primers with one 
additional sequencing primer (indicated as →). 
 
PCR amplification and sequence-based typing 
HLA-DRB1 group-specific RNA-SBT can be applied based on earlier low or  
high-resolution DNA typing results. Allele group-specific hemizygous full-length 
sequences are established by two overlapping amplification reactions (Figure 1). These 
are achieved by combining an HLA-DRB-specific primer in the 5′UTR with a  
3′ group-specific primer (Table 3A) in exons 2 or 3 and a group-specific 5′ primer in 
exon 2 with an HLA-DRB-specific primer in the 3′UTR, ensuring a sufficient overlap 
between the two fragments. To establish one universal amplification protocol, some  
5′ group-specific primers were newly designed or taken from previous studies (14), all 
3′ primers were newly designed for this study, as indicated in Table 3  
(S1, Supporting Information, PDF). For samples with two alleles from the same allelic 
group or two alleles from highly homologous allelic groups, e.g. HLA-DRB1*15 and 
HLA-DRB1*16, that cannot be discriminated with the group-specific primer, separation 
is achieved by combining the DRB-specific primer with an allele-specific primer 
designed to amplify the required allele. For instance, for DRB1*03:07 (TER459: 
DRB1*03:07, *13:01:01), allele-specific primers are required because both alleles 
belong to the DRB1*03/11/13/14 group (Figure 2). The sequences of both alleles have 
been aligned based upon the available IMGT/HLA database sequences for exons 2 and 
3. According to this alignment, allele-specific primers for DRB1*03:07 are designed in a 
way that DRB1*13:01:01 is not co-amplified. These tailored allele-specific primers are 
combined with the DRB-locus-specific primers in the 5′ and 3′UTR in the same way as 
the group-specific primers described in Table 3, resulting in the full-length  
allele-specific nucleotide sequence of the HLA-DRB1*03:07 allele. 
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Table 3 Primers used for hemizygous full-length RNA sequencing of DRB1. (A) HLA-DRB1  
group-specific amplification primers. (B) Generic forward sequencing primer located in exon 3. Location is 
indicated as the position in the cDNA sequence according to the IMGT/HLA database. 
 
 
PCR amplification was performed according to previously described SBT protocols  
(10, 15). In detail, amplification was carried out in a volume of 30 μl, consisting of 
67mMTris–HCl (pH 8.8) (Merck, Darmstadt, Germany), 16.6mM ammonium sulphate 
(Merck), 0.01% Tween 20 (Merck), 1.5mM MgCl2 (Life Technologies), 0.2mM of each 
dNTP (GE Healthcare, Diegem, Belgium), 0.1 μg/μl cresol red (Sigma-Aldrich, St. Louis, 
MO), 5% glycerol (Alfa Aesar, Karlsruhe, Germany), 15 pmol of each primer  
(Sigma-Aldrich), 1.4U expand high fidelity enzyme mix (Roche, Basel, Switzerland) and 
3 μl of sample cDNA. The PCR cycling steps were composed of an initial denaturation 
step of 2 min at 94oC followed by 10 cycles of 15 s at 94oC, 30 s at 63oC, 4min at 68oC; 
10 cycles of 15 s at 94oC, 30 s at 60oC, 6 min at 68oC and 10 cycles of 15 s at 94oC, 30 s 
at 60oC, 10 min at 68oC, and a final elongation step of 7 min at 68oC. PCR amplification 
products were visualized on a 1.5% agarose gel with a final concentration of 0.5 μg/ml 
ethidium bromide (Sigma-Aldrich). PCR products were purified using ExoSAP-IT 
(Affymetrix, Santa Clara, CA), according to manufacturer’s protocol. 
 
  
 
(A) 
DRB1 allele group 5’ primer (5’-3’)  Location 3’ primer (5’-3’)  Location 
*01 CTTGTGGCAGCTTAAGTTTGAAT1 108-130 CAGGGTCTGGAAGGTCCAA 542-561 
*03 (+*11/*13/*14) GTTTCTTGGAGTACTCTACGTC1 104-125 GTAGTTGTGTCTGCAGTAGT 317-336 
*04 GTTTCTTGGAGCAGGTTAAAC1 104-124 TGTGAGAGGGCTCGTCAG 625-642 
*07 TCCTGTGGCAGGGTAAGTATA1 107-127 GGCGACAGGCCGCCCT 246-261 
*08 (+*12) AGTACTCTACGGGTGAGTGTT1 113-133 CTGCAGTAGGTGTCCACCA 308-326 
*09 CGTTTCTTGAAGCAGGATAAGTT1 103-125 CTCAGGATGGACTCGCCT 364-381 
*10 CGGTTGCTGGAAAGACGCG 161-178 CCCCACGTCGCTGTCGT 206-222 
*11 (+*03/*13/*14) GTTTCTTGGAGTACTCTACGTC1 104-125 TGGCTGTTCCAGTACTCCT 260-278 
*12 (+*08) AGTACTCTACGGGTGAGTGTT1 113-133 TTATGGAAGTGTCTCTCCAGT 165-185 
*13 (+*03/*11/*14) GTTTCTTGGAGTACTCTACGTC1 104-125 CCACCGCGGCCCGCTC 298-313 
*14 (+*03/*11/*13) GTTTCTTGGAGTACTCTACGTC1 104-125 TGTTCCAGTGCTCCGCAG 257-274 
*15 (+*16) TTCCTGTGGCAGCCTAAGAGG1 106-126 GCTGGGTCTTTGAAGGATAT 390-409 
*16 (+*15) TTCCTGTGGCAGCCTAAGAGG1 106-126 GCTGGGTCTTTGAAGGATAT 390-409 
 
(B) 
Sequencing primer (5’-3’)  Location 
TCCAGGCAGCATTGAAGTC 456-474 
 
1 primers are derived from (14). 
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Figure 2 Primer design strategy for allele-specific amplification of DRB1*03:07 in an individual typed 
DRB1*03:07, DRB1*13:01:01; both alleles belonging to the DRB1*03/11/13/14 allelic group.  
For the separation of these highly homologous alleles, tailored primers are designed, located at specific 
nucleotide differences between these alleles. Forward primer 1, with DRB1*03:07-specific nucleotides at 
positions 294 & 295, is combined with the DRB-locus-specific 3′ untranslated regions (UTR) reverse 
amplification primer. Reverse primer 2, with DRB1*03:07-specific nucleotide at position 423, is combined 
with the 5′UTR DRB-locus-specific forward primer. – indicates nucleotide identical to DRB1*03:07; an | 
indicates exon border. 
 
 
Subsequent Sanger sequencing was performed as previously described (10, 15). 
Bidirectional sequencing was achieved using the amplification primers as sequencing 
primers and an additional forward sequencing primer positioned in exon 3 was used 
for full-length coverage (Table 3B). Cycle sequencing of 1 μl of PCR product was 
performed using the BigDye Terminator (Life Technologies) chemistry on an ABI 3730 
DNA analyser (Applied Biosystems, Foster City, CA) according to manufacturer’s 
instructions. 
After visual inspection and editing of the electropherograms the SeqPilot software 
(version 3.5.2, JSI medical systems GmbH, Kippenheim, Germany) was used for analysis 
and HLA allele assignment, whereas Lasergene software  
(DNASTAR Lasergene 9 Core Suite, Madison, USA) was used for alignments. 
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Results 
Polymorphic index 
The IMGT/HLA database version 3.18 reports 1582 HLA-DRB1 allele sequences based 
on known exon 2 sequences. However, only 13% of these alleles have known exon 3 
sequences and this percentage decreases further with additional exons, as only 7% 
have also known exons 1 and 4 sequences, and 6% exons 5 and 6. The polymorphic 
content of the individual exons is calculated and presented as the Polymorphic Index 
(PI) (Table 4), which is the number of polymorphic positions over the length of a 
particular exon. 
 
 
 
 
 
 
 
 
 
 
Table 4 The Polymorphic Index (PI) of each individual exon calculated based on the currently known 
allele sequences (IMGT/HLA v3.18). 
 
 
As expected, exon 2 displays the highest degree of polymorphism (PI=0.89), because it 
encodes part of the peptide binding groove which is related to present a wide 
spectrum of different peptides. The PI of the remaining exons, as far as sequences are 
known, indicated a high degree of polymorphism dispersed among the different exons 
with exons 3 and 5 having a PI of 0.11 and 0.13, respectively. 
 
Validation of hemizygous RNA-SBT method 
The HLA-DRB1 group-specific amplification and subsequent sequencing approach was 
successfully validated on a reference panel of HLA-DRB1 alleles covering the 
serological DR antigen groups and having fully known coding region sequences. For all 
13 samples, the RNA-SBT results were identical to the full-length DNA exon sequences 
known in the IMGT/HLA database. These results show that this uniform RNA-SBT 
protocol provides reliable group-specific full-length hemizygous HLA-DRB1 sequences 
for all HLA-DRB1 allele groups. 
  
 Polymorphic 
positions 
Exon 
length 
PI 
Exon 1 9 100 0.09 
Exon 2 239 270 0.89 
Exon 3 32 282 0.11 
Exon 4 6 111 0.05 
Exon 5 3 24 0.13 
Exon 6 0 14 0.00 
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Full-length coding sequences by hemizygous RNA-SBT 
The RNA-SBT approach was applied on a panel of 54 alleles that have partial allele 
sequences in the IMGT/HLA database (v3.18). Resulting sequences were compared 
with their allele equivalent (see Table 2), that has a fully known allele coding sequence. 
For instance, when HLA-DRB1*14:17 was compared with the full-length sequence of 
HLA-DRB1*14:01:01, DRB1*14:17 has two new exon 3 polymorphisms, one 
nonsynonymous change at position 421 (TAC>CAC; Tyr>His) and a synonymous 
polymorphism at position 429 (CTG>CTC). However 421C is present in all alleles of the 
DRB1*14 group except DRB1*14:01:01. Furthermore, 429C is present in 9 of the 27 
DRB1*14 alleles with known exon 3 sequences. Apparently, DRB1*14:17 is more 
similar outside exon 2 to DRB1*14:03:01 than to DRB1*14:01:01 and therefore 
DRB1*14:03:01 was used as allele equivalent for DRB1*14:17. 
The full-length analysis and comparison resulted in the identification of one new and 
one corrected allele (new: HLA-DRB1*08:77 and corrected: HLA-DRB1*11:11). The 
other 52 alleles were shown to have identical sequences beyond exon 2 compared 
with their allelic group equivalents. 
The new HLA-DRB1*08:77 allele was identified in a sample with the unusual  
DR8-DRB3 haplotype (HLA-A*01, 26; B*08, 41; C*07, 17; DRB1*03:01:01, 08:77; 
DRB3*01:01, 02:02:01; DQA1*04:01:01, 05:01:01; DQB1*02:01:01, 04:02). Regular 
HLA typing by exon 2 DNA sequencing of this sample showed the presence of 
DRB1*08:01, either 08:01:01 or 08:01:03, whereas RNA sequencing showed an ‘A’ at 
position 97 (exon 1), which identified the allele as HLA-DRB1*08:01:03 (Table 5). 
However, with RNA sequencing two nucleotide differences with DRB1*08:01:03 were 
observed; one in exon 4 at position 654 (T654A; Ser189Arg) and one in exon 5 at 
position 785 (C785G, Thr233Arg). Because these nucleotides and amino acids were 
also present in the DRB3-associated DRB1 alleles (03/11/12/13/14), the new DRB1*08 
allele was thought to originate from a recombination event between DRB1*08:01:03 
and one of the DRB3-associated DRB1 alleles, which might also explain the presence of 
DRB3 on this haplotype. To investigate this possibility, the full-length sequence from 
exon 2 to the 3′UTR was determined for this new allele and compared with the  
DRB3-associated DRB1 alleles of which full-length sequences were known, as well as 
the DRB1*08:03:02 allele. The latter allele is the only DRB1*08 allele of which  
full-length sequences are known and therefore full-length sequencing of two 
additional samples, previously typed DRB1*08:01:03, was also performed for 
comparison. Because no DRB1*08:01:01 positive individual was available, we used the 
Madura cell line in which DRB1*08:01:01 was originally identified, as a reference for 
this allele, but sequencing exon 1 showed the presence of DRB1*08:01:03 instead of 
DRB1*08:01:01 and therefore this cell line could not be used as reference for  
full-length sequence of DRB1*08:01:01. Table 5 shows the comparison of nucleotides 
present at illustrative polymorphic positions of the new DRB1*08:77 allele, 
DRB1*03:01:01, 11:01:01, 12:01:01, 13:01:01, 14:54:01, 08:03:02 and the two samples 
with DRB1*08:01:03. From the comparison it is clear that the new DRB1*08 allele is a 
recombination of DRB1*08:01:03 and a DRB1*11 allele, with crossover point located 
somewhere between position 7277 and 7405 in intron 2. Because the sequences of the 
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three DRB1*11 alleles, of which full-length sequences are known, are identical from 
position 7405 to the end of the 3′UTR, it cannot be determined which DRB1*11 allele is 
involved. 
Three different DRB1*11:11 alleles are known: 11:11:01, 11:11:02 and 11:11:03. RNA 
sequencing of DRB1*11:11 from Ter-144, which is known as reference cell for 
DRB1*11:11:01, showed an exon 2 sequence identical to DRB1*11:11:01 and 11:11:02, 
but the exon 1 sequence showed a mismatch with both the DRB1*11:11:01 at position 
97 (C97A) and DRB1*11:11:02 at position 14 (A14G) (Figure 3). At this latter position 
the sequence of DRB1*11:11:01 is unknown. Since the European Molecular Biology 
Laboratory (EMBL) entries of DRB1*11:11:01 and 11:11:02 did not match the IMGT 
sequences, the here reported DRB1*11:11 sequence is accepted as correction of the 
DRB1*11:11:01, whereas the DRB1*11:11:02 seems to be identical and will therefore 
be deleted. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Parts of the forward exon 1 sequence of the corrected HLA-DRB1*11:11 allele compared with 
the DRB1*11:11:01 and *11:11:02 sequence as present in the IMGT/HLA database (v3.18). In red blocks are 
nucleotide positions 14 and 97, that are discrepant with the known sequences. * indicates unknown 
sequence. 
 
 
The remaining 52 full-length coding sequences of the tested alleles (Table 2), were 
submitted as extended sequences to the EMBL and IMGT/HLA databases and assigned 
as confirmatory sequences by the WHO Nomenclature Committee (16). 
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Discussion 
Here we describe a validated RNA-based HLA-DRB1 group-specific hemizygous 
sequencing approach using one universally applicable PCR protocol. Among the  
HLA-DRB1 alleles, 1582 have been identified, with more than 90% having incomplete 
sequences. Of the 54 alleles collected for this study with partially known allele 
sequences, 43 are listed in the CWD HLA allele database version 2.0.0  
(24 Well Documented and 19 Common) (6, 17), showing that not only rare alleles have 
incomplete exon sequences. The method described in this study enables unambiguous 
identification of full-length coding sequences required to study the function of 
polymorphism outside exon 2 and to redefine the common CWD alleles. Furthermore, 
the approach is applicable on RNA isolated from PBMC’s and cell lines, and was 
positively tested on RNA isolated from sputum using the DNAGenotek (Kanata, 
Ontario, Canada) Oragene RNA collection kits (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6 Separation of HLA-DRB1*03/11/13/14 alleles based on polymorphic positions 423 and 429 in 
exon 3 (IMGT/HLA v3.18). 
 
 
The unusual DRB1*08:77, DRB3*02:02 association that we detected in one individual 
was previously identified on three separate occasions in individuals with different HLA 
haplotypes (18–20). In two of the three studies, a recombination event of DRB1*08 
with a DRB3 positive haplotype (DRB1*03/11/12/13/14) has been suggested as origin 
for the unusual association, but in neither of them extended sequencing was 
performed to unravel the recombination event (19, 20). In a third study, cDNA 
sequencing showed a difference between the 3′UTR sequence of DRB1*08:02 and 
08:03 (18). In this paper, we have resolved the complete coding sequence as well as 
the non-coding sequence from exon 2 to the 3′UTR of the DRB1*08 allele associated 
with the DRB3*02:02 and identified that the new allele is a combination of a 
DRB1*08:01:03 allele and a DRB1*11 allele. In the past, the DR8 allele group has been 
described as a sublineage within the DRB3-associated DRB1 lineage, that was 
Position 423 429 
DRB1 allele group   
03:01:01/02/23, 03:04/06/07/10/15/55/116 
T C 
03:01:08, 03:02/115 
11:01/02/03/04/05/06/08/09/11/12/14/15/17/18/19/21/27/29/31/32/34/35/39/46/70/
97/129/154/169N/170/171/176 
13:01/02/03/04/05/06/10/11/12/14/17/19/20/21/26/27/29/36/56/87/113N/117/185N/
190/192/194 
14:02/03/06/13/17/21/24/46/144 
C C 
11:13/149 
13:08 
14:01/04/05/07/08/10/11/14/54/57/82/137N/141/152N 
C G 
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generated by a deletion of the region between the 3′ ends of the HLA-DRB1 and the 
HLA-DRB3 gene (21–23). The here described DR8 variant with DRB3*02:02 on the 
same haplotype could therefore either be the lost remnant of the ancient DR8 lineage, 
still bearing the DRB3 gene, or it could be the result of a single recombination event 
combining the centromeric end of the DQ4-DR8 haplotype with the telomeric end of 
the DR11–DRB3 haplotype. 
Comparing the exons 3–6 sequences of the different allele groups, both in the IMGT 
database as well as in our samples, there are only a few alleles that show nucleotide 
differences within the allele group in these exons. The only exceptions are exon 3 of 
the DRB3 associated alleles and exon 5 of the DRB1*08 allele group. Within the DRB3 
associated DRB1 alleles, we have analysed three DRB1*03, 10 DRB1*11, 11 DRB1*13 
and 8 DRB1*14 alleles. In exon 3, two SNPs are present within these allele groups, one 
at position 423 (T/C) and one at position 429 (C/G). The separation of all alleles with 
known exon 3 sequences for these allele groups according to these SNPs is shown in 
Table 6. All three DRB1*03 alleles showed a T at 423, confirming this DRB1*03-specific 
SNP. In all DRB1*11 and *13 alleles, a C at position 429 was identified, except for 
DRB1*11:13:02 and DRB1*13:08, confirming a G at this position (3). For the DRB1*14 
alleles, either a C or a G was present at position 429, the sequences of the alleles with 
a C were compared with the DRB1*14:03:01 allele, whereas the alleles with a G were 
compared with DRB1*14:54:01 (Table 2). The C/G polymorphism at position 429 might 
reflect two separate lineages within the DRB1*14 group, including some additional 
members of the DRB1*11 and *13 group (DRB1*11:13, 11:149 and 13:08). The 
suggestion of two separate lineages within DRB1*14 is strengthened by additional 
polymorphism in exon 2 that is shared within the lineage, e.g. positions 196–197 are 
TT in the G429 lineage, but AA in the C429 lineage. Furthermore, also the DQB1 
association is in favour of different lineages within the DRB1*14 group. The alleles with 
G429 were most frequently associated with DQB1*05:03 in the Caucasian population. 
Even the DRB1*11:13 and 13:08 with a G at 429 have DQB1*05:03 as the most 
frequently associated DQB1 allele (24). In contrast, the alleles with C429 were most 
frequently associated with DQB1*03:01 (DRB1*14:02, 14:03, 14:06) or DQB1*06:03 
(DRB1*14:17, 14:21). Also the DRB3 association follows the separation in that the 
G429 alleles are most frequently associated with DRB3*02:02, whereas C429 is 
associated with DRB3*01:01 (24). Whether the DRB1*03:02 allele served as founder of 
the DRB1*14 C429 lineage, as was suggested for the alleles DRB1*14:02, 14:06 and 
14:13 (3), remains unclear. DRB1*03:02 is indeed also most frequently associated with 
DRB3*01:01, but also with DQB1*04:02 and not DQB1*03:01. Furthermore, although it 
was previously suggested that no unique group-related motifs for the DRB3-associated 
DRB1 alleles could be identified in exon 3 (3), there are two positions in exon 3, T489 
and C534, that are unique for the DRB3-associated DRB1 alleles and DRB1*08, which 
might implicate that DRB1*08 belongs to the DRB3-associated alleles from an 
evolutionary point of view, as was previously suggested (18, 21–23). Another unique 
SNP, G785, is present in exon 5 in all DRB3-associated DRB1 alleles. 
Within the DRB1*08 group, there is a SNP present at position 777 in exon 5, which is 
either a T or a C. Of the nine DRB1*08 alleles known in the IMGT/HLA database (3.18), 
four have a T (08:01:03, 08:02:01, 08:09, 08:13), whereas five have  
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a C (08:03:02, 08:18, 08:41, 08:60N, 08:63). Of the eight DRB1*08 alleles analysed 
here, five have a T777 and were compared with the DRB1*08:01:03 sequence and 
three have a C777 and were compared with DRB1*08:03:02 (Table 2). It is tempting to 
speculate that these might reflect two different lineages. Although there are no 
corresponding differences in the other exon sequences, comparing DQB1 associations 
within the Caucasian population, there seems to be a prevalence for DQB1*04:02 in 
individuals with DRB1*08 alleles with T777 compared with DQB1*03:01 with C777, but 
there are also some clear exceptions, like DQB1*08:06 associated with DQB1*06:02 
(24). 
Characterization of the antibody response to epitopes of anti-HLA antibodies is 
important for the management of patients targeted for transplantation (25). For 
development of the HLA matchmaker algorithm, 49 polymorphic amino acid positions 
were identified in DRB1/3/4/5 with other amino acids nearby to form patches that 
could act as a potential epitope recognized by antibodies. Of these 49 amino acids,  
21 showed a molecular surface expression graded as prominent, whereas 28 were 
either readily (n=24) or somewhat (n=4) visible. Interestingly, 13 of the 21 prominent 
positions were located in the β2 domain, encoded by exon 3 of the DRB gene (26). 
Because high-resolution molecular typing of all relevant polymorphism is necessary for 
correct determination of the HLA immunogenetic profile of antibody producer and 
immunizer (27), the here presented RNA-based sequencing method could be easily 
applied to determine the complete coding sequence of HLA-DRB1 from patient and 
donor in a transplantation setting. 
In HLA matching procedures, it is important to determine and take into account the 
expression patterns of abnormally expressed HLA variants. In the IMGT/HLA database, 
there are 36 HLA-DRB1 null alleles identified having a polymorphism, insertion or 
deletion positioned in exon 2 leading to the formation of premature stop codons (1). 
However, polymorphism outside exon 2 can also lead to null alleles by introducing stop 
codons. Although not yet found in DRB1, there are examples for DRB3 (DRB3*02:29N) 
and DRB5 (DRB5*01:08N) where deletions in exon 3 cause frame shifts that lead to 
premature stop codons (1, 28). This polymorphism will be overlooked when DNA 
sequencing is limited to exon 2. Furthermore, certain SNPs can cause alternative 
splicing by affecting the normal splice sites and leading to an inclusion or exclusion of 
partial sequences. For example, HLA-DRB4*01:03:01:02N has a defect at the acceptor 
splice site 5′ end of the second exon. This leads to the skipping of the regular splice site 
and the activation of two cryptic sites resulting in the formation of two incomplete 
splice products. One transcript is longer and leads to the inclusion of an additional  
52 amino acids, the other transcript is shorter and introduces a premature stop codon, 
both transcripts are not able to form a functional HLA class II molecule and thus causes 
a null expression (29). RNA sequencing will not only be able to identify full-length 
polymorphism, but also has the ability to detect alternatively spliced mRNA variants as 
has been shown in our RNA-SBT HLA class I method (10). Furthermore, we used our 
RNA-SBT method with especially designed HLA-DRB4-specific amplification primers to 
identify the presence of alternatively spliced products in an individual positive for 
DRB4*01:03:01:02N (data not shown), thus confirming the suitability of this method 
for detection of aberrantly spliced mRNA products. 
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RNA has the advantage over DNA of a short amplicon length. The long intron length, 
especially for the HLA-DRB1 introns, necessitates the usage of multiple amplification 
reactions with a separate amplification of DRB1 exon 1. Compared with DNA, the 
allele-specific full-length sequences for HLA-DRB1 can already be obtained by two 
amplification and five sequencing reactions using RNA. Because of the overlap of 
sequences between the two amplification products, the full-length sequence of each 
allele can reliably be determined, without any questionable phasing as is the case with 
DNA when exon 1 is separately amplified. Furthermore, improvements of RNA 
isolation methods have facilitated the applicability of RNA analysis in routine 
laboratories. 
This study describes an HLA-DRB1 RNA-SBT approach that easily achieves  
group-specific full-length hemizygous sequencing results in a limited sequencing effort. 
When samples are encountered in a clinical setting having alleles with incomplete  
HLA-DRB1 exon sequences, RNA can be isolated from remaining PBMC’s, only 5 × 106 
cells are needed, and sequenced using this approach. With the RNA-based method 
described here, identification of both insertions/deletions in exons beyond exon 2 as 
well as alternative spliced products can be encountered. Furthermore, resulting  
full-length allele sequences are useful for correct epitope identification in a 
transplantation setting and for studying the functional relevance of HLA-DRB1 
polymorphism. 
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Abstract 
Among the large number of HLA alleles, only a few have been identified with a 
nucleotide polymorphism impairing correct splicing. Those alleles show aberrant 
expression levels, due to either a direct effect of the polymorphism on the normal 
splice site or to the creation of an alternative splice site. Furthermore, in several 
studies the presence of alternatively spliced HLA transcripts co-expressed with the 
mature spliced transcripts were reported. We evaluated the splice site sequences of all 
known HLA class I alleles and found that, besides the consensus GT and AG sequences 
at the intron borders, there were some other highly conserved nucleotides for the 
different class I genes. In this review we summarize the splicing mechanism and 
evaluate what is known today about alternative splicing of HLA class I genes. 
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Introduction 
The Human Leukocyte Antigen (HLA) molecules play a pivotal role in the immune 
system by presenting peptides to immune cells. When these peptides are identified as 
foreign, e.g. originating from a viral infection, the interaction between  
HLA antigens and their receptors expressed by immune cells will trigger lymphocyte 
activation. HLA molecules are encoded by the most polymorphic gene complex in the 
human genome, comprising 13,840 different HLA alleles as reported in the IMGT/HLA 
database (v.3.22, October 2015) (1). The HLA genes are clustered into HLA class I and 
class II, based on the structure of the HLA molecule, the origin of the presented 
peptides being intra- or extracellular, and the type of immune cells to which they 
present the peptides. HLA class I genes are defined as the classical HLA-A, -B and -C loci 
and non-classical loci HLA-E, -F and -G. Structurally the class I molecules are composed 
of a single α-chain associated with a non-covalently bound β2-microglobulin protein. 
They mainly present peptides originating from intracellular proteins to CD8+ T-cells 
and natural killer (NK) cells. The HLA class II molecules, HLA-DR, -DQ and -DP, are a 
complex of two separate protein chains, the α- and β-chain, and mainly present 
peptides derived from extracellular proteins to CD4+ T-cells (2). 
The HLA genes are known for their high polymorphic density (3), possibly due to the 
high evolutionary pressure of being able to present a diverse array of peptides (4, 5). 
HLA polymorphism is mainly located in the peptide binding groove, encoded by exons 
2 and 3 for HLA class I, and determines the type of peptides able to bind to the HLA 
molecules. Although the number of polymorphic residues in the remaining exons is 
lower compared to exons 2 and 3, the polymorphic index, defined as the number of 
polymorphic positions compared to the length of a particular exon indicated that the 
other exons display a relatively high degree of polymorphism as well (6). Due to the 
direct functional relevance of polymorphism of the peptide binding groove, alleles are 
mainly defined by polymorphism in exons 2 and 3. Therefore, more than 90% of the 
HLA class I alleles in the IMGT/HLA database have incomplete nucleotide sequences 
(1). The HLA class I genes consist of 8 exons (HLA-B 7 exons). Exon 1 encodes for the 
leader peptide, exons 2 and 3 the peptide binding groove, exon 4 for the α3 domain 
involved in CD8 interaction, exon 5 for the transmembrane region responsible for 
anchoring the molecule in the cell membrane, and exons 6, 7 and 8 encode for the 
cytoplasmic tail (2). 
The IMGT/HLA database lists a number of alleles having a single or multiple 
polymorphism in their DNA sequence leading to alternative splicing of the resulting 
mRNA transcript (1). These alternatively spliced mRNA variants can lead to the 
formation of structurally different HLA molecules having an abolished function, as they 
might be unable to be expressed on the cell surface or to perform their designated 
task of presenting peptides to the immune system. Furthermore, alternative splicing of 
HLA can occur in addition to the mature splicing, adding an additional layer of diversity 
to the MHC molecule.  
The majority of the HLA alleles are solely identified based on DNA analysis and data on 
their encoded mRNA transcript sequences is lacking. Mutations or polymorphism in 
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the template DNA leading to an aberrant mRNA expression pattern are therefore not 
necessarily identified nor are any additional alternative splice variants. Furthermore, 
the role of alternative splicing in HLA expression, and additional possible 
polymorphism influencing regular splicing mechanism, remain unexplored. In this 
review we determined the conserved nucleotide sequence of the HLA class I splice 
sites and focused on the reported observations of alternatively spliced HLA alleles 
resulting in an aberrant HLA (co-)expression profile. 
 
Splicing mechanism 
RNA splicing forms an integral part of pre-mRNA processing by removing the  
non-coding introns and joining the remaining exons. This results in a full-length mRNA 
transcript encoding the protein by translation of the nucleotide codons into amino 
acids by the ribosomes. Splicing usually takes place in the cell nucleus directly after or 
concurrently with transcription of the DNA template (7, 8). 
For the majority of eukaryotic pre-mRNA, splicing is catalysed by the major 
spliceosome which recognizes the most common form of introns, the U2-type introns. 
The major spliceosome is composed of a complex of five small nuclear 
RiboNucleoProteins (snRNPs), identified as U1, U2, U4, U5 and U6. The snRNP is an 
RNA/protein complex that consists of a specific small nuclear RNA (snRNA) that is 
associated with different snRNA dependent protein components. 
A rarer type of introns, identified as the U12-type introns, is targeted by the minor 
spliceosome. Compared to the major spliceosome, the minor variant has structurally 
similar variants named U11, U12 U4atac and U6atac, that are comparable to the U1, 
U2, U4 and U6 snRNPs of the major complex. The minor shares the U5 snRNP with the 
major spliceosome. Furthermore, the minor complex also has its own set of protein 
components associating with the snRNPs. Regarding splicing mechanisms, the two 
spliceosome variants are mostly similar, although there are some differences in the 
assembly pathways and interactions between the spliceosome and the target  
pre-mRNA. For example, the U11 and U12 attach to the pre-mRNA as a single complex, 
compared to the separate binding of the major spliceosome’s equivalents of these 
snRNPs, U1 and U2 (9). 
The first step of splicing by the major spliceosome is the identification of the  
5’ splice site by means of the U1 snRNP with the U1 snRNA that pairs with the 
conserved RNA GU sequence and thereby defines the 5’ exon-intron boundary  
(Figure 1). Subsequently, the SF1 (Splicing Factor 1) attaches to the adenine of the 
intron Branch Point Sequence (BPS) near the 3’ end of the intron, and the  
U2AF1 (AF = Auxiliary Factor) binds at the 3’ splice site by recognizing the AG 
sequence, followed by U2AF2 attaching to the PolyPyrimidine Tract (PPT), a region rich 
in pyrimidine nucleotides. When combined, these first four splicing elements form the 
early spliceosome complex, or E complex, and define the 5’ and 3’ intron boundaries.  
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Figure 1 The mechanism of pre-mRNA splicing by the major spliceosome. Figure adapted from  
(7, 10). 
 
 
The E complex is followed by the formation of the pre-spliceosome, or A complex, by 
the replacement of SF1 by U2 at the branch point site. The next step in splicing is 
binding of the [U4/U6.U5]-snRNP trimer, resulting in the pre-catalytic spliceosome, or 
B complex. Conformational rearrangements and release of U1 and U4 transform the B 
complex into the catalytically active B* complex. This complex catalyses the first 
transesterification step of splicing in which the branch site is coupled to the 5´splice 
site of the intron. The resulting C complex (catalytic complex) carries out the second 
transesterification step, coupling the 3´ end of the first exon to the  
5´ end of the second exon. The post-spliceosomal complex C* dissociates, releasing the 
spliced mRNA product and finally the lariat intron products and snRNPs are 
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disassembled; the lariat is to be degraded and the snRNPs are recycled to form the 
next spliceosome (7, 10). 
In the majority of splicing reactions, the complete intron is removed from the  
pre-mRNA as a single lariat. However, in certain Drosophila melanogaster genes with 
long introns, there is an additional splicing element present in the introns known as a 
Recursive Splice site (RS-site), which enables the removal of an intron in multiple steps 
(11, 12). Recently, this recursive splicing mechanism was also identified in the human 
brain, with the difference that there is an intermediate RS-exon present, that 
facilitates recognition of the recursive splice site. This multi-step process to remove 
long introns adds another layer to splicing control (12, 13). As HLA-DRB has a long 
intron 1 sequence, with a length varying between approximately 5 and 10 kb, this 
intron might be removed by this recursive splice mechanism. 
Alternative splicing, leading to different mRNA isoforms, results in an increase of 
protein diversity in eukaryotic organisms. The first description of alternative mRNA 
splicing was published in 1980 on the discovery of two mRNA isoforms of the 
immunoglobulin µ gene, one variant is membrane-bound and the other soluble  
(14, 15). In later studies, it was shown that more than 90% of the human genes encode 
for a minimal of two isoforms, and some genes have been shown to produce a 
multitude of transcripts from a single DNA template: e.g. the human gene KCNMA1, 
also known as slo, can encode for > 500 mRNA isoforms (16-20). The alternative mRNA 
variants resulting from a single pre-mRNA template can be produced by five different 
forms of alternative splicing: exon skipping, alternative 5’ splice site, alternative  
3’ splice site, mutually exclusive exons, or intron retention (17, 18, 21). 
 
Splicing regulation by splice site selection 
The snRNPs of the major spliceosome recognize and define the exon-intron boundaries 
by attaching to conserved nucleotide sequences in the pre-mRNA, with a GU sequence 
at the 5’ splice site and AG at the 3’ splice site. However, ample studies show that 
nucleotides down- and upstream of these conserved sites are also important in 
determining splice site selection by influencing the strength of the splice site. Analysis 
of large numbers of splice site nucleotide sequences resulted in identification of the 
conserved sequence MAG/GTRAGT for the 5’ splice site, and YYYYYYYYYYNCAG/G for 
the 3’ splice site (NC-IUB codes used, / denotes actual splice site (22)) (23-25). The 
strength of a splice site, determined by the complementarity of the 5’ splice site to U1 
snRNA and the extent of the polypyrimidine tract and the 3’ splice site sequence, can 
be calculated using the online Analyzer Splice Tool 
(http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm); the score expresses how similar the 
splice sites fits the consensus sequences, with a maximum score of 100 (24, 26). Beside 
the 5’ and 3’ splice site consensus, also the presence of a branch point sequence is a 
prerequisite for correct splicing. The branch point is located approximately  
30 nucleotides upstream of the 3’ splice site and although a consensus sequence of 
YUNAY has been reported, this seems to be a more degenerative consensus (27). For 
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the branch point sequence a consensus value score can be calculated using the online 
HSF3.0 tool (http://www.umd.be/HSF3/HSF.html (28)), indicating the probability of a 
sequence being used as a branch point. 
Based on the nucleotide sequences of the classical and non-classical HLA class I genes, 
according to the IMGT/HLA database (1), we have analysed the 5’ and 3’ splice site 
consensus sequences taking all known sequences into account. Figures 2 and 3 
illustrate the 5’ and 3’ splice sites, respectively, with the frequency on the Y-axis and 
the nucleotide position on the X-axis according to Crooks et al. (2004) (29). In all HLA 
class I alleles the highly conserved 5’ GT and 3’ AG splice site nucleotides are present, 
although in HLA-F all alleles show an AA sequence as 3’ splice site of intron 6 and 
skipping of exon 7 has been reported (30). All other nucleotides around the splice sites 
are less conserved, with the exception of a G nucleotide at position -1 of the 5’ splice 
site of HLA-A, -B and -F, a G nucleotide at position 4 of the 5’ splice site of HLA-E and a 
C nucleotide at position -3 of the 3’ splice site in HLA-A, -B, -C and -G. Furthermore, 
from the consensus sequence of the 5’ splice site it can be concluded that the introns 
of HLA class I belong to the U2 type introns that are spliced by the major spliceosome. 
 
Additional factors influencing splicing 
Apart from the splice site, branch point and polypyrimidine tract consensus sequences, 
there are other Splicing Regulatory Elements (SRE) present in the surrounding exon 
and intron sequences, that play an important role in pre-mRNA splicing. Four different 
types of SRE sequences have been recognized, Exonic Splicing Enhancer (ESE), Intronic 
Splicing Enhancer (ISE), Exonic Splicing Silencer (ESS) and Intronic Splicing Silencer (ISS). 
These regulatory elements function by recruitment of trans-acting factors that 
influence the splicing machinery. The Enhancer sequences can serve as binding sites 
for SR (Serine/arginine-Rich) and other proteins, that are involved in recruiting the 
spliceosomal proteins to the splice sites. The silencing sequences can interact with 
negative regulators that often belong to the heterogeneous nuclear 
ribonucleoproteins (hnRNP) family, protein particles able to repress splicing by various 
mechanisms (16, 21, 31). The influence of these factors has not been extensively 
studied in HLA, however, studies by Královičová et al. showed the importance of these 
elements in the alternative splicing and haplotype specific expression of HLA-DQB1 
(32, 33). Overall, with this extra layer of sequences influencing the splicing process, 
one can predict that the high level of polymorphism of HLA, due to selection driven 
DNA variability, might indeed affect pre-mRNA splicing.  
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Figure 2 Nucleotide sequence variation of the HLA class I 5’ splice sites. The nucleotide positions  
-3 to -1, depicted by the X-axis, are the three exonic nucleotides preceding the intron, followed by the first  
6 nucleotides of the intron. The height of each nucleotide displayed by the Y-axis depicts its frequency 
among the alleles of the IMGT/HLA database (v3.19).  
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Figure 3 Nucleotide sequence variation of the HLA class I 3’ splice sites. Nucleotide positions are 
indicated on the X-axis; the height of each nucleotide displayed by the Y-axis depicts its frequency among 
the alleles of the IMGT/HLA database (v3.19).  
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Aberrant expression patterns of HLA class I alleles caused by 
incorrect splicing 
The first level of control in splicing is the selection of the 5’ and 3’ splice site, including 
the branch point sequence and the polypyrimidine tract (23-27, 31). In several HLA 
alleles polymorphism is present in either of these sites, directly resulting in 
deactivation of the splicing, leading to exon skipping or intron retention and resulting 
in aberrant expression. On the other hand there are HLA alleles with polymorphism 
creating an alternative splice site or another branch point site, that likewise results in 
incorrect splicing and aberrant expression. For the classical class I alleles the IMGT/HLA 
database (v3.22) lists 463 null alleles (lacking HLA surface expression), 44 Q alleles 
(with questionable expression), 5 L alleles (with low expression) and one S allele  
(with soluble expression). In 13 of these cases, aberrant expression is due to incorrect 
splicing as indicated in Table 1. 
 
Incorrect splicing due to direct nucleotide substitution of splice site 
consensus sequences 
In both the HLA-A*31:01:02:03N and B*15:01:01:02N alleles the absence of expression 
is caused by missing the branch point sequence resulting in the retention of an intron 
(34). The B*15:01:01:02N allele has a 10 bp deletion in intron 1 including the critical 
adenosine residue of the branch point sequence, needed for an adequate removal of 
intron 1 by splicing. This deletion leads to the retention of intron 1 in the mRNA and 
finally to a frameshift and premature stop codon at the start of exon 2. The human 
branch point consensus sequence, YUNAY, with the critical adenosine underlined, is 
less conserved than the splice sites (27). Analysis of all possible branch point positions 
in the nucleotide sequences of the expressed HLA-B*15:01:01:01 allele and the 
B*15:01:01:02N null allele, using the online HSF3.0 tool 
(http://www.umd.be/HSF3/HSF.html) (28), revealed that a strong branch point 
(GTCTCAG) with a score of 92.28 is located at position 179-185 of B*15:01:01:01 in 
intron 1, exactly at the position of the deletion found in B*15:01:01:02N. An 
alternative branch point with a score of 75.98 is present at position 136-142 
(GGCGCAG), but apparently, this branch point seems too far off to form a functional 
lariat needed for the effective removal of intron 1 (27, 34, 35). Although less well 
studied, the A*31:01:02:03N allele has also a 10 bp deletion in intron 1. Analysis of 
possible branch point positions for A*31:01:02:01 and A*31:01:02:03N revealed a 
comparable strong branch point at position 180-186 (ATCTCAG, score 89.86), with the 
critical adenosine residue at position 185. The 10 bp deletion of A*31:01:02:03N 
includes this critical adenosine residue and therefore it is tempting to speculate that 
also in the A*31:01:02:03N allele intron 1 is present in the mRNA. Retention of intron 1 
results in the presence of a stop codon (TAG) at position 151-153, even before the 
deletion of the 10 nucleotides.  
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In four HLA-A null alleles incorrect splicing occurs, because the 5’ splice site is affected 
by either polymorphism or deletions. In these alleles the strength of the splice site 
decreases as shown in Table 1 and this results in deactivation of the splice site (44). 
The null alleles A*03:01:01:02N and A*29:01:01:02N have a substitution at position 
1846, which disrupts the GT 5’ splice site sequence, leading to a drop of the splice site 
strength (see Table 1). As for both alleles no mRNA data are available, it is assumed 
that intron 4 is retained in the sequence (36). This leads to a premature stop codon 
and a resulting protein sequence of 294 or 295 amino acids. Whether this truncated 
protein is expressed is unclear, although it was postulated that this corresponds with 
the 35 kDA soluble HLA molecules (36). 
The allele A*01:01:01:02N has a deletion of 4 nucleotides near the 5’ splice site of 
intron 2, leading to a decrease of the splice site strength score. The deactivation of the 
5’ splice site leads to retention of intron 2 in the mRNA transcript, resulting in  
a frameshift and a premature stop codon. For A*23:19N (previously known as 
A*23:19Q), the substitution of G to A at the border of exon 3 results in a further 
strength score decline of the already rather weak 5’ splice site (Table 1) leading to 
deactivation of the splice site and formation of multiple mRNA transcripts produced by 
uncontrolled splicing. Two main mRNA variants were identified: one transcript lacking 
exon 3 due to exon skipping, and the other variant including introns 2 and 3 together 
with exon 3. However, no HLA-A23 molecule was detectable at the cell surface (37). 
In the IMGT/HLA database there is only one allele, B*44:02:01:02S present in which 
the 3’ splice site is affected. The substitution (A>G) present at position 1934 in intron 4 
disrupts the AG 3’ splice site sequence (Table 1), leading to complete skipping of exon 
5, as was shown by cDNA sequencing (38). The skipping of exon 5 does not alter the 
reading frame and this allele is therefore thought to be expressed as a soluble HLA 
molecule, because the resulting molecule lacks the transmembrane anchor. However, 
with an ELISA no differences in soluble B44 were found between the individual with 
B*44:02:01:02S and individuals with the normal B*44:02:01:01 allele (38). 
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Incorrect splicing due to creation of alternative splice site 
Cryptic splice sites can already be present in the DNA template, but can also be newly 
created by polymorphism introducing the basic GT or AG sequences of a splice site. In 
the null allele A*01:11N, the substitution of G to T at position 968 results in formation 
of a new 5’ splice site, with a higher splice site strength score than the original one, as 
illustrated in Figure 4. The synonymous substitution in A*01:11N, would be unnoticed 
if only DNA sequencing data were analysed. This alternative splicing can only be 
discovered when the resulting mRNA transcript is sequenced. The use of the 
alternative splice site results in deletion of 24 nucleotides at the end of exon 3 and 
apparently abrogates any expression of the molecule (39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Alternative splicing of HLA-A*01:11N, with blocks depicting the exons. The G>T substitution 
in A*01:11N, compared to its mature expressed allele equivalent A*01:01:01:01, results in the introduction 
of the basic GT nucleotide sequence needed for a 5’ splice site. This new cryptic splice site has a higher splice 
strength score as it matches better with the U1 snRNA consensus sequence GUCCAUUCA (matches indicated 
in green, mismatches in red). 
 
 
The allele HLA-A*01:01:38L has a substitution of G to A at position 1655 in exon 4, 
which results in the formation of an alternative 3’ splice site that is stronger than the 
original (Table 1). Furthermore, the presence of a sequence resembling the branch 
point at positions 1604-1610, approximately 40 nucleotides from the alternative splice 
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site, results in a functional 3’ splice site that is in direct competition with the regular 
splice site. The presence of this alternative splice site has apparently led to the 
majority of the splicing reactions being catalysed by the spliceosome choosing the 
alternative splice site, as was shown by cDNA sequencing (40). A far smaller number of 
splicing reactions are performed using the regular splice site. The alternative splice site 
results in mRNA with a deletion of 87 nucleotides at the 5’ end of exon 4 (40), which is 
thought to affect expression of the mature protein on the cell surface, explaining the 
lower expression pattern. In three other cases, A*02:01:14Q (1), A*24:02:03Q (41) and 
A*33:03:03Q (45), a substitution of G to A at position 1655 in exon 4 was detected, 
identical to the substitution in the low expressed allele A*01:01:38L allele. In all three 
cases the sequence of positions 1604-1610, resembling the branch point sequence, is 
identical to A*01:01:38L and therefore might have a comparable low expression. 
However, as the genomic DNA and/or mRNA sequences of the three questionable 
alleles are unknown, they remain listed as questionable in the IMGT/HLA database. In 
the original study of the identification of A*24:02:03Q the non-expression of the allele 
was suggested to be attributed to hypermethylation of CpG sequences, because the 
allele was resistant to digestion by methylation-sensitive restriction endonucleases 
(41). It seems however more plausible, that the alternative splicing mechanism seen in 
A*01:01:38L is also responsible for the aberrant expression of these questionable 
alleles. 
HLA-A*24:02:01:02L allele was also found to be alternatively spliced, with the major 
splice product having a deletion of 17 nucleotides in exon 3 (43). The only difference 
between A*24:02:01:01 and A*24:02:01:02L is the substitution of G708 into A. This 
nucleotide is located in the 3’ splice site of intron 2 and therefore it was postulated to 
affect this splice site and to induce the use of another splice site present at positions 
718-732 in exon 3. The latter alternative splice site is also present in other HLA-A 
alleles, but is apparently not used as splice site according to our mRNA study (6). 
Calculating splice site strength scores for HLA-A, it was found that the normal 3’ splice 
site of intron 2 has a rather low score (61.39) and that the substitution G708A in 
A*24:02:01:02L does not have a significant effect on the strength score (61.68). The 
strength score of the alternative splice site in exon 3 (varying from 74.71 to 78.34, 
depending on allele group) is higher than the regular splice site. As this alternative 
splice site is present in other HLA-A alleles, but is not used as such, there are 
apparently other factors influencing the use of this alternative splice site. One of the 
possibilities is that the substitution of G708A creates an alternative branch point in the 
A*24:02:01:02L allele facilitating the use of the alternative splice site. Indeed, the 
branch point consensus value, calculated with HSF3.0, is higher for A*24:02:01:02L 
(GGTCGAG) than it is for A*24:01:01:01 (GGTCGGG).  
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Co-expressed alternatively spliced HLA products 
Beside the solely aberrantly expressed HLA alleles due to a nucleotide substitution, 
also co-expressed alternatively spliced HLA variants, in addition to the normal HLA 
variant, have been reported. One of the most well-known examples is the  
non-classical HLA-G molecule with 7 variants, but also in classical HLA molecules this 
phenomenon has been described and has been considered to add another layer of 
diversity to the polymorphism of HLA molecules (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Overview of published studies on alternatively spliced HLA classical class I transcripts. 
 
Classical HLA class I molecules 
One of the first publications implicating co-expression of alternatively spliced  
HLA-A and -B molecules is based on the finding of a 39 kDA soluble HLA form secreted 
by activated PBLs and the assumption that this 39 kDA soluble form is identical to the 
in vitro secreted HLA form in a mutagenized B lymphoblastoid cell line that was 
identified as the result of an alternative RNA splicing mechanism that deletes exon 5 
(46-48). In a later study, Norgaard et. al identified 4 differently spliced HLA-A 
transcripts, in which either exon 3, exons 2 and 3, exons 3 and 4 or exons 2, 3 and 4 are 
skipped from the mRNA, but these alternatively spliced transcripts were observed in 
cancer cell lines and PBLs isolated from patients suffering from myeloma and 
colorectal cancer, implicating that this alternative splicing could be due to malignant 
transformation (49). Very typical co-expressed alternative transcripts were observed in 
HLA-A*11 positive individuals, where, in addition to the mature transcript, another 
transcript was detected that was 18 bp longer (50). This additional transcript was the 
result of alternative splicing using a second donor splice site introduced by a unique 
polymorphism (2081A) present in all HLA-A*11 alleles. This alternatively spliced mRNA 
variant has an insertion of 18 nucleotides at the 3’ end of exon 5, encoding an extra 
stretch of 6 amino acids in the cytoplasmic tail of the molecule (50). This observation 
References Cell identification HLA Alternative transcripts co-expressed to 
mature transcripts 
Krangel, 1985 (46) Mutant 8.14.1 from T5-1 cell line A2 Skipping exon 5 
Krangel, 1986 (47) HPB-ALL cell line A24 Skipping exon 5 
Norgaard et al., 1999 (49) HCT-15 (colon tumour cell line) A*02, A*23/24 Skipping exon 3 
 05142/95 (colorectal cancer patient) A*02 Skipping exons 2-4, exons 3-4 and exon 3 
 05142/95 (colorectal cancer patient) A*26 Skipping exons 2-3, exons 2-4 and exon 3 
 05302/95 (colorectal cancer patient) A*02 Skipping exons 2-3 and exon 3 
 04867/95 (colorectal cancer patient) A*02 Skipping exons 2-3 and exon 3 
 04867/95 (colorectal cancer patient) A*26 Skipping exon 3 
 01820/95 (colorectal cancer patient) A*23 Skipping exon 3 
 02117/92 (myeloma patient) A*31 Skipping exons 2-3 and exon 3 
Tijssen et al., 2000 (50) Surinam family, WT100bis cell line, TTL cell line A*11 Insertion of 18 nucleotides from intron 5 
This study 3 unrelated healthy individuals A*11 Insertion of 18 nucleotides from intron 5 
Tamouza et al., 2000 (51) Sickle cell anaemia patient and family B*36:16 Deletion of 19 nucleotides from exon 3 
Serrano et al., 2000 (52) 808 cervical carcinoma cell line and others A*02, B*44 Skipping exon 3 
Dai et al., 2014 (54) Healthy individuals A*24 Skipping exon 3 
This study 4 unrelated healthy individuals C*03 Insertion of 18 nucleotides from intron 5 
Wang et al., 1999 (72) 624MEL98 (melanoma cell line) A*02 Skipping exon 2, retention of intron 2, no 
mature transcript 
Huang et al., 1997 (73) C1R and U937 transfected with B*27 B*27 Skipping exon 5 
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of alternative splicing in A*11 was confirmed with the mRNA sequencing strategy for 
class I (6), using three different HLA-A*11:01:01 positive individuals. Also in the 
B*39:16 allele a co-expressed mRNA isoform was present, missing the first 19 
nucleotides of exon 3. This isoform accounted for about 10% of the mRNA transcripts 
and was due to a unique polymorphism (733C) creating an alternative splice site (51).  
Serrano et al. found alternative HLA-A (*02) and -B (*44) transcripts missing exon 3 in 
PBLs of normal individuals, albeit that either a second PCR amplification or  
a specific primer spanning exons 2 and 4 was needed to detect these transcripts (52). 
A study on the transcription status of the MHC region using microarrays on 3 HLA 
homozygous cell lines revealed that alternative splicing is enriched among MHC genes 
compared to non-MHC immune genes and that it is related to haplotypes (53). 
Recently, Dai et al. have reported an alternatively spliced isoform of HLA-A*24, present 
in healthy individuals, missing the alpha2 domain due to deletion of exon 3 in the 
transcript. The corresponding molecule could not be detected in vivo, but in 
transfected cells this isoform was able to be transported to the cell surface and was 
found to interact with full-length HLA-A forming a heterodimeric complex, implicating 
that this variant might have an immune regulatory function (54).  
In a RNA-based study, the RNA sequencing approach (6) identified the presence of an 
alternatively spliced mRNA transcript in low amounts in the HLA-C*03 allelic group. 
The mRNA variant includes 18 additional nucleotides from the 3’ end of intron 5, 
compared to the mature transcript. Analysis of the genomic sequence revealed that 
indeed a possible cryptic 3’ splice site is present in the intron 5 sequence of all HLA-C 
alleles, except C*07, including the polypyrimidine tract and NCAG/G sequence with the 
actual splice site located at position 2520. The strength of this cryptic splice site was 
calculated with the online Analyser Splice Tool to be 85.24, whereas the strength of 
the normal 3’ splice site is 93.73. Although all HLA-C alleles (except C*07) have 
identical sequences for this polypyrimidine tract and cryptic splice site, the 
alternatively spliced transcript was only observed in HLA-C*03 alleles. The difference 
between HLA-C*03 and all other C alleles is the presence of an adenine at position 
2499. This adenine may represent an alternative branch point site connected to the 
alternative splice site, because the sequence of this BPS for HLA-C*03, CTGAC, fits 
perfectly with the consensus YUNAY. The fact that the alternative transcript is absent 
in any of the other HLA-C alleles implicates the major importance of the presence of a 
suitable branch point site. Whether the alternative spliced HLA-C*03 transcript leads 
to an alternative protein with 6 amino acids extra at the start of the cytoplasmic tail 
remains to be determined. 
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HLA-G 
Alternative splicing of the non-classical locus HLA-G was first described in 1992, and 
has been shown in consecutive studies to be responsible for the formation of seven 
mRNA isoforms, and their subsequently translated proteins, identified as variants G1 
to G7 (55-58). Variants G1 to G4 include a transmembrane part, encoded by exon 5, 
and are expressed on the cell membrane. In contrast, variants G5 to G7 lack the 
transmembrane region and are soluble HLA isoforms. G1 is encoded by the  
full-length mRNA and has a structure that is comparable to classical HLA class I 
molecules including a signal peptide encoded by exon 1; the extracellular α 1-3 chains 
of the molecule encoded by exons 2-4; and a transmembrane part encoded by exon 5. 
HLA-G1 can be shed from the cell surface by proteolytic cleavage (59). The G2 to G4 
variants express incomplete α-chains on the cell surface due to the absence of exon 3 
in G2; exon 3 and 4 in G3 and exon 4 in G4 transcripts (55, 60). The absence of the 
transmembrane part in the G5 and 6 variants is caused by intron 4 retention leading to 
a stop codon in intron 4 (56). While the G5 variant has a complete α-chain encoded by 
exons 2-4, the G6 isoform does not include alpha 3 due to the absence of exon 4. The 
G7 isoform is the result from a translation termination signal in intron 2 (58). Secreted 
HLA-G5 has been detected in cell supernatants and in a variety of body fluids  
e.g. plasma of pregnant woman (58, 61, 62). It is however unclear whether the HLA-G6 
and 7 variants are also extracellularly secreted as soluble HLA molecules or whether 
they remain intracellularly.  
In addition to splicing leading to the seven isoforms, a 14 bp insertion/deletion 
positioned in exon 8 has been demonstrated to influence HLA-G expression levels 
either directly or through alternative splicing. Although some controversy exists, most 
studies report that the 14 bp insertion variant is associated with lower levels of HLA-G 
compared to the 14 bp deletion variant (63-67). Additionally, the 14 bp insertion 
introduces an alternative splice site that is associated with the removal of a 92 bp 
sequence from the mature mRNA resulting in shorter and more stable transcripts  
(63, 64).  
HLA-G alternative splicing has also shown to be influenced by environmental factors. 
For example, for Fon melanoma cells, mainly expressing HLA-G1 in vivo,  
it has been demonstrated that the production of cell surface G1 molecules switched to 
production of intracellular G2 upon ex vivo culturing of the cells, and that this G2 
production was associated with loss of resistance to NK-cells (68). 
 
Alternative splicing of HLA alleles in disease 
Up to now, HLA-G is the best studied HLA gene in relation to alternative splicing. 
Specific HLA-G isoforms have been associated with a number of diseases as extensively 
reviewed elsewhere, e.g. various cancer types and inflammatory bowel diseases, which 
could also indicate a pathophysiological role for HLA-G alternative splicing (69, 70). 
Also for the classical class I genes, alternative splicing in relation to disease has been 
reported, albeit limited. One of the methods for tumour escape from immune 
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recognition is the loss or decreased expression of MHC antigens on the tumour cell 
surface. Although this loss can be accomplished by loss and/or mutations of the  
β2-microglobulin gene (71), direct loss of the HLA heavy chain is possible as well. In the 
melanoma cell line 624MEL28, Wang et al. have shown that the selective loss of an 
HLA A*02 allele was due to a base substitution at the 5’ splice site of intron 2 of the 
A*02 gene. This substitution resulted in alternative splicing leading to two aberrant 
transcripts, one with exon 2 skipping, the other with intron 2 retention, both not able 
to produce detectable A2 molecules on the cell surface (72). 
Another study described that a bacterial invasion was also able to induce alternative 
splicing of a HLA allele. Experiments with cell lines transfected with B*27, showed that 
an in vitro invasion by arthritis inducing bacteria, like Salmonella or Yersinia, resulted 
in an increase of an alternatively spliced transcript with exon 5 skipping, compared to 
noninvasive bacterial mutants. A comparable increase in soluble HLA-B27 molecules as 
analysed by immunoprecipitation was observed (73). Soluble HLA molecules were 
found to trigger apoptosis of CD8+ T-cells and soluble B27 was able to inhibit the 
cytotoxic activity of B27 specific T-cells, thus enabling bacterial persistence (74, 75). 
Therefore, the induction of alternative splicing of HLA-B27 might be a bacterial 
defence mechanism. 
 
Conclusions 
Overall, there is a number of HLA alleles known with an aberrant splicing pattern due 
to nucleotide substitutions. Since serological typing is no longer the first method of 
choice and might not even be available in the laboratory, aberrant expression levels 
might go unnoticed. This is also the case when nucleotide polymorphism is observed in 
the genomic DNA sequence, but no mRNA or cDNA sequencing is performed, leaving 
differentially spliced transcripts unnoticed. Therefore, the splice variation among HLA 
alleles might be highly underestimated. One of the risk factors in this matter is that a 
synonymous nucleotide substitution is accepted for a bone marrow transplantation, 
with no knowledge about the effect of this substitution on splicing and/or on 
expression levels. Routinely applicable RNA sequencing approaches, as previously 
published by our group for HLA class I, DRB1 and DPB1 (6, 76, 77) might be a first start 
to determine transcript sequences and to detect transcriptional aberrations. 
Knowledge about alternative splicing resulting in the co-expression of different 
transcripts is limited for HLA class I, except for HLA-G. However, the studies mentioned 
in this review overall seem to implicate a functional and/or pathophysiological impact 
of alternatively splicing of HLA, warranting further investigations. 
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Abstract 
The assignment of null alleles is clinically relevant in stem cell transplantation, in 
particular for donor selection. It is unclear how questionable (Q) alleles, having an 
unknown expression profile, should be considered in matching criteria. In this study we 
analysed the RNA and protein expression profile of a questionable allele encountered 
in a sample of the Guadeloupe population: GD23Q, HLA-A*23:19Q, 29:02:01.  
Full-length DNA sequencing of HLA-A*23:19Q revealed a single polymorphism at 
position 619 (G>A) compared to HLA-A*23:01:01. Serological typing showed only the 
presence of HLA-A29; HLA-A*23:19Q was not detected on the cell surface. The 
absence of HLA-A*23:19Q surface expression was shown by flow cytometry using a 
directly labelled monoclonal antibody and a panel of five indirectly labelled polyclonal 
antibodies all directed against HLA-A23 (HLA-A9) molecules. Allele-specific 
amplification revealed the absence of intact full-length mRNA, but the presence of two 
major alternatively spliced mRNAs: sequencing identified that in one variant exon 3 is 
missing and in the other variant introns 2 and 3 are retained. Based upon the lack of 
HLA-A*23:19Q surface expression and the presence of aberrant mRNA transcripts only, 
this study shows that HLA-A*23:19Q is non-expressed. 
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Introduction 
Immune recognition of infectious pathogens is mediated through the presentation of 
foreign peptides by the Human Leukocyte Antigen (HLA) molecules. The HLA class I  
(A, B and C) and class II (DR, DQ and DP) genes are the most polymorphic loci in the 
human genome with 12,242 different HLA alleles currently known (IMGT/HLA v3.18) 
(1). The high level of HLA polymorphism reflects its biological importance i.e. having 
the potential to present a large diversity of peptides to the immune system and trigger 
an effective immune response (2). Most polymorphisms are located in exons 2 and 3 
for HLA class I and in exon 2 for class II, which encode the peptide binding groove 
involved in binding and presentation of peptides to T-cells (3). 
In the transplantation setting, HLA polymorphism leads to strong adverse reactions 
when transplanted between HLA mismatched individuals (4). In the cases where a 
mismatch search is necessary, the interval between diagnosis and transplantation 
should be kept to a minimum decreasing the risk of a disease progression caused by a 
prolonged search for a more suitable donor (5). HLA-A and particularly HLA-B 
mismatches were shown to be strongly associated with an adverse outcome, 
compared to a HLA-C mismatch which showed a low impact on the overall survival (6). 
Furthermore, certain mismatched HLA class I alleles have shown to lead to less severe 
complications. This is due to specific key residues, present in the peptide binding 
groove, that are associated with severe acute graft-versus-host disease and mortality, 
therefore donor-recipient pairs having certain mismatches at these positions should be 
avoided (7). A strong effect of HLA-DRB1 mismatching was seen on transplant-related 
mortality, whereas an HLA-DQB1 mismatch is acceptable (6, 8). High-resolution HLA 
typing leads to a more accurate matching of the HLA-A, -B, -C, -DRB1 and -DQB1 alleles 
and better patient survival (8, 9). 
In HLA matching procedures it is important to determine and take into account the 
expression patterns of abnormally expressed HLA variants (10). Null (N) alleles are not 
expressed on the cell surface, secreted (S) alleles encode for proteins that are 
expressed as soluble molecules and lowly expressed (L) alleles are characterized by a 
weak surface expression of an intact HLA molecule (1). For the questionable (Q) HLA 
alleles it remains unclear how they should be considered in the matching criteria, 
because their expression has not been confirmed. This could lead to a mismatch 
between donor and recipient caused by the questionable allele being a possible null 
allele. The only option is to search for a donor having the exact same haplotype, which 
is difficult due to the low frequency of the questionable alleles. 
HLA-A*23:19Q was first assigned in 2007 as a questionable allele due to its unknown 
surface expression. The allele has been found in 7 different individuals and was 
confirmed in 4 laboratories by sequence analysis, although only partial allele 
sequences have been submitted (exons 2, 3 and 4) (1). We encountered this allele, 
GD23Q: HLA-A*23:19Q, 29:02:01, in a sample of the Guadeloupe population (11, 12). 
In the current study we used this sample to determine the RNA and protein expression 
profiles of HLAA*23:19Q by RNA sequencing, serology and flow cytometry. 
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Material and methods 
Cell lines 
HLA-A*23:19Q was encountered in a Peripheral Blood Mononuclear Cells (PBMC) 
sample of an individual from Guadeloupe (GD23Q: HLA-A*23:19Q, 29:02:01) and an 
EBV B-lymphocyte cell line was established. In addition, B-cell lines were selected as 
negative or positive controls (Table 1). All cell lines were cultured in RPMI-1640 (Gibco, 
Life Technologies, Bleiswijk, the Netherlands) containing 15% FCS (Gibco) and  
2% Penstrep (Gibco). 
 
 
 
 
 
 
 
 
 
Table 1 HLA class I typing of GD23Q and control cell lines. 
 
DNA/RNA isolation and cDNA synthesis 
Approximately 1×107 cells were used for DNA isolation following manufacturer’s 
protocol (QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany). Total RNA isolation 
was performed using about 5×106 cells according to protocol (RNeasy minikit, Qiagen). 
DNA and RNA concentration and quality were determined by measuring the A260/280 
ratio using the NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, 
USA). To ensure removal of all DNA in the RNA samples, a DNase step was applied 
using the deoxyribonuclease I kit (Life Technologies). For the transcription of RNA into 
cDNA, the Superscript III first-strand synthesis system kit for RT-PCR (Life Technologies) 
was used. 
 
Sequence-based typing on DNA and RNA templates 
Full-length RNA and DNA sequencing of the coding and intron sequences was 
performed by using HLA-A*23 specific amplification primers located in the 5’ and  
3’ untranslated region (UTR) as described previously (13, 14). The region from the 
promoter to exon 1 has been amplified with a 5’ primer upstream:  
5’-GTGGACTCACACAGAAACTC-3’ (pos. -859 to -840), and a 3’ primer in exon 1:  
5’-CCCCGAGAGTAGCAGGAC-3’ (pos. 28 to 45). The promoter, including the class I 
regulatory complex (CRC), is located at -219 to -149 upstream the start codon (15). 
Sequencing this region was performed with the amplification primers, and  
Cell ID HLA-A HLA-B HLA-C 
GD23Q *23:19Q,29:02:01 *08:01:01,35:01:01 *03:04:01,08:02:01 
TER241 *23:01:01 *07:02:01,41:01:01 *07:02:01,08:02:01 
TER364 *29:02:01,68:01:01 *27:05:02,44:03:01 *02:02:02,16:01:01 
TER174 *02:01:01,02:07:01 *46:01:01 *01:02:01 
K562 - - - 
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2 forward and 2 reverse sequencing primers. The 3’UTR was amplified using a  
5’ primer located in intron 7, 5’-CTCACTGTGACAGATATGAAG-3’, and a 3’ primer,  
5’-CAAATCAGCATAAGCAACACG-3’, located 450 bp downstream of the TGA stop 
codon. Sequencing the 3’UTR was performed using the amplification primers as 
sequencing primers. All PCR amplification and sequencing reactions were carried out 
as previously described (13, 14). 
PCR products were visualized on a 1.5% agarose gel (Life Technologies) with a final 
concentration of 0.5 µg/ml ethidium bromide (Sigma-Aldrich, Zwijndrecht, The 
Netherlands). In case of multiple alternatively spliced RNA products, separation was 
achieved on a 0.6% low melting point agarose gel for 2.5 h at 50 V in 1× TAE buffer 
(Life Technologies). The MinElute gel extraction kit (Qiagen) was used to extract the 
products from the gel which were subsequently used for sequence analysis. Resulting 
sequences were analysed using Lasergene software (DNASTAR Lasergene 9 Core Suite, 
Madison, USA). 
 
Serological typing 
Serological typing of GD23Q was performed by the Complement-Dependent 
Cytotoxicity test (CDC). Antisera routinely used for serological detection were obtained 
locally, commercially and by exchange with national and international colleagues. In 
brief, 1 µl antiserum and 1 µl lymphocyte suspension at a concentration of  
4×106 cells/ml were incubated for 30 min at 20oC. Five µl rabbit complement  
(Life Technologies) was added and incubation was prolonged for 60 min at 20oC. After 
addition of 5 µl FluoroQuench (One lambda, Canoga Park, USA) and 10 min incubation 
at room temperature, cell lysis was assessed by automated fluorescence ratio 
measurements for intact and lysed cells, respectively. 
 
Flow cytometric analysis of HLA-A*23:19Q surface expression 
Protein expression of the GD23Q and control cell lines (Table 1), was determined by 
flow cytometry using a FITC-conjugated monoclonal anti-HLA-A9 (HLA-A23 & HLA-A24) 
IgG2b antibody (FH0964, One Lambda) and 5 patient sera containing polyclonal 
antibodies directed against HLA-A23 or A9. 
Approximately 5×104 cells were incubated on ice for 30 min with an increasing amount 
of undiluted monoclonal antibody ranging between 0.1 and 5 µl. As an isotype control, 
cells were incubated with 1 µl of FITC-conjugated mouse IgG2b isotype control 
antibody (Immunotools GmbH, Friesoythe, Germany). Cells were washed twice with 
PBS buffer containing 1% FCS and analysed by flow cytometry (FACSCanto II,  
Becton–Dickinson, New Jersey, USA). Stainings were performed in triplicate. 
For the polyclonal antibodies, about 3×105 cells were incubated for 30 min at room 
temperature with 50 µl of the anti-HLA-A9 patient sera. Subsequently, cells were 
washed 3 times with PBS/1% BSA (Bovine Serum Albumin) followed by labelling for  
30 min at 4oC with an anti-human IgG FITC-conjugated antibody (Sigma–Aldrich). Upon 
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staining, cells were washed with PBS buffer containing 1% BSA and suspended in  
200 µl of PBS/1% BSA. Positive and negative control sera used were those that 
routinely are used for diagnostic flow cytometry crossmatch analysis. Stainings were 
performed in duplicate. Analysis was performed using BD FACSDiva™ software 
(Becton–Dickinson, version 7). 
 
Results 
HLA-A*23:19Q DNA sequencing 
Group-specific DNA amplification of HLA-A*23:19Q results in an amplicon of  
3107 bp, which required seven forward and seven reverse primers for full-length 
sequencing. The promoter and 5’UTR region, sequenced by using a combination of two 
amplification primers and four sequence primers, results in a transcript of  
861 bp upstream from the ATG start codon, which is sufficient to cover the complete 
CRC region. Amplification and sequencing of the 3’UTR region results in a sequence of 
450 bp downstream of the TGA stop codon using two amplification and sequence 
primers. The resulting full-length coding, promoter and 5’ and 3’UTR sequences 
revealed no additional polymorphism compared to its equivalent  
HLA-A*23:01:01, apart from the already known polymorphism at position  
619 (G>A). This polymorphism is nonsynonymous and results in an amino acid change 
at codon 207 of an Aspartic Acid to Asparagine (GAC>AAC). Sequences were submitted 
to the EMBL (accession numbers: HLA-A*23:19Q: HG974606,  
HLA-A*23:01:01: LN813010), and IMGT/ HLA databases (submission numbers:  
HLA-A*23:19Q: HWS10025208, HLA-A*23:01:01: HWS10025206). 
 
HLA-A*23:19Q RNA amplification and sequencing 
PCR amplification of cDNA using HLA-A*23 specific primers resulted in multiple PCR 
fragments, among those, two major alternatively spliced mRNA products for  
HLA-A*23:19Q compared to only a single fragment for HLA-A*23:01:01 (1301 bp, 
Figure 1A). The PCR amplification fragments were separated on a low melt agarose gel, 
isolated and re-amplified for sequence analysis. The largest alternative spliced 
fragment (2120 bp, variant 1) retained intron 2, intron 3 and exon 3. In the 
alternatively spliced variant 2 (1026 bp), exon 3 was deleted. Sequences of the 
exon/exon and exon/intron boundaries of both variants are illustrated in Figure 1B.  
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Figure 1 Group-specific amplification of HLA-A*23:19Q and subsequent sequencing. (A) Agarose gel of 
HLA-A*23:01:01 and HLA-A*23:19Q RNA PCR amplification products with a 250 bp marker.  
(B) Sequencing the two major mRNA variants, variant 1 retains introns 2 and 3 and in variant 2 exon 3 has 
been deleted. Intron/exon or exon/exon boundaries are shown of forward sequences only. 
 
HLA-A*23:19Q serological typing and surface expression 
Standard serological typing of GD23Q (HLA-A*23:19Q, 29:02:01) identified this sample 
as HLA-A29 only. Two HLA-A23 and two HLA-A9 specific sera did not show a positive 
reaction with the GD23Q cells, whereas 3 HLA-A29 sera were positive, indicating that 
only HLA-A29 is expressed at the cell surface and not HLA-A23. 
Additional evidence for the absence of HLA-A23 was obtained by flow cytometric 
analysis using a FITC labelled monoclonal HLA-A9 antibody and 5 patient sera with 
polyclonal antibodies directed against HLA-A23 or A9. The homozygous  
HLA-A*23:01:01 cell line (TER241) was used as positive control. Potential  
cross-reactivity of the antibodies with the co-expressed HLA-A*29:02:01 allele was 
determined using the TER364 (HLA-A*29:02:01, 68:01:01) cell line. The TER174 cell line 
(HLA-A*02:01:01, 02:07:01), having antigens which are not present on the GD23Q cell 
line, and the K562 cell line (devoid of HLA surface expression), were used as negative 
controls. 
  
 88Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (A) Flow cytometric analysis of HLA-A23 expression on GD23Q and control cell lines. Cells 
were in triplicate incubated with increasing amounts of HLA-A9 monoclonal antibody followed by analysis of 
HLA-A23 expression by flow cytometry. Graph depicts mean fluorescence intensity  
(MFI) +/- SD. (B) representative histograms of HLA-A9-FITC signal for the different cell lines at 0.25 µl of  
HLA-A9 monoclonal antibody. HLA-A9 MFI signal is indicated in grey, isotype control in black. 
 
 
For the monoclonal HLA-A9 antibody, the MFI signal obtained at all tested antibody 
dilutions for the GD23Q cell line was comparable or below the negative control cell 
lines, TER364 (HLA-A*29:02:01, 68:01:01) and TER174 (HLA-A*02:01:01, 02:07:01) 
(Figure 2A and B), indicating HLA-A23 was not expressed on the cell surface. For all cell 
lines, except K562, the MFI signal increased in an antibody concentration dependent 
manner and the signal with the HLA-A9 antibody was slightly higher than that of the 
isotype control which could be suggestive of some cross-reactivity with the other HLA 
alleles on the cell surface of the HLA expressing cell lines. The MFI signal obtained with 
the positive control cell line HLA-A*23:01:01 was, at all antibody concentrations, 
considerably higher than the level observed for any of the other cell lines. The absence 
of HLA-A*23 expression by GD23Q was also found with five patient sera containing 
polyclonal antibodies directed against HLA-A23 or A9 (Figure 3); the signal for the 
GD23Q cell line was below or at the level of the negative controls for all sera except 
serum 4. For this serum, the GD23Q signal was higher than for the other sera, which is 
explained by cross-reactivity with the co-expressed HLA-A*29:02:01 allele since also 
TER364 (HLA-A* 29:02:01, 68:01:01) showed an increased MFI signal. 
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Figure 3 Flow cytometric analysis of HLA-A23 expression by GD23Q and controls. Shown are the mean 
MFI values of duplicate measurements for monoclonal HLA-A9 antibody (at 0.25 µl), and for  
5 patient sera having polyclonal antibodies directed against HLA-A23. 
 
Discussion 
Aberrantly expressed alleles should be considered in HLA matching procedures (10). 
Low expressed alleles have a weak expression of an intact antigen which is still 
detectable on the cell surface by flow cytometry but not by serological typing, as 
shown for HLA-A*24:02:01:02L, which has a SNP near the splice acceptor site for 
intron 2 that impairs the production of correctly spliced mRNA. Mismatching a 
recipients HLA-A*24:02:01:02L allele with the normally expressed  
HLA-A*24:02:01:01 variant is nonimmunogenic because of a tolerance induction in the 
recipients T-cells for HLA-A*24:02 (16). This is not the case when donor null alleles are 
matched with a patients corresponding expressed allele, which leads to allorecognition 
and activation of the donor T-cells (10). 
Questionable alleles require confirmation of their exact HLA expression pattern. These 
alleles have an unknown surface expression which makes it unclear whether they 
should be considered as a null, lowly, alternatively or normally expressed  
HLA allele. In the IMGT/HLA database (version 3.18), 45 Q alleles have been identified 
(1), 43 of them within class I (14 HLA-A, 12 -B, 17 -C) and only 2 within class II  
(2 HLA-DQB1). This might be due to lack of reliable serological typing for class II, 
overlooking non-expression. There are 4 different types of Q alleles, the first and major 
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one, observed in 32 alleles, is mostly due to a point mutation, changing cysteines 
(C101 or C164) into another amino acid, therewith affecting the disulphate bond and 
the conformation of the HLA molecule (17). The second one, present in 9 alleles, is due 
to an insertion or deletion of one or more amino acids, affecting the structure and 
probably the surface expression. The third type includes 3 different HLA-A alleles  
(HLA-A*02:01:14Q, 24:02:03Q, 33:03:03Q) that all have one nucleotide difference 
G705A in exon 4 compared to its common counterpart. For the HLA-A*24:02:03Q, 
non-expression was shown by serology and thought to be due to hypermethylation, 
inducing gene inactivation (18). The other 2 HLA-A Q alleles (HLAA*02:01:14Q and 
*33:03:03Q) were identified by molecular methods only, but since they also have the 
same nucleotide at position 705 in exon 4, they might show comparable questionable 
expression. The fourth type concerns the HLA-A*23:19Q allele with a polymorphism at 
the exon border, potentially affecting the splice site strength and therefore expression 
was questionable. 
To identify aberrantly expressed alleles, full-length DNA and RNA sequences are 
required. Once SBT is restricted to exons 2 and 3, polymorphism (SNP, insertion or 
deletion) outside these exons leading to the aberrant expression, will be overlooked, 
such as in HLA-A*24:09N and HLA-C*04:09N (16, 19). A synonymous DNA 
polymorphism might lead to the formation of alternative splice variants and a null 
expression, as shown in HLA-A*01:11N, which can only be detected by sequencing the 
RNA transcript (20). By combining full-length DNA and RNA sequencing with flow 
cytometric analysis, the effect of a deletion, insertion or polymorphism in the DNA can 
be shown on the resulting mRNA transcript and cell surface expression of the HLA 
molecule. In the present study we used this combined methodology to determine the 
expression profile of HLA-A*23:19Q, encountered in an individual of Guadeloupe. 
The full-length DNA, promoter and UTR sequences of HLAA*23:19Q differed from its 
allele equivalent HLA-A*23:01:01 with a single polymorphism at the end of exon 3 
(619, G>A). Interestingly, HLA-A*23:19Q is not the only HLA class I allele having a G>A 
polymorphism at the end of an exon. Three HLA-C alleles, HLAC*01:11, C*12:112 and 
HLA-C*14:11, have the same polymorphism as HLA-A*23:19Q at the end of exon 3. 
However, to our knowledge no RNA analysis has been performed and only partial 
coding allele sequences are known (exons 2–4 for C*01:11, C*14:11; exons 1–6 for 
C*12:112). Moreover, multiple HLA class I alleles have the same G>A polymorphism at 
the 30 end of other exons and all are considered to have a normal HLA expression. In 
HLA-B*73:01, having the G>A polymorphism at the end of exon 4, no aberrant mRNA 
expression profile was found (data not shown). 
The impact of the sequence at the 3’ end of an exon on splicing has already been 
described in 1990, showing that mutations at the end of an exon weakened the 
recognition of the exon boundaries by splicing factors (21). There are several reports of 
naturally occurring mutations at the 3’ end of an exon, including G to A substitutions of 
the last nucleotide of the exon, impairing correct splicing (22-24). Norgaard et al. 
demonstrated that multiple variants of HLA-A, caused by alternative splicing exist in 
addition to the normal transcript (25). There are also examples of polymorphism 
outside the HLA coding region influencing the HLA expression level. For example,  
HLA-A*02:01:01:02L and HLA-B*39:01:01:02L both have polymorphisms in their 
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promoter region leading to a low expression of their alleles (26), which was not the 
case in HLA-A*23:19Q. 
In the case of HLA-A*23:19Q, the A at position 619 presumably causes aberrant 
splicing of the transcript, causing absence of expression of the allele. Serology and flow 
cytometry using a monoclonal antibody and multiple polyclonal antibodies confirmed 
there is no HLA-A23 expression on the cell surface of the GD23Q PBMC and cell lines. 
For all cell lines except K562, which lacks HLA surface expression, the signal obtained 
with the specific antibodies was somewhat higher than the signal obtained for their 
respective control antibodies. Most likely this was caused by some cross-reactivity of 
the antibodies with the other HLA alleles expressed by the cell lines due to a high 
degree of shared epitopes. Rodey et al. have shown that HLA-A2, A23, A24 and A28 
share a public epitope as they all fall in the CREG (Cross-Reactive Group) 2C group, 
which would explain the weak reaction with the other cell lines (27). Furthermore, 
HLA-A9 and A29 both belong to CREG group 1C, which explains the cross-reactivity 
with the cell line expressing the HLA-A*29:02:01 allele. Because the MFI signal of the 
GD23Q cell line always was below the negative control cell lines with the multiple 
antibodies tested, both the RNA sequencing and flow cytometry results indicate, that 
HLA*23:19Q is non expressed and should be considered as a null allele. 
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General discussion 
RNA as SBT sequencing template 
High-resolution analysis of HLA polymorphism is important to accurately predict 
adverse reactions to drugs; for the selection of donors for transplantation; or to 
determine the presence or absence of disease predisposing HLA alleles during 
diagnosis of a strongly HLA-associated disease. Current HLA SBT typing techniques are 
mainly based on using DNA as sequencing template and are mostly restricted to the 
analysis of polymorphism in exons 2 and 3 (1). A limitation of this approach is that 
polymorphism outside exons 2 and 3 is not taken into account while it can influence 
immunogenicity of the allele. In addition, alternative splicing of HLA alleles will remain 
unnoticed even though it can be of immunological importance through its effect on 
protein structure and expression levels of the HLA molecule. In the studies described in 
this thesis we first addressed feasibility of the RNA-SBT approach to obtain full-length 
HLA sequences (chapter 2 and 3). After that, we obtained evidence that RNA-SBT is 
instrumental to study the functional consequences of extended polymorphism 
(chapter 5 and 6). 
Full-length SBT sequencing on DNA is complicated by the long non-coding introns 
placed between the exons, for example the intron 1 sequence of the HLA-DRB1 locus 
has a length varying between 5 and 10 kb (chapter 3). Inclusion of the introns would 
result in a transcript length of ±2,900 bp for the HLA class I alleles and ±10,000 bp for 
HLA-DRB1 (2). The individual sequencing of each exon requires a separate PCR 
reaction, which means that the HLA class I alleles require at least 8 amplification 
reactions when full-length sequencing is required. Most alleles have been identified 
exclusively based on their exon 2 or 3 sequence and only 8% of the currently known 
HLA class I alleles have a known exon 1 through exon 8 nucleotide sequence in the 
IMGT/HLA database (chapter 2) (2). The large percentage of unknown exon sequences 
hampers the study of the effect of polymorphism outside the HLA binding groove. The 
introduction of next-generation sequencing techniques might be a solution for this 
problem since it enables multiple clonal sequencing reactions at the same time (3). 
However, the high degree of HLA polymorphism makes it difficult to align resulting 
sequencing reads to reference genes, furthermore, in most labs NGS techniques are 
still in set up phase (3, 4). 
Using cDNA generated from mRNA as SBT sequencing template delivers full-length 
nucleotide sequences using the already available reagents and thoroughly validated 
SBT protocols. The short amplicon length of ±1000 bp for HLA class I and ±800 bp for 
HLA-DRB1 makes the generation of full-length allele-specific nucleotide sequences 
possible in only two amplification reactions combined with a limited number of 
sequencing reactions (chapter 2 & 3). Furthermore, current RNA isolation kits have 
simplified and solved the issues regarding incomplete phase separation known to be 
related to isolating RNA using previous methods based on the acid guanidinium 
thiocyanate-phenol-chloroform extraction, or the TRIzol method (5). Modern-day RNA 
isolation methods use a spin column-based nucleic acid purification which relies on the 
knowledge that nucleic acid binds to the solid phase of silica under specific conditions 
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(6). Although the modern-day RNA isolation kits have solved the issues involved with 
the RNA isolation technique, using RNA as SBT sequencing template still demands 
some additional requirements regarding pre- and post-isolation sample handling.  
A well-known fact is the presence of ribonucleases in blood and all other tissues whom 
are able to breakdown RNA. When the resulting isolated RNA samples are not properly 
handled and protected, they are rendered useless for subsequent sequencing analysis 
(6). The addition of β-Mercaptoethanol, or the less toxic and smelling and equally 
potent dithiothreitol (DTT), will inhibit the destructive properties of ribonucleases on 
RNA and protect the RNA during the RNA isolation procedure (7). 
Our studies showed that when a clean and ribonuclease free workflow and space is 
used, which is already available at most routine HLA laboratories, RNA of an adequate 
and usable quality can be isolated from PBMC or sputum samples using the  
modern-day isolation kits. These column-based techniques deliver a high quality RNA 
proven to be suitable for RNA-SBT sequencing of the HLA class I loci (chapter 2),  
HLA-DPB1 locus (8), HLA-DRB1 locus (chapter 3), and the HLA-DQA1 and HLA-DQB1 loci 
(data not shown). 
 
The functional relevance of full-length HLA polymorphism 
The highly polymorphic peptide binding groove is encoded for the HLA class I alleles by 
exons 2 and 3, and by exon 2 for the HLA class II alleles, and enables a population to 
present a large diversity of peptides (9-11). This direct functional relevance led to a 
focus in HLA typing techniques on determining polymorphism in these exons, and are 
thus identifying the resulting polymorphic amino acids in the peptide binding groove 
(1, 12). However, by calculating the polymorphic index of the HLA class I loci HLA-A, -B 
and -C, and the HLA class II locus HLA-DRB1, which is a measure for the number of 
polymorphic positions of an exon compared to its length, we showed that the 
remaining exons also express a relatively high degree of polymorphism (chapter 2 & 3). 
As discussed in more detail below, polymorphism in these exons has previously been 
shown to have diverse functional effects based on the particular exon and resulting 
domain of the HLA molecule they are positioned in. 
Polymorphism in exon 1, encoding for the leader peptide, might affect the HLA surface 
expression levels. This has been shown for HLA-E which mainly presents leader 
peptides derived from the classical HLA class I molecules. These leader peptides have a 
specific amino acid sequence and polymorphism leading to a deviation of this 
sequence had a direct regulatory effect of the HLA-E expression levels and resulting 
NK-cell lysis (13, 14). The α3 domain in the HLA class I protein, encoded by exon 4, acts 
as a central structure for the HLA molecule, it binds the β2-microglobulin domain, 
keeps the HLA molecule positioned upright, and functions as a binding site for the CD8 
co-receptor of the T-cell receptor (TCR) (15, 16). Polymorphism in this region might 
cause a decreased binding affinity for the TCR co-receptor CD8 as this receptor binds 
to specific residues in the α3 domain (17). For HLA class II, the CD4 co-receptor of the 
CD4+ T-cells binds to the α2 and β2 domains of the HLA molecule, and polymorphism 
in this region affects the strength of this binding (18, 19). The transmembrane domain 
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of the HLA molecule anchors the protein on the cell surface, the length of this domain 
has been shown to determine the cell surface stability of HLA class I molecules (20). 
Furthermore, polymorphism in this region has a functional effect on a subset of NK-cell 
interaction, especially due to a cysteine located at position 309 of the HLA class I 
molecule (21). The last domain of the HLA molecule is the internally placed 
cytoplasmic tail, the presence and length of this domain plays a critical role in the  
HLA-G and -F internal cellular transportation and resulting surface expression  
(22, 23). Furthermore, the length of the HLA-DQB1 cytoplasmic tail can differ due to an 
allele-specific insertion of residues, and a longer HLA-DQB1 cytoplasmic tail has been 
shown to have an increased risk for the formation of achalasia, a disease of the 
oesophagus muscles (24, 25). 
These studies show that polymorphism outside the peptide binding groove may be 
important for the function of HLA in directing the (allo)immune response. However, 
studying the influence of HLA polymorphism is hampered by the large percentage of 
unknown exonic nucleotide sequences in the IMGT/HLA database  
(chapter 2 & 3). RNA-SBT can be a first step to generate full-length HLA nucleotide 
sequences based on which allele definition could be refined and studies on the 
functional consequences of extended HLA polymorphism can be performed. 
 
The influence of HLA polymorphism on alternative splicing 
Besides delivering full-length HLA nucleotide sequences, RNA-SBT will also visualize the 
effect of alternative RNA splicing on the resulting mRNA transcript. RNA splicing is the 
process of removing the non-coding introns and joining exons from the  
pre-mRNA template and is catalysed by the spliceosome (reviewed in chapter 4). 
Alternative splicing also involves the spliceosome, but, it leads to the formation of 
isoforms of the mature mRNA transcript and the production of structurally different 
proteins. Several HLA alleles have been shown to express such alternatively spliced 
transcripts due to specific polymorphism in their DNA sequence (2). However, since 
HLA polymorphism is mainly studied by analysis of genomic DNA sequences, the 
number of alleles having alternative splice variants is likely underestimated and by 
RNA-SBT additional alternative splicing of HLA alleles will be identified. 
One of the first steps in splicing regulation is the recognition of the 5’ and 3’ splice 
sites, comprised of specific nucleotide sequences in the template DNA, by the small 
nuclear ribonucleic proteins (snRNPs) of the spliceosome (26). Besides the presence of 
the highly conserved sequence of GT in the 5’ splice site and AG in the 3’ splice site, 
additional nucleotides up- or downstream from the splice site increase or decrease the 
affinity, or strength, of the splice site to the spliceosome (27, 28). Some HLA alleles 
have weak splice sites which are still selected by the spliceosome, which might suggest 
the presence of a tight regulatory system for the splicing in the HLA genes, as was also 
hypothesized by Magor et al. (29). 
Polymorphism can influence alternative splicing in several ways: it can impact splice 
site strength; lead to the activation of a cryptic splice site and the inactivation of a 
splice site. We analysed the nucleotide sequences of all HLA 5’ and 3’ splice sites and 
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formed a consensus sequence, which indicated there is a degree of sequence 
conservation bordering the basic GT and AG sequences of the splice sites  
(chapter 4). Using the consensus sequence we subsequently attempted to scan the 
HLA genomic sequences for the presence of possible cryptic splice sites that by one 
SNP could become a novel splice site. However, this seemed impossible due to the 
multitude of these potential alternative splice sites present in the HLA DNA sequence 
(chapter 4). These cryptic splice sites can become activated only when the novel splice 
site is of an equal or higher strength to the normal splice site (chapter 4) (30). The 
effect has been observed in HLA-A*01:11N having a G>T polymorphism activating a 
cryptic splice site in exon 3 that completely annuls the normal splice site (31). The 
deactivation of a regular splice site or activation of a cryptic splice site can lead to the 
production of a single alternatively spliced mRNA transcripts, as for HLA-A*01:11N, or 
production of multiple isoforms co-expressed along the normal transcript as we 
observed for the mRNA isoform of HLA-C missing exon 5 in the mature mRNA 
(chapters 4 and 5) (30, 32, 33). 
Besides polymorphism directly influencing the splice sites, an additional level of 
splicing regulation is the effect of the splicing regulatory elements (SRE), with the 
enhancement (SR-proteins) or inhibition (hnRNP-proteins) of local splicing by the 
attraction or steric hindering of the spliceosome (30). It is possible that the high degree 
of HLA polymorphism could have activated multiple SRE elements, either positively 
promoting the selection of a weak splice or inhibiting a stronger cryptic splice site, and 
only the alleles having these polymorphism have survived the evolutional selection 
(34, 35). A study by Voelker et al. proposed a model for the gain and loss of SRE, with 
ancestral U-rich SRE located in genomic regions having high A/T to G/C conversions 
resulting in an increased formation of G-rich SRE (36). The effect of these SRE has been 
shown to influence the skipping of an exon, caused by polymorphism in 
neurofibromatosis type I patients disrupting the attachment of exonic splicing 
enhancer elements (37). In HLA, the influence of the SRE has only been shown in  
HLA-DQB1 where the proximal splicing of this HLA locus is regulated by at least seven  
SR-proteins and three hnRNP-proteins (38). 
 
Functional relevance of alternative splicing of HLA 
Alternative splicing can lead to the production of structurally different HLA molecules 
that are aberrantly expressed. The correct identification of aberrantly expressed HLA 
alleles is an essential part in SCT HLA matching procedures, since mistaking an 
aberrantly expressed HLA allele for a normally expressed allele might lead to 
transplantation related complications (39). When patients are encountered having a 
null expressed HLA allele, the resulting donor match should have the same HLA null 
allele or be homozygous for the normally expressed variant of the respective locus 
(39). However, the procedure for handling HLA matching procedures might be 
complicated when HLA alleles are encountered having a lowered, soluble or unknown 
surface expression (40). Furthermore, for some HLA alleles, the exact mRNA and 
surface expression is yet to be revealed, these alleles are identified as the questionable 
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(Q) HLA alleles. RNA-SBT will assist in identifying alternatively spliced HLA alleles by 
visualising their alternatively spliced mRNA transcript. 
Polymorphism in the genomic template are able to cause alternative splicing of the 
mRNA transcript, leading to either the insertion, or deletion of nucleotides in the 
resulting mRNA product (chapter 5 + 6). When placed in the extracellular domains of 
the HLA molecule, this will lead to the production of an incorrectly folded or unstable 
HLA molecule unable to be expressed on the cell surface. This effect was observed in 
HLA-A*01:11N having a deletion of 8 amino acids at the end of the α2 domain due to 
the activation of a cryptic splice site in exon 3 (31). HLA-A*23:19Q was previously 
designated Q based on a polymorphism at an exon border that could influence splice 
site strength. By RNA-SBT we observed two mRNA variants one missing exon 3 and the 
other variant having introns 2 and 3 retained. In combination with the absence cell 
surface expression the allele was renamed HLA-A*23:19N (chapter 5). 
Alternatively spliced isoforms can also be co-expressed aside the mature transcript. 
The activation of a cryptic splice site can lead to the production of multiple mRNA 
isoforms co-expressed with the normal mRNA transcript, as was observed for a HLA-C 
variant lacking exon 5 (chapter 6). This co-expression can result in a lowered mRNA 
and surface protein expression level of the normally folded HLA molecule. In allo-SCT, 
alleles functionally identified as having a low (L) expression should still be matched to a 
normally expressed allele equivalent as is the case for HLA-A*24:02:01:02L to avoid 
adverse GVH and HVG reactivity (41, 42). Interestingly, HLA-C expression levels have 
been shown to influence progression of HIV to AIDS, susceptibility to Crohn’s disease 
and immunogenicity of HLA-C mismatches in unrelated SCT (43-45). These studies 
illustrate that better understanding of the effect of HLA polymorphism on alternative 
splicing and HLA expression levels can help to understand the (patho)physiological role 
of HLA and could even be important to predict mismatches that are more or less 
permissible. 
Alternative splicing can also lead to the production of soluble HLA molecules. Only a 
single HLA allele, HLA-B*44:02:01:02S, is listed in the IMGT/HLA database that solely 
produces a soluble HLA protein due to a deactivated 3’ splice site (46). However, 
soluble HLA has been found in the plasma of healthy individuals, with certain HLA 
allele types leading to a higher concentration (47, 48). Whether this resident level of 
soluble HLA in the blood stream is introduced by an underlying hidden pathological 
cause, or is caused by a “normal” process that continuously produces a certain level of 
soluble HLA, remains unknown (48). Our research has found the presence of a  
co-expressed HLA-C mRNA variant, alongside the normal mRNA transcript, that misses 
exon 5 encoding for its transmembrane. The presence of this HLA-C mRNA isoform was 
shown to be allele group-specific, with certain groups having no, a low or high 
presence of the variant (chapter 6). Although we did not show it, this process could 
lead to the production of soluble HLA-C alongside the surface expression. Soluble HLA 
molecules have been shown to have an effect on the immune system by inhibiting  
NK-cell cytotoxic function, inducing apoptosis of T-cells, or might be presented as 
minor histocompatibility antigens and contributing to a form of tolerance acquisition 
(49-51). For HLA-G, the presence of the soluble variant of HLA-G, G5, might be a good 
predictor for the severity of Graft-versus-Host Disease (GVHD) in a SCT (52). However, 
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the exact functional role and regulation for the production of soluble HLA in stem cell 
transplantation remains unclear. 
 
Future directions 
With most of the HLA typing strategies mainly focussed on DNA sequencing instead of 
serological typing, incorporating RNA sequencing in HLA typing strategies will not only 
deliver full-length allele sequences, but is also a suitable strategy for the exclusion of 
known and possibly unknown aberrantly expressed HLA alleles (chapter 4 + 6). Our 
studies, using the currently available Sanger sequencing protocols, have already shown 
the applicability and benefits of full-length RNA sequencing (chapters 2 + 3). 
Transferring this technique to the NGS platforms will give a complete picture of all the 
present transcripts that can be translated into HLA molecules (53). Furthermore, the 
latest generations of NGS approaches, the third and even fourth generation in the 
form of the MinION by Oxford Nanopore Technologies, will make the sequencing of 
the complete transcriptome possible. Sequencing the complete transcriptome will 
surely discover the presence of a multitude of yet unknown alternatively expressed 
HLA alleles and enables the study for the functional role of alternative splicing in HLA 
expression. 
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Summary 
HLA proteins are the human variant of the major histocompatibility complex and have 
been shown to be, since their discovery in the early 1900s, encoded by the most 
polymorphic genes in the human genome. The HLA molecules are clustered in the class 
I and class II proteins based on their function and protein structure. Class I molecules 
are present on most somatic cells and play a critical role in the immune reaction, 
whereas the HLA class II molecules are only expressed on certain subsets of antigen 
presenting cells. Within the HLA class I and II alleles three classical distinct HLA class I 
loci, HLA-A, -B and -C, and class II loci HLA-DR, -DP and -DQ have been identified. 
The high polymorphic nature of the HLA molecules enables the presentation of a large 
diversity of peptides to the immune system. This diversity may cause transplantation 
related complications when stem cells are transplanted from one individual to another 
as in a Stem Cell Transplantation (SCT). The best transplantation outcome has been 
shown in patient and donor pairs matched for their HLA-A, -B, -C, -DRB1 and -DQB1 
alleles. When a mismatch in these loci cannot be avoided, certain HLA mismatches are 
non-immunogenic and thus tolerated. Besides the expressed HLA alleles that might 
complicate SCT donor searches, there are also aberrantly expressed HLA alleles having 
a null, low or still unknown surface expression. These factors, together with the large 
diversity of the HLA alleles, complicate the search for a suitable donor-patient pair and 
require a thorough consideration in the HLA matching procedures. 
There are a number of HLA typing techniques available, using either serological and 
molecular methods, to identify the HLA alleles of a patient and donor. Molecular 
techniques rely on using specifically designed allele- or locus-specific PCR primers and 
probes that attach to specific polymorphic positions characteristic for single HLA genes 
or groups. However, the highly diverse HLA alleles pose a challenge for molecular 
typing techniques as they require the design of a multitude of primers and probes and 
are mostly restricted to some exons. Furthermore, when HLA typing is solely based on 
DNA, mRNA expression levels and alternatively spliced HLA alleles that may occur 
remain unidentified. 
 
In chapter 2, a RNA Sanger sequencing approach was developed and validated for the 
HLA class I alleles, using either a single locus-specific or overlapping group-specific PCR 
amplifications, resulting in full-length nucleotide sequences. A reference panel 
representing the major antigen groups, was used to validate this RNA approach which 
resulted in identical results compared to DNA Sanger typing. Furthermore, 13 alleles 
having unknown exonic nucleotide sequences in the IMGT/HLA database, and  
3 alternatively expressed samples, have been successfully addressed by the  
group-specific RNA Sanger sequencing approach. This RNA Sanger sequencing 
approach was shown to be feasible for the full-length sequencing of HLA class I alleles 
and its alternatively spliced variants. 
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In chapter 3, the RNA Sanger sequencing approach was developed for hemizygous 
sequencing for the HLA-DRB1 locus. More than 90% of the HLA-DRB1 alleles have 
incomplete allele sequences complicating the study for the functional relevance of 
polymorphism beyond exon 2. The RNA Sanger sequencing approach was successfully 
validated on a panel of DRB1 alleles covering all serological equivalents and having 
fully known coding sequences in the IMGT/HLA database. Subsequently, the approach 
was applied to a panel of 54 alleles having incomplete allele sequences, resulting in 
full-length coding sequences and the identification of one new allele and one that has 
been corrected. This study shows the universal applicability of the RNA-based 
sequencing approach to identify full-length coding sequences and to define the 
polymorphic content of HLA-DRB1 alleles. Furthermore, unravelling the unknown 
exonic HLA-DRB1 nucleotide sequences will enable studies on the function of 
polymorphism located outside the peptide binding groove. 
 
In chapter 4, the overall knowledge and influence of alternative splicing on HLA 
expression was reviewed. Alternative splicing can be induced by single nucleotide 
polymorphism (SNP) when they lower the affinity of a regular splice site to the 
spliceosome catalysing all splicing reactions or introduce secondary splice sites. The 
recognition of a nucleotide sequence as a splice site is based on the number of 
nucleotides a certain sequence has in common with a conserved splice site nucleotide 
sequence with the 5’ splice sites adhering to GT and the 3’ splice sites to AG of the 
introns. However, by analysing all HLA class I 5’ and 3’ splice sites additional conserved 
nucleotides were identified up- and downstream of the basic conserved GT and AG 
splice site nucleotides. When the number of nucleotides complement to this 
consensus sequence changes due to SNP’s, it can become strong enough to function as 
a cryptic splice site and compete with the normal splice site. This splice site selection 
determines the splicing pattern, mature or alternative, of HLA mRNA and influences 
the resulting surface expression. An interesting finding was that not all HLA splice sites 
adhere to the splice site consensus but are still selected by the spliceosome, suggesting 
multiple regulatory mechanism can actively influence HLA splicing. 
 
In chapter 5, the ability of RNA sequencing to study alternatively spliced mRNA 
transcripts was applied to the HLA-A*23:19N allele having a previously questionable 
expression pattern. This allele was initially flagged as a questionable (Q) allele,  
HLA-A*23:19Q, having a yet unresolved mRNA and protein expression profile. The 
assignment of aberrantly expressed HLA alleles, such as null alleles, is clinically relevant 
in SCT, in particular for donor selection. However, it is unclear how questionable alleles 
should be considered in matching criteria. The HLA-A*23:19Q allele was encountered 
in a sample of the Guadeloupe population: GD23Q, HLA-A*23:19Q, 29:02:01.  
Full-length DNA sequencing of HLA-A*23:19Q revealed a single polymorphism at 
position 619 (G>A) compared to HLA-A*23:01:01. Serological typing showed only the 
presence of HLA-A29 and HLA-A*23:19Q was not detected on the cell surface. The 
absence of HLA-A*23:19Q surface expression was confirmed by flow cytometry using a 
directly labelled monoclonal antibody and a panel of five indirectly labelled polyclonal 
antibodies all directed against HLA-A23 (HLA-A9) molecules. Allele-specific 
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amplification revealed the absence of intact full-length mRNA and the presence of two 
major alternatively spliced mRNAs. Based upon the lack of HLA-A*23:19Q surface 
expression and the presence of aberrant mRNA transcripts only, this study showed 
that HLA-A*23:19Q is non-expressed and has been renamed to HLA-A*23:19N. 
 
In chapter 6, the presence of a co-expressed HLA-C mRNA variant is described missing 
the exon 5 nucleotide sequence. This alternatively spliced mRNA isoform possibly 
encodes for a HLA-C molecule expressed as a soluble protein. The role of soluble HLA 
in immune processes is still mostly unstudied, although it is tempting to speculate 
soluble HLA might interfere with the immune regulation by activating or inhibiting the 
immune cells. This mRNA variant found in this study is co-expressed alongside the 
mature full-length mRNA transcript and its strength and presence is dependent on the 
HLA-C allele group, with some groups lacking, or having a strong or weak presence of 
the isoform. Except for the HLA-C*03 allelic group that has a varying expression 
pattern among the different allele groups. Since this mRNA transcript encodes for a 
HLA-C molecule missing its transmembrane part, it is most likely expressed as a soluble 
HLA molecule and might have a role in producing a resident level of soluble HLA-C in 
certain individuals. 
 
Incorporating RNA sequencing will enable the visualization of mRNA isoforms caused 
by alternative splicing that possibly encodes for transcripts having an aberrant surface 
or soluble expression. RNA sequencing will also resolve full-length HLA polymorphism 
which enables the study for the functional effect of polymorphism located outside 
exons 2 and 3 for HLA class I and exon 2 for HLA class II, encoding for the peptide 
binding groove. 
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Samenvatting 
De HLA eiwitten zijn de humane variant van het Major Histocompatibiliteits Complex 
(MHC) en sinds hun initiële ontdekking in de vroege jaren 1900 is gebleken dat ze 
gecodeerd worden door polymorfe genen in het menselijke genoom. De HLA 
moleculen zijn geclusterd in klasse I en klasse II eiwitten op basis van hun functie en 
eiwitstructuur. De HLA klasse I moleculen zijn aanwezig op de meeste kernhoudende 
cellen en spelen een belangrijke rol bij de immuunreactie, terwijl de HLA klasse II 
moleculen alleen tot expressie gebracht worden op bepaalde subsets van cellen 
namelijk de antigeen presenterende cellen. Binnen de HLA klasse I en II clusters van 
genen zijn drie verschillende klassieke HLA klasse I loci, HLA-A, -B en -C, en in klasse II 
de loci HLA-DR, -DP en –DQ, geïdentificeerd. 
De hoge mate van variatie in de HLA moleculen maakt de presentatie van een grote 
verscheidenheid aan peptiden aan het immuunsysteem mogelijk. Tegelijkertijd zorgt 
deze diversiteit voor problemen in transplantatie omdat peptiden van gemismatchte 
HLA donoren gepresenteerd worden op cellen van de patiënt en andersom, hetgeen 
complicaties kan veroorzaken bij een transplantatie. Het beste resultaat van een 
transplantatie is aangetoond in patiënt-donor paren die gematched zijn voor hun  
HLA-A, -B, -C, -DRB1 en -DQB1 allelen. Wanneer een mismatch in deze loci niet te 
vermijden is, blijken bepaalde HLA mismatches niet immunogeen en worden 
getolereerd. Naast HLA allelen die tot expressie komen op het celoppervlak zijn er HLA 
allelen met een afwezige, lage of nog onbekende oppervlakte expressie die mogelijk 
het zoeken naar een geschikte donor compliceren. Deze factoren, gecombineerd met 
de grote diversiteit van de HLA allelen, bemoeilijken de zoektocht naar een geschikt 
donor-patiënt paar en vereisen een grondige overweging in de HLA matching 
procedures. 
Er zijn verschillende technieken beschikbaar voor HLA typering die met behulp van 
serologische of moleculaire methoden de HLA allelen van de patiënt en de donor 
identificeren. Moleculaire technieken zijn afhankelijk van speciaal ontworpen  
allel- of locus-specifieke PCR primers en probes die hechten aan specifieke polymorfe 
posities kenmerkend voor één HLA allel of een groep van allelen. De zeer hoge 
diversiteit aan HLA allelen vormt een uitdaging voor de moleculaire typeer technieken 
aangezien zij het ontwerp van een zeer groot aantal primers en probes vereisen en dan 
nog meestal beperkt zijn tot het identificeren van HLA polymorfismen van enkele 
exonen van de HLA genen. Wanneer een HLA typering uitsluitend op DNA is 
gebaseerd, worden de RNA expressie niveaus en eventueel aanwezige alternatief 
gesplicede HLA allelen niet geïdentificeerd. 
 
In hoofdstuk 2 is een benadering met behulp van RNA Sanger sequencing beschreven, 
die ontwikkeld en gevalideerd is voor de HLA klasse I allelen. Dit werd bereikt met 
behulp van een enkele locus-specifieke of twee overlappende  
groep-specifieke PCR amplificaties en resulteerde in de volledige lengte van de 
coderende nucleotide sequenties. Om deze RNA benadering te valideren werd een 
referentie panel geselecteerd met samples die tot de belangrijkste antigen-groepen 
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behoorden. Analyse van deze nieuwe RNA benadering resulteerde in identieke 
resultaten vergeleken met DNA Sanger typeren. In deze studie zijn van 13 allelen met 
onbekende exon nucleotide sequenties in de IMGT/HLA database, en 3 allelen met 
afwijkende expressie, met succes de nucleotide sequenties bepaald met behulp van de 
groep-specifieke RNA Sanger sequencing methodologie. De RNA Sanger sequencing 
methodologie is opgezet voor het bepalen van de volledige coderende sequentie van 
HLA klasse I allelen. Met deze benadering zijn ook alternatief gesplicede varianten te 
definiëren. 
 
In hoofdstuk 3 is de RNA Sanger sequencing methodologie beschreven die ontwikkeld 
is voor het hemizygoot sequencing van het HLA-DRB1 locus. Meer dan 90% van de 
HLA-DRB1 allelen hebben onvolledige allel sequenties die de studie van de functionele 
relevantie van polymorfismen buiten exon 2 niet mogelijk maken. De RNA Sanger 
sequencing benadering werd succesvol gevalideerd op een panel van DRB1 allelen, 
waarin alle serologische equivalenten vertegenwoordigd zijn die volledig bekende 
coderende sequenties in de IMGT/HLA database hadden. Vervolgens werd de methode 
toegepast op een panel van 52 samples waarin 54 allelen vertegenwoordigd zijn die 
een onvolledige allel nucleotide sequenties hebben. Van alle 54 allelen werd een 
volledig coderende sequentie bepaald en toegevoegd aan de HLA allel database  
(HLA-IMGT) waarbij één nieuw en één gecorrigeerd allel gerapporteerd werden. Deze 
studie toont de universele toepasbaarheid aan van de op RNA sequencing gebaseerde 
benadering voor het bepalen van de volledige coderende sequentie. Hierdoor zal het 
volledige polymorfisme van HLA-DRB1 allelen gedefinieerd kunnen worden. Daarnaast 
zal het verder ontrafelen van de onbekende nucleotide sequenties van de HLA-DRB1 
exonen, studies naar de functie van polymorfismen buiten de peptide bindingsgroeve 
mogelijk maken. 
 
In hoofdstuk 4 werd de huidige kennis en de invloed van alternatieve splicing op HLA 
expressie bestudeerd en besproken. Alternatieve splicing kan worden beïnvloed door 
één enkel nucleotide polymorfisme (SNP) wanneer het enerzijds de affiniteit verlaagd 
van een reguliere splice site voor het spliceosome, die verantwoordelijk is voor het 
katalyseren van alle splicing reacties, of anderzijds als het een secundaire splice site 
introduceert. De herkenning van een nucleotide sequentie als mogelijke splice site is 
gebaseerd op het aantal nucleotiden dat deze sequentie gemeen heeft met een hoog 
geconserveerde nucleotide sequentie die geldt voor alle splice sites, met een GT voor 
de 5' splice sites en voor de 3' splice sites een AG in het upstream intron. Echter, bij 
het analyseren van alle HLA klasse I 5' en 3' splice sites werden er aanvullende 
geconserveerde nucleotiden geïdentificeerd rondom deze GT en AG nucleotiden. 
Wanneer het aantal nucleotiden van een bepaalde sequentie complementair aan deze 
consensus sequentie verandert door SNP’s, kan het effect sterk genoeg zijn om de plek 
te laten functioneren als een cryptische splice site en dus te laten concurreren met de 
reguliere splice site. Deze selectie van splice site bepaalt het splicing patroon, regulier 
of alternatief, van het HLA mRNA en beïnvloedt de resulterende oppervlakte expressie. 
Een interessante bevinding was dat niet alle HLA splice sites voldoen aan deze 
consensus sequentie, maar desondanks nog steeds worden geselecteerd door het 
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spliceosome. Dit suggereert dat er meerdere regulatoire mechanismen actief HLA 
splicing kunnen beïnvloeden. 
 
In hoofdstuk 5 werd RNA sequencing toegepast om alternatief gesplicede mRNA 
transcripten te bestuderen van het HLA-A*23:19N allel dat eerder geclassificeerd als 
een Q allel, HLA-A*23:19Q, met een nog niet opgelost mRNA en eiwit expressie profiel. 
De identificatie van HLA allelen met een afwijkend expressie profiel, zoals niet tot 
expressie komende allelen, zogenaamde nul allelen, zijn klinisch relevant bij een SCT, 
met name voor donor selectie. Het is echter onduidelijk hoe de allelen met een 
onbekende alternatieve expressie beschouwd moeten worden in de HLA matching 
criteria. Het HLA-A*23:19Q allel werd aangetroffen in een sample uit Guadeloupe: 
GD23Q, HLA-A*23:19Q,29:02:01. De volledige DNA sequentie van HLA-A*23:19Q bleek 
één enkel polymorfisme op positie 619 (G>A) te hebben ten opzichte van  
HLA-A*23:01:01. Serologische typering toonde slechts de aanwezigheid van HLA-A29 
op het cel oppervlak, daarentegen werd HLA-A23 niet gedetecteerd. De afwezigheid 
van een HLA-A23 oppervlakte expressie werd bevestigd door flowcytometrie met 
gebruik van een rechtstreeks gemerkt monoklonaal antilichaam en een panel van vijf 
indirect gemerkte polyklonale antilichamen gericht tegen alle HLA-A23 (HLA-A9) 
moleculen. Vervolgens identificeerde een allel specifieke amplificatie de afwezigheid 
van volle lengte mRNA en de aanwezigheid van twee alternatief gesplicede mRNA's. 
Gebaseerd op het gebrek aan HLA-A23 oppervlakte expressie en de aanwezigheid van 
enkel afwijkende mRNA transcripten, toonde deze studie aan dat HLA-A*23:19Q een 
niet tot expressie komend HLA allel is en op grond van deze studie geherclassificeerd is 
als HLA-A*23:19N. 
 
In hoofdstuk 6 is de aanwezigheid van een tot co-expressie komende HLA-C mRNA 
variant beschreven waarin de exon 5 nucleotide sequentie ontbreekt. Deze alternatief 
gesplicede mRNA isovorm zou kunnen coderen voor een niet membraan gebonden 
maar in de circulatie voorkomend HLA-C molecuul. De exacte rol van niet membraan 
gebonden HLA moleculen in de immunologische processen is grotendeels niet 
bestudeerd. Maar het is verleidelijk om te speculeren dat deze moleculen zouden 
kunnen interfereren met de regulatie van het immuunsysteem door het activeren of 
remmen van de immuun cellen. De in deze studie ontdekte mRNA variant komt tot  
co-expressie naast het normale volledige mRNA transcript en de concentratie en 
aanwezigheid blijkt afhankelijk te zijn van de HLA-C allel groep, met enkele groepen die 
een ontbrekende, sterke of een zwakke aanwezigheid van de isovorm hebben. 
Uitzondering hierop is de HLA-C*03 allel groep die een variërend expressie patroon 
van de verschillende allelen groepen vertoond. Aangezien dit mRNA transcript codeert 
voor een HLA-C molecuul dat zijn transmembraan gedeelte mist, is het zeer 
waarschijnlijk dat het tot expressie komt als een niet membraan gebonden maar in de 
circulatie voorkomend HLA molecuul en dat het mogelijk ook in sommige individuen 
een rol speelt bij de productie van een normaal aanwezige concentratie oplosbaar 
HLA-C. 
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Het introduceren van RNA sequencing maakt de visualisatie van mRNA isovormen 
mogelijk die geproduceerd worden door alternatieve splicing en die mogelijkerwijs 
coderen voor transcripten met een afwijkende oppervlakte of niet membraan 
gebonden expressie. RNA sequencing zal ook leiden tot het oplossen van de volledige 
coderende nucleotide sequenties van allelen en daarin nog onbekende HLA 
polymorfismen aantonen. Dit zal studies mogelijk maken naar het functionele effect 
van polymorfismen buiten de exonen 2 en 3 van HLA klasse I, en exon 2 van HLA klasse 
II, coderend voor de peptide bindings groeve. 
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Valorisation 
Economic and social relevance 
Hematopoietic Stem Cell Transplantation (SCT) is one of the possible curative medical 
treatments for certain blood or bone marrow malignancies. Patients suffering from 
such malignancies are transplanted with stem cells originating from an autologous or 
allogenic source. To achieve a full HLA match between patient and donor, the most 
ideal donor for an allogeneic SCT is a HLA identical sibling, however, only a small 
percentage of patients have such a sibling available. Currently a NK alloreactive 
haploidentical SCT is considered when no identical sibling is available. However, for the 
largest percentage of patients needing a SCT, a search has to be performed to find a 
suitable Matched Unrelated Donor (MUD) in e.g. the BMDW stem cell donor database 
of possible voluntary donors (1-8). 
 
To minimize transplantation related complications it is necessary to select a donor 
whose HLA alleles match with the patient HLA-A, -B, -C, -DRB1 and -DQB1 alleles, 
according the current matching procedures (4, 9). However, the functional relevance 
of polymorphism located outside the peptide binding groove is still mostly not studied 
due to the low percentage of known exonic nucleotide sequences and their 
polymorphism outside the exons encoding for the peptide binding groove. Generating 
full-length nucleotide sequences will enable the study of the function of polymorphism 
located in the exons outside exons 2 and 3 for HLA class I and exon 2 for HLA class II. 
The ultimate aim of optimizing HLA matching procedures is improving SCT patient 
survival by functional matching. 
 
Most molecular HLA typing techniques focus on polymorphism in the exons encoding 
for the peptide binding groove, resulting in a high number of partially known HLA 
genes. However, polymorphism outside this region has varying effects on the 
immunological reaction as shown for HLA class I and II loci, and for the  
non-classical loci HLA-E, -F and -G (10-16). Furthermore, certain polymorphism lead to 
alternative splicing of the mRNA template resulting in an aberrant expression profile of 
the HLA molecule. Therefore, determining and mapping these polymorphism is 
relevant in a transplantation setting since they may have a functional effect when they 
create a HLA null allele.  
 
This thesis describes HLA RNA sequencing approaches that generate allele-specific  
full-length nucleotide sequences using a limited number of amplification and 
sequencing primers. The resulting full-length nucleotide sequences will further 
improve HLA matching procedures as it will enable the study for the functional effect 
of HLA expression levels, full-length HLA polymorphism and alternative mRNA splicing, 
on SCT outcomes and survival. HLA expression levels have an effect on the 
immunological defence against pathogens and is an important consideration factor in 
SCT (17, 18). 
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Activities and products 
In chapters 2 and 3 we provide an improved and validated RNA Sanger sequencing 
method for the HLA class I loci HLA-A, -B and -C, and the HLA class II locus  
HLA-DRB1. The direct applicability of RNA approaches in determining full-length HLA 
polymorphism was shown in full-length nucleotide sequencing of a panel of HLA class I 
and HLA-DRB1 alleles having an unknown nucleotide sequence in the IMGT/HLA 
database. Since a large percentage of HLA alleles have incomplete nucleotide 
sequence in the IMGT/HLA database, it is highly likely that a multitude of new alleles 
will be discovered when full-length sequences are determined. RNA sequencing is ideal 
in these settings as full-length sequences are accessible in a single or two PCR 
amplification reactions, compared to a separate reaction for each additional exon 
when using DNA. 
 
Besides generating full-length sequences, RNA sequencing is able to directly visualize 
alternatively spliced mRNA variants produced by polymorphism dependent alternative 
splicing mechanisms as reviewed in chapter 4. This mechanism was visualized by  
HLA-class I RNA sequencing of the HLA-A*23:19Q allele which previously had an 
unknown expression pattern. This allele has now been assigned as A*23:19N, and RNA 
sequencing showed the presence of multiple alternatively spliced mRNA transcripts, as 
shown in chapter 5. Furthermore, RNA sequencing of the HLA-C locus led to the 
identification of an alternatively spliced HLA-C mRNA transcript, of which the presence 
was shown to be dependent on the HLA-C allele group, as shown in chapter 6. 
 
The results described in this thesis illustrate the direct applicability and additional 
value of RNA sequencing in HLA typing strategies. The here described RNA approaches 
reveal not only the full-length cDNA sequences but also address the presence of 
alternatively spliced mRNA products and RNA expression levels. Translating these 
methods to next generation sequencing approaches will introduce even more 
possibilities as it will enable the study of the complete HLA transcriptome (19). 
 
  
 Valorisation137 
Implementation in clinical practice 
The RNA sequencing approaches for HLA-A, -B, -C and -DRB1 described in this thesis 
can be applied to only 5 x 106 cells. Our preliminary results showed that besides using 
RNA isolated from PBMC, RNA isolated from sputum could also be used for the  
RNA-SBT approach of HLA-DRB1 alleles. Furthermore, studies have shown that RNA of 
a suitable quality could also be isolated from dried blood spots or buccal epithelial cells 
(20, 21). 
 
RNA sequencing has an additional value as it enables the study of the influence of 
polymorphism outside the HLA peptide binding groove. Incorporating this RNA-SBT in 
the clinic will enable the collection of large patient sample data that identify functional 
single nucleotide polymorphism that require a match for the best SCT outcome.  
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List of abbreviations 
AIDS  Acquired ImmunoDeficiency Syndrome 
AS  Alternative Splicing 
BD  Becton-Dickinson 
BPS  Branch Point nucleotide Sequence 
BSA  Bovine Serum Albumin 
CD8  Cluster of Differentiation 8 
CDC  Complement-Dependent Cytotoxicity test 
cDNA  Copy or Complementary DNA, DNA copy of mRNA 
CDS  CoDing Sequence 
CLIP  CLass II-associated Invariant chain Peptide 
CMV  CytoMegaloVirus 
CRC  HLA Class I Regulatory Complex 
CREG  Cross-Reactive Group 
CWD  Common and Well Documented HLA alleles database 
ddNTP  DiDeoxyNucleotide TriPhosphate 
DNA  DeoxyriboNucleic Acid 
dNTP  Deoxyribose Nucleotide TriPhosphate 
DTT  DiThioThreitol 
EBV  Epstein-Barr Virus 
EDTA  EthyleneDiamineTetraAcetic acid 
EFI  European Federation for Immunogenetics 
EMBL  European Molecular Biology Laboratory 
ER  Endoplasmic Reticulum 
ESE  Exonic Splicing Enhancer 
ESS  Exonic Splicing Silencer 
FACS  Fluorescence-Activated Cell Sorting 
FBS  Fetal Bovine Serum, also known as Fetal Calf Serum (FCS) 
FCS  Fetal Calf Serum, also known as Fetal Bovine Serum (FBS) 
GVHD  Graft-Versus-Host Disease 
HIV  Human Immunodeficiency Virus 
HLA  Human Leukocyte Antigen 
hnRNP  Heterogeneous RiboNucleoProtein 
hSCT  Haematopoietic Stem Cell Transplantation 
HvG  Host versus Graft immune reaction 
IFN-γ  Interferon gamma 
IHIWS  International HLA and Immunogenetics WorkShop 
IMGT/HLA IMmunoGeneTics of the HLA system database 
ISE  Intronic Splicing Enhancer 
ISS  Intronic Splicing Silencer 
KIR  Killer-cell Immunoglobulin-like Receptor 
L allele  Suffix for a HLA allele with a Low surface expression 
MHC  Major Histocompatibility Complex 
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miR  microRNA 
mRNA  Messenger RNA 
N allele  Suffix for a Null HLA allele having no surface expression 
NGS  Next-Generation Sequencing 
NK-cell  Natural Killer cell of the immune system 
PBL  Peripheral Blood Lymphocytes 
PBMC  Peripheral Blood Mononuclear Cells 
PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PESE  Predictable Exonic splicing elements 
PI  Polymorphic Index 
PPT  PolyPyrimidine Tract 
Q allele  Suffix for a HLA allele with a Questionable expression pattern 
RNA  RiboNucleic Acid 
RPMI  Roswell Park Memorial Institute 
RS site  Recursive Splicing site 
RT-PCT  Reverse Transcriptase Polymerase Chain Reaction 
S allele  Suffix for a Soluble HLA allele 
SBT  Sequence-Based Typing 
SCT  Stem Cell Transplantation 
SF1  Splicing Factor 1 
SNP  Single Nucleotide Polymorphism 
snRNA  Small Nuclear RNA 
snRNP  Small Nuclear RiboNucleic Protein, element of the spliceosome 
SR proteins Serine/arginine-Rich proteins 
SRE  Splicing Regulatory Elements 
TAE  Tris-Acete-EDTA buffer 
TAP  Transporters Associated with antigen Processing 
TBE  Tris-Borate-EDTA buffer 
TCR  T-Cell Receptor 
TER  Paul TERasaki cell line of the B-cell line exchange program 
TRIzol  Thiocyanate-phenol-chloroform RNA extraction method 
U2AF  U2 Auxiliary Factor 
UCLA  University of California, Los Angeles 
UTR  UnTranslated Region 
WHO  World Health Organisation 
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Dankwoord 
Nou, eindelijk is het moment aangebroken. Het laatste verlossende hoofdstuk dat ik 
nog moet, maar wel graag wil schrijven. Er zijn in de loop der jaren al zo veel versies 
door mijn hoofd gegaan maar dit is dan toch de finale. Het moment waarop ik eindelijk 
het dankwoord mag schrijven en allemaal de personen mag bedanken die me op de 
een of andere manier hebben geholpen met de lange en soms zware weg die 
promoveren heet. Zonder jullie zou ik het ook zeker weten nooit gehaald hebben! 
 
Marcel, bedankt dat jij me de kans hebt gegeven om te mogen promoveren onder 
jouw supervisie. Deze, zoals elke goede aio ook eigenlijk moet zijn, “eigenwijze” 
promovendus heeft de eindstreep gehaald en daar ben ik ontzettend trots op! Jij hebt 
me laten zien hoe hard de wetenschapswereld kan zijn en geleerd hoe ik me hierin 
staande kan houden. Mijn copromotoren Lotte en Christien, bedankt voor jullie wijze 
raad en advies tijdens mijn promotietraject en ik wens jullie veel succes met de 
volgende aio. 
 
De rest van de afdeling weefseltypering was natuurlijk even belangrijk. Joris, ik heb 
altijd bewondering gehad voor het feit dat jij ontzettend goed je drukke werk weet te 
combineren met het belangrijkste in je leven en dat is je gezin. Ik heb je altijd gezien 
als mijn derde “onofficiële” copromotor die altijd tijd maakte voor een amusant 
praatje of wijze raad. Ik wens je veel succes met je carrière en je leuke gezin.  
Mijn kamer genoot Mathijs. Ik heb in die vier jaar toch vaak met je kunnen lachen als 
mede-nerd. Vooral als die schuifdeur wel eens dicht ging om net dat ene plaatje, dat 
altijd zo vervelend in ons hoofd vast zat, te beluisteren. En de dan veelal nieuwsgierige 
blikken van anderen door de glazen deur voegde zeker toe aan het plezier.  
Diana, Mieke en Audrey, bedankt voor het beantwoorden of helpen bij mijn soms 
lastige vragen en verzoeken. Vooral Diana bedankt voor het regelen van allemaal die 
bureaucratische rompslomp rond het afronden van mijn promotie en submitten van 
mijn papers. 
Alle analisten hebben natuurlijk hun steentje bijgedragen, al was het maar alleen af en 
toe door te vragen hoe het ging met mijn promotie zodat ik weer eens even lekker kon 
luchten bij jullie. Het meiden groepje dat ook elk jaar met mijn verjaardag, behalve het 
laatste jaar ;), mijn pc stiekem wist te versieren: Veronique, Esther, Kim, Maud, Simone 
en Fabienne. Bedankt voor jullie leuke gesprekken, steun en kleine snacks met soms 
zelfs service tot aan mijn bureau. Veronique, Kim en Fabienne, veel succes met jullie 
nieuwe baan en ik weet zeker dat jullie nog meer zullen uitblinken in jullie nieuwe 
baan.  
Fausto en Stefan, wat heb ik toch vaak moeten lachen met jullie heerlijke droge 
humor, en bijna weekend Fausto! De rest van de moleculaire kant Sophie, Christel, 
Veerle en Lisette, bedankt voor jullie input en hulp! 
Ook al was ik niet vaak daar, maar natuurlijk vergeet ik de serologische kant niet. 
Coline, wat kon ik toch altijd jouw heerlijke eerlijkheid en humor waarderen. Els en 
Ilse, ook al deed ik jullie naam wel eens verwarren in het begin, jullie stonden toch 
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altijd gereed om een wijs advies of gewoon een luisterend oor aan te bieden. 
Jacqueline, wat heb ik jou toch altijd als een fijn persoon ervaren die altijd tijd maakte 
om gewoon even te luisteren naar mijn gezeur. 
De overige van de afdeling wil ik natuurlijk niet vergeten, Sandra, Annette, Marjolijn, 
Timo, en mijn stagiaires Franka, Remco en Anja, allen bedankt voor jullie input.  
 
De steun van het minstens even en misschien nog wel belangrijkere vrienden front. 
René, wat ben jij toch een fantastische kerel. Als er wel eens over een bromance, ja dat 
bestaat voor de niet 9gaggers, tussen twee mannen wordt gesproken dan hebben ze 
het toch over ons. Het blijft me altijd verbazen hoe wij hetzelfde kunnen denken over 
de meest gekke onderwerpen en dan toch niet broers kunnen zijn, a brother from 
another mother dan maar. Ik was vereerd toen ik je mocht bijstaan tijdens jouw 
geneeskunde diploma uitreiking, en natuurlijk kon je er ook al vanuit gaan dat je mijn 
paranimf zou worden. Kerel, bedankt dat je me maar weer eens bijstaat tijdens deze 
laatste loodjes van mijn promotie en dat we als echte bro’s naast elkaar kunnen staan. 
Ik wens je alle succes met je carrière en ik weet zeker dat je een fantastische arts 
wordt.  
Mijn andere bro for life Jordy. Jezus man, wat kennen wij elkaar al lang. Ik heb speciaal 
voor deze gelegenheid eens terug gezocht hoe lang nou precies. De eerste schoolfoto 
waar we samen op staan dateert uit 1989, tsjonge dat is dus al 27 jaar en still going 
strong. Ik heb er respect voor, en ben er ook wel een beetje jaloers op, hoe jij van je 
hobby je werk hebt gemaakt. En ook al geeft je lengte het niet weer, maar ouwe 
vechtersbaas, bij elke gevecht zou ik jou toch aan mijn zijde willen hebben. En prijs 
maar vooral dat vrouwtje van je, zo een ga je niet meer zo snel vinden. Laura, houdt 
hem maar flink onder de duim.  
Thomas, wat hebben wij al een potje tegen elkaar zitten zeuren tijdens de pauzes. 
Tsjonge, en wat was dat af en toe nodig en zeer geapprecieerd. Wij als allebei aio 
zijnde, begrijpen natuurlijk elkaars frustraties en problemen. Ik zal ook nooit onze 
roadtrips door Colorado en India vergeten. Succes met je eigen promotie en verdere 
loopbaan.  
Giel, ik zal nooit vergeten hoe wij elkaar eerst een tijdje in het “Hollands” aanspraken 
en we pas na een tijdje ontdekten dat we allebei uit het mooie Mestreech komen en 
dus ook allebei Sjengisstaans spraken. Nou, toen was natuurlijk meteen de trend gezet 
en was de stageplek bij Medische Microbiologie ook meteen een stuk leuker. Veel 
succes met je eigen carrière en met je nieuwe rol als pappa, vooral niet vergeten de 
kleine ook Sjengistaans aan te leren. De zeer leuke stagetijd bij Medische 
Microbiologie werd natuurlijk ook mede mogelijk gemaakt door de dames Dionne en 
Laura waarmee we toch al vele gezellige en vooral luidruchtige pauzes hebben 
doorgemaakt. Ik wens jullie alle drie heel veel succes met jullie loopbaan en privé 
leven.  
Stefan, wij hebben ons leren kennen tijdens onze master en daar vonden we al snel 
een steun aan elkaar voor tijdens de saaie colleges. De week in Stockholm zal ik niet 
snel vergeten en vooral the Anchor niet! Succes met het afronden van je eigen 
promotie in juni en je nieuwe baan in Canada, we drinken er een aantal op tijdens mijn 
en jouw feest.  
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Mark, ik heb jou toch echt leren kennen tijdens onze dagelijks koffie 3 uurtje. We 
hebben samen gelachen en gezeurd en ik weet zeker dat het helemaal goed gaat 
komen met het afronden van je PhD. 
Eerst een fantastische collega maar inmiddels een goede vriend, Talia. Wat heb ik met 
jou toch al gelachen tijdens onze ongelofelijk luidruchtige maar vooral niet te vergeten 
pauzes. Je bent een fantastisch persoon en ik hoop dat we je nog vaak mogen 
verwelkomen in onze crib. 
Ik wil natuurlijk niet de overige HBO boys vergeten, ik hoop dat we nog vaak en lang de 
hilarische eet afspraakjes kunnen houden met mijn HBO brazilian boys Erik (Smeetsos) 
en Arthur (Keesie). 
 
Mijn steun van thuis uit waarbij jullie me toch altijd weer wisten op te beuren en te 
motiveren. Mijn grote (op leeftijd dan, lengte al lang niet meer) broer en zus. Wat heb 
ik toch altijd opgekeken naar jullie als alwetende broer en zus. Maar vandaag kunnen 
jullie aanwezig zijn bij de promotie van jullie “kleine” broertje en ik hoop dat ik jullie 
trots gemaakt hebt. Sandra, wat heb ik toch veel van je geleerd. Mijn grote zus waar ik 
vroeger tijdens het weekend ging logeren, ook al woonden we in hetzelfde huis, en 
dan de goede cult films keken zoals Aliens, Terminator etc. De grote zus die altijd veel 
met haar kleine broertje heeft opgetrokken. En toch mooi hoe jij nog steeds na al die 
jaren mijn verslagen corrigeert (ja ook dit proefschrift) en met je fantastisch oog voor 
spelling er toch nog fouten uit haalt (ja ook uit dit proefschrift). Mijn excuses mochten 
er nog kleine foutjes in het dankwoord staan, maar dit stuk moest ook een verrassing 
voor jou zijn. Maar gelukkig kan nu niet meer een leraar gaan vragen of het verslag nu 
door mij, of door mijn grote zus geschreven is. Maar om hier toch zeker van te zijn dat 
dat niet gebeurt sta je op de dag van mijn promotie naast me als mijn paranimf ;).  
Patrick, mijn grote broer. Ik ben er altijd jaloers op geweest hoe ogenschijnlijk 
gemakkelijk en relaxed jij door het leven gaat. En vooral dat je het geschopt hebt tot 
piloot heeft me altijd trots gemaakt. Je staat altijd klaar om ons hartelijk te ontvangen 
tijdens onze mini vakanties in Noorwegen. Ik wens je veel geluk met je mooie gezin en 
kusjes voor mijn nichtjes en schoonzus. 
Pap en mam. Ik denk dat er niet veel mensen zijn die oprecht kunnen zeggen dat ze 
zo’n fantastische ouders hebben als mij. Ik heb al veel met jullie gelachen en hoop het 
nog lang te mogen blijven doen. Jullie hebben een fantastische prestatie geleverd met 
de manier waarop jullie ons hebben opgevoed tot de volwassen mensen die we nu 
zijn. En ik hoop dat we jullie even trots maken. Pap, ik heb er altijd, en nu nog steeds, 
respect voor gehad hoe jij altijd alles gegeven hebt voor je gezin. Die tijd als hulp 
monteur zal ik nooit meer vergeten, desondanks we af en toe letterlijk met de hoofden 
botsten. Jij hebt mij een perfect werkethos bijgeleerd en bent daarin altijd een 
voorbeeld voor mij geweest en ik hoop dat ik dat ooit zal kunnen evenaren. Mam, als 
iemand de definitie is van een liefhebbende moeder dan ben jij het wel. Jij neemt altijd 
de tijd voor je kinderen en heeft zichzelf daarbij altijd opzij geschoven zonder ook maar 
eerst te wachten op een aanleiding. Ik zal nooit mijn “snipperdag” van school vergeten 
waar we dan gezellig samen ergens naar toe gingen. En ook al schamp ik er wel eens 
op dat ik door je geklets versleten oren krijg, wil ik ze nog lang aan kunnen horen. Pap 
en mam, ook al zeg ik het misschien niet vaak genoeg, ik hou van jullie. 
 148Dankwoord 
Ik mag ook nog van geluk spreken dat ik zelfs nog een opa en oma mag bedanken in 
mijn dankwoord. Opa en oma dank jullie wel voor de vele leuke bezoekjes en verhalen 
van vroeger. En vooral respect voor mijn Rambo opa, niet velen kunnen het 
navertellen wat u heeft meegemaakt.  
Mijn oom en tante Math en Jacqueline en neef Sem, dank jullie voor jullie altijd leuke 
bezoekjes en ik hoop dat er dat alleen maar meer worden in de toekomst. 
Mijn lieve schoonfamilie Friedel, Clara, Tim en Carmen. Fijn hoe jullie me opnamen in 
jullie gezin. Ik denk dat ik er vooral trots op mag zijn dat ik me zo thuis, soms te thuis ;), 
kan en mag voelen bij jullie. Ik wens jullie allen veel succes en liefde toe. 
 
En het belangrijkste van alles bewaar je altijd tot het laatst. Mijn paranimf voor het 
leven, mijn maatje, mijn grote liefde, en mijn alles, Nina. Het is ongelofelijk van geluk 
spreken dat wij elkaar zijn tegen gekomen en voor elkaar gekozen hebben. Wij hebben 
al heel wat tegenslagen samen het hoofd kunnen bieden en zijn er beter uitgekomen. 
Jij bent wat betreft alle opzichten mijn droom vrouw. Je kijkt dezelfde films als mij, 
hebt dezelfde interesses (desondanks je dan soms uitfaseert tijdens mijn klokhuis 
verhalen), houdt van hetzelfde eten, dezelfde humor (gelukkig maar), en we delen 
onze liefde voor elkaar. Ik mag van geluk spreken dat wij samen zijn en samen de hele 
wereld doen bereizen. Ik weet ook zeker dat we weer met even veel plezier in onze 
volgende levens fase en bijbehorende avonturen zullen stappen. 
 
En hiermee eindig ik mijn dankwoord en blijft nu nog alleen de officiële afronding van 
mijn promotie over. En zoals ik wel vaker zeg, alles heeft een einde, zelfs een 
promotie, behalve een worst, die heeft er twee. 
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Curriculum vitae 
Kevin Gerritsen werd geboren op 30 november 1984 te Maastricht. Hij behaalde zijn 
HAVO-diploma in 2002 aan het Trichter College te Maastricht. Vervolgens begon hij de 
opleiding Biomedisch Laboratoriumonderzoek aan de Hogeschool Zuyd te Heerlen. 
Tijdens deze opleiding heeft hij twee stages doorlopen waarvan de eerste op de 
afdeling Medische Microbiologie in het Academisch Ziekenhuis Maastricht onder 
leiding van Dr. Frank Stassen. Hier deed hij onderzoek naar de ontwikkeling van de 
ziekte van Alzheimer door een infectie van de hersenspecifieke afweercellen, de 
microglia, als gevolg van een bacteriële infectie. Het onderwerp van zijn tweede en 
tevens afstudeerstage, was het bestuderen van de activatie van de bloedstollingsfactor 
FXII, op de afdeling Biochemie aan de Universiteit Maastricht onder leiding van  
Dr. Jose Govers-Riemslag. 
Na het voltooien van deze opleiding tot research laborant in 2008, vervolgde hij zijn 
opleiding met de Master studie Clinical Molecular Sciences aan de Universiteit 
Maastricht. Tijdens deze opleiding doorliep hij twee stages waarbij de eerste op de 
afdeling Fysiologie aan de Universiteit Maastricht onder leiding van Dr. Frans van 
Nieuwenhoven en Dr. Anneleen Daniels. Hier deed hij onderzoek naar de rol van 
groeifactoren in het structureel hermoduleren van het hartweefsel onder pathogene 
omstandigheden. Zijn afstudeerstage heeft hij doorlopen op de afdeling Klinische 
Chemie in het Academisch Ziekenhuis Maastricht onder begeleiding van  
Prof. Dr. Marja van Dieijen-Visser en Dr. Leo Jacobs. Het onderwerp van deze stage 
was het onderzoeken van de vrijlating van het hartspecifieke proteïne troponine in het 
bloed onder gezonde alsook stressvolle omstandigheden. 
Na het afstuderen voor zijn Master in 2011, begon hij in 2012 zijn promotieonderzoek 
op de afdeling Weefseltypering in het Academisch Ziekenhuis Maastricht. Hier deed hij 
onderzoek naar de functionaliteit van HLA polymorfismen op RNA expressie en 
alternatieve mRNA splicing, onder leiding van Prof. Dr. Marcel Tilanus, Dr. Christina 
Voorter en Dr. Lotte Wieten. De resultaten van zijn promotieonderzoek staan 
beschreven in dit proefschrift en zijn tevens gepubliceerd als artikels in meerdere 
medische tijdschriften.  
 152Curriculum Vitae 
  
 153 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
List of publications 
 
  
 154Publications 
  
 Publications155 
List of publications 
Gerritsen KEH, Olieslagers TI, Voorter CEM & Tilanus MGJ. HLA-C exon 5 skipping by 
alternative splicing 
Manuscript in preparation 
 
 
Voorter CEM, Gerritsen KEH, Groeneweg M, Wieten L & Tilanus MGJ.  
The role of gene polymorphism in HLA class I splicing.  
International Journal of Immunogenetics 2016: 43: 65-78 
 
 
Gerritsen KEH, Groeneweg M, Meertens CMH, Voorter CEM & Tilanus MGJ.  
Full-length HLA-DRB1 coding sequences generated by a hemizygous RNA-SBT 
approach. 
Tissue Antigens 2015: 86: 333-342 
 
 
Gerritsen KEH, Voorter CEM, Joannes MORF, Senden-Gijsbers BLMG, Agis F, 
Wieten L & Tilanus MGJ. RNA and protein expression of HLA-A*23:19Q. 
Human Immunology 2015: 76: 4: 286-291 
 
 
Gerritsen KEH, Olieslagers TI, Groeneweg M, Voorter CEM & Tilanus MGJ. 
An improved and validated RNA HLA class I SBT approach for obtaining full-length 
coding sequences.  
Tissue Antigens 2014: 84: 5: 450-458 
 
 
Theunissen BHJJ, Lardenoye S, Hannemann PH, Gerritsen KEH, Brink PRG  
& Poeze M. Fast track by physician assistants shortens waiting and turnaround times of 
trauma patients in an emergency department. 
European Journal of Trauma and Emergency Surgery 2014: 40: 1: 87-91 
 
 
  
 156Publications 
  
 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 158 
 
 
